mehdi h. hamadani md curriculum vitae cv

Date of Document: April 4, 2022

CURRICULUM VITAE

Mehdi H. Hamadani MD

ProfessorDepartment of Medicine

Division of Hematology and Oncology - Medicine

OFFICE ADDRESS: Clinical Cancer Center9200 W Wisconsin AveMilwaukee, WI 53226

EDUCATION: 1993 - 1994 Higher Secondary School Certificate, Government College, Lahore, Pakistan1995 - 2001 M.B., B.S. (Honors), King Edward Medical College, Lahore, Pakistan

POSTGRADUATE TRAINING AND FELLOWSHIP APPOINTMENTS: 06/05/2001 - 02/28/2003 House Officer, Internal Medicine, Cheema Hospital Lahore, Lahore, Pakistan03/01/2003 - 07/30/2003 Research Officer, Hematology and Oncology, Shaukat Khanum Cancer Hospital and

Research Center, Lahore, Pakistan08/01/2003 - 07/31/2004 Intern, Internal Medicine, University of Oklahoma Health Sciences Center,

Oklahoma City, OK08/01/2004 - 07/31/2006 Resident, Internal Medicine, University of Oklahoma Health Sciences Center,

Oklahoma City, OK08/01/2006 - 07/31/2009 Fellow, Hematology and Oncology, The Ohio State University, Columbus, OH

FACULTY APPOINTMENTS: 08/01/2006 - 07/31/2009 Clinical Instructor of Medicine, Hematology and Oncology, The Ohio State

University, Arthur G. James Comprehensive Cancer Center, Columbus, OH08/04/2009 - 06/30/2013 Assistant Professor of Medicine, Hematology and Oncology, Blood and Marrow

Transplantation Program, West Virginia University-SOM, Morgantown, WV08/04/2009 - 10/07/2013 Associate Member, Mary Babb Randolph Cancer Center, Alexander B. Osborn

Hematopoietic Malignancy and Transplantation Program, West Virginia University, Morgantown, WV07/01/2013 - 10/07/2013 Associate Professor of Medicine, Hematology and Oncology, Blood and Marrow

Transplantation Program, West Virginia University-SOM, Morgantown, WV10/14/2013 - 06/30/2018 Associate Professor of Medicine, Department of Medicine, Hematology and

Oncology, Medical College of Wisconsin, Milwaukee, WI07/01/2018 - Present Professor of Internal Medicine, Medicine, Hematology and Oncology, Medical College

of Wisconsin, Milwaukee, WI

ADMINISTRATIVE APPOINTMENTS: 04/11/2012 - 10/07/2013 Medical Director, Hematology and Oncology, Myeloma and Lymphoma Service,

West Virginia University, Morgantown, Morgantown, WV10/07/2013 - Present Scientific Director, Medicine, Center for International Blood and Marrow Transplant

Research, Medical College of Wisconsin, Milwaukee, WI11/01/2017 - Present Director, Adult Blood and Marrow Transplantation Program, Medicine, Hematology &

Oncology, Medical College of Wisconsin, Milwaukee, WI

HOSPITAL STAFF PRIVILEGES: 2009 - 2013 Attending Physician, Mary Babb Randolph Cancer Center, Hematological Malignancy Clinic,

West Virginia University, WV

1 / 59

2009 - 2013 Attending Physician, Ruby Memorial Hospital, Hematological Malignancy Service, WestVirginia University, WV

2009 - 2013 Attending Physician, Ruby Memorial Hospital, Bone Marrow Transplantation Unit, WestVirginia University, WV

2013 - Present Attending Physician, Clinical Cancer Center, Hematological Malignancy Clinic, Froedtert &Medical College of Wisconsin, WI

2013 - Present Attending Physician, Froedtert Memorial Lutheran Hospital, Hematological MalignancyService, Froedtert & Medical College of Wisconsin, WI

2013 - Present Attending Physician, Froedtert Memorial Lutheran Hospital, Bone Marrow TransplantationUnit, Froedtert & Medical College of Wisconsin, WI

SPECIALTY BOARDS AND CERTIFICATION:

Certificates Issued By Issue Date ExpirationECFMG Step 1: 99/255; Step

2: 97/258; Step 3:89/217; CSA: Passed

2002 2003

American Board of InternalMedicine

2006 2016

American Board of MedicalOncology

2009 2019

American Board ofHematology

2010 2020

Licensure Number Issue Date ExpirationOklahoma Board of Medical

Licensure andSupervision

23561 2003 2006

State Medical Board of Ohio57-011465 2006 2009West Virginia Board of

Medicine23463 2009 2014

Wisconsin Depart of Safetyand ProfessionalServices

61253-20 2012 None

AWARDS AND HONORS: 1995 Merit Scholarship, Pakistan Atomic Energy Foundation1995 Merit Scholarship, Board of Intermediate and Secondary Education1997 Gold Medal for Under Graduate Research, Pakistan Physiological Society, King Edward Medical

College2001 Lt. General Burki Gold Medal in Clinical Ophthalmology, King Edward Medical College09/2004 1st Place, Original Research Competition, American College of Physicians, Oklahoma Chapter

Scietific Session09/2004 1st Place in American College of Physicians Original Research Competition, Oklahoma Chapter

Scientific Session08/2007 Selected participant, ASCO/AACR Workshop: Methods in Clinical Cancer Research02/2009 Travel Grant, American Society for Bone Marrow Transplantation06/2009 Excellence in Hematology & Oncology Research Award, The Ohio State University06/2009 James V. Warren Award for Accomplishments as The Most Outstanding Research Fellow, The Ohio

State University06/2009 Clinical Research Impact Recognition by Faculty, 1000 Medicine2009 Young Investigator Award, KEMCAANA02/2011 New Investigator Award, ASBMT & MIllennium05/2011 Press Ganey Top Doctors Award, WVU Healthcare05/2011 Press Ganey Top Doctors Award, WVUH Healthcare, Morgantown, WVU Healthcare

2 / 59

06/2011 Career Development Award, Conquer Cancer Foundation of ASCO06/2011 Best Attending Physician, WVU Department of Internal Medicine06/2012 Selected for inclusion in Academic Keys Who's Who in Medicine Academia05/2013 Press Ganey Top Provider for Inpatient Service WVU Hospitals, Morgantown, WVU Hospitals05/2013 Press Ganey Top Provider for Outpatient Clinics, WVU Hospitals06/2013 Outstanding Teacher Award, WVU Department of Internal Medicine2015 - 2016 Best Doctors in America2016 - 2017 Best Doctors in America2017 - 2018 Best Doctors in America09/2018 MCW Cancer Center Outstanding Achievement Award for Adult Clinical Research10/2018 Magnanimous Mentor , Medical College of Wisconsin2019 - 2020 Best Doctors in America02/2020 BMT CTN Purple Heart Award2020 - 2021 Best Doctors in America®2020 Castle Connolly Top Doctor2021 Castle Connolly Top Doctor

MEMBERSHIPS IN HONORARY AND PROFESSIONAL SOCIETIES: 2001 - Present Pakistan Medical and Dental Council2003 - 2004 American College of Physicians2006 - 2008 American Medical Association2007 - 2008 American Association for Cancer Research2007 - Present American Society of Clinical Oncology2007 - Present American Society of Hematology2007 - Present American Society for Blood and Marrow Transplantation2009 - Present Eastern Cooperative Oncology Group2009 - Present West Virginia Oncology Society2010 - Present West Virginia State Medical Association2012 - Present Alliance for Clinical Trials in Oncology

EDITORSHIPS/EDITORIAL BOARDS/JOURNAL REVIEWS: Editorship

2010 52nd American Society of Hematology Annual Meeting2014 - Present Leukemia2016 58th American Society of Hematology Annual Meeting2017 59th American Society of Hematology Annual Meeting2017 - 2019 ASH News Daily2017 - Present HCT for Malignant Conditions2017 - Present Hematopoietic Cell Transplant for Malignant Conditions2019 - Present 61st American Society of Hematology Annual Meeting2019 - Present American Society of Clinical Oncology Annual Meeting2020 62nd American Society of Hematology Annual Meeting2020 - Present Hematology Oncology & Stem Cell T2020 - Present American Society of Clinical Oncology Annual Meeting2021 - Present American Society of Clinical Oncology Annual Meeting

Editorial Board2010 - 2013 Journal of Blood Disorders and Transfusion2011 - Present World Journal of Transplantation2011 - Present American Journal of Blood Research2012 - Present Modern Chemotherapy2014 - Present Bone Marrow Transplantation2016 - Present Clinics in Oncology2017 - Present Advances in Cell & Gene Therapy2018 - Present Clinical Lymphoma, Myeloma & Leukemia2019 - Present PLOS One

Ad-Hoc Reviewer2005 - Present American Journal of Health System Pharmacy

3 / 59

2006 - Present Journal of Postgraduate Medicine2007 - Present Indian Journal of Cancer2007 - Present Journal of Medical Case Reports2007 - Present Biology of Blood and Marrow Transplantation2007 - Present Southern Medical Journal2007 - Present Medical Science Monitor2008 - Present Bone Marrow Trnasplantation2009 - Present Expert Review of Anticancer Therapy2009 - Present Haematologica2009 - Present Leukemia and Lymphoma2010 - Present Drugs2010 - Present Advances in Hematology2010 - Present US Hematology2011 - Present Journal of Oncology2011 - Present American Journal of Hematology2012 - Present Experimental Hematology & Oncology2012 - Present Hematology Reports2013 - Present British Journal of Haematology2013 - Present Blood2013 - Present Cytotherapy2013 - Present JSM Hematology & Transfusion2013 - Present Clinical Transplantation2015 - Present Journal of Clinical Apheresis2015 - Present Clinical Lymphoma, Myeloma & Leukemia2015 - Present Journal of Clinical Oncology2016 - Present Journal of Community and Supportive Oncology2016 - Present Oncoimmunology2016 - Present Hematology/Oncology and Stem Cell Therapy2017 - Present Blood Advances2018 - Present Lancet Haematology2018 - Present Cancer2018 - Present Annals of Hematology2018 - Present Lancet Oncology2019 - Present ASH Hematology, The Education Program

LOCAL/REGIONAL APPOINTED LEADERSHIP AND COMMITTEE POSITIONS: 2009 - 2013 Member, Protocol Review and Monitoring Committee, WVU2009 - 2013 Chair, Data Safety and Toxicity Committee, MBRCC2009 - 2013 Member, IM Residency Candidate Interview Committee, WVU2010 - 2013 Member, Fellowship Education Sub-Committee, WVU2011 - 2013 Member, Fellowship Recruitment Committee, WVU2011 - 2012 Member, Hematology/BMT Faculty Search Committee, WVU2012 - 2013 Member, Elections Committee, West Virginia Oncology Society2012 - 2013 Member, Research Committee, WVU2013 - 2015 Member, Young Investigator Award Committee, KEMCAANA2013 - 2014 Member, Antimicrobial Stewardship Advisory Group, MCW2015 - Present Member, PNT Oncology Subcommittee, MCW2016 - 2019 Member, Data Safety and Monitoring Committee, MCW2016 - Present Member, Fellowship Recruitment Committee, MCW2017 - Present Chair, Accountable Care Team-BMT Service Line/8-CFAC, MCW2017 - Present Chair, BMT Faculty Research Committee, MCW2017 - Present Member, Clinical Program Leadership, F&MCW2019 - 2020 Member, Chicago Lymphoma Symposium Advisory Committee

NATIONAL ELECTED/APPOINTED LEADERSHIP AND COMMITTEE POSITIONS: 2009 - Present Member, Hodgkin and NHL Working Committee, CIBMTR2009 - Present Member, Chronic Leukemia Working Committee, CIBMTR

4 / 59

2009 - Present Member, Multiple Myeloma Working Committee, CIBMTR2009 - Present Member, Clinical Investigator, National Cancer Institute2009 - Present Member, Acute Leukemia Working Committee, CIBMTR2012 - 2013 Principal Investigator, Alliance for Clincial Trials in Oncology, WVU2013 - 2018 Member, CLT-008 Data Safety & Monitoring Board, Cellerant2013 - 2019 Protocol Officer, 1501 Study Protocol Team, BMT CTN2013 - Present Member, Steering Committee, BMT CTN2013 - Present Scientific Director, Lymphoma Working Committee, CIBMTR2014 - Present Protocol Officer, 1506 Study Protocol Team, BMT CTN2015 - Present Member, Friday Satellite Symposia Study Section, ASH2016 - Present Member, 1503 Eligibility Review Committee, BMT CTN2016 - Present Member, Practice Guidelines Committee, ASBMT2017 - 2018 Chair, Friday Satellite Symposia Study Section, ASH2017 - 2018 Member, Industry Engagement Task Force, BMT CTN2018 - 2019 Member, Program Committee, ASH2018 - Present Protocol Officer, 1705 Study Protocol Team, BMT CTN2018 - Present Protocol Officer, 1802 Study Protocol Team, BMT CTN2018 - Present Protocol Officer, 1703 Study Protocol Team, BMT CTN2018 Member, Working Group on Media Strategy, ASH2019 - Present Protocol Officer, 1904 Study Protocol Team, BMT CTN2019 - 2020 Track Leader - Leukemia/Transplant), ASCO Annual Meeting Education Committee2019 - Present Member, Scientific Program Committee, ASCO2020 - Present Protocol Officer, 2002 Study Protocol Team, BMT CTN2020 - 2021 DCC Liaison, SOSS Lymphoma Committee, BMT CTN2020 - Present Co-Chair, Practice Guidelines, ASTCT2020 - 2021 Course Director, 1st Midwest Cellular Conference

RESEARCH GRANTS/AWARDS/CONTRACTS/PROJECTS:

ActivePeer Review

Title: A prospective, multicenter observationalstudy to evaluate hematopoieticprogenitor cell mobilization in patientswith newly diagnosed multiplemyeloma.

Source: Sanofi GenzymeRole: Principal InvestigatorDates: 05/22/2017 - 05/22/2022

Title: U24 HL138660 Blood and Marrow

Transplantation Clinical ResearchNetwork Data Coordinating Center.

Source: NHLBIRole: Co-InvestigatorPI: Mary HorowitzDates: 09/15/2017 - 08/31/2024Direct Funds: $45,673,177 (0.6 Cal (Yr 2-3) 2.4 Cal

(Yr 4-7))

Title: A phase II, open-label, study ofpropylene glycol-free melphalan HCI incombination with fludarabine and totalbody irradiation based reduced intensityconditioning for haploidenticaltransplantation.

Source: Spectrum Pharmaceuticals

5 / 59

Role: Principal InvestigatorDates: 03/13/2018 - 12/31/2026Direct Funds: $108,685

Title: HOFFMANN-LAROCHE-GO40515: A

phase Ib/II, open-label, multicenter,randomized, controlled studyinvestigating the safety, tolerability,pharmacokinetics, and efficacy ofmosunetuzumab (BTCT4465A) incombination with CHOP or CHP-polatuzumab vedotin in patients with B-Cell non-Hodgkin Lymphoma.

Source: GenentechRole: Institutional PIDates: 03/06/2019 - 08/27/2019

Title: A multicenter, open label phase 1/2

study of Cyt-0851, an oral Rad51inhibitor, in patients withrelapsed/refractory B-cell malignanciesand advanced solid tumors.

Source: CyteirRole: Institutional PIDates: 2020 - Present

Title: INCB-50465-204: A phase 2, open-label,

2-cohort study of INCB050465, a PI3KInhibitor, in subjects with relapsed orrefractory marginal zone lymphoma withor without prior exposure to a BTKinhibitor (CITADEL-204).

Source: IncyteRole: Institutional PI

Title: A phase 2, open-oabel, single-srm study

to evaluate the efficacy and safety ofcamidanlumab tesirine (ADCT-301) inpatients with relapsed or refractoryHodgkin lymphoma.

Source: ADC TherapeuticsRole: Institutional PI

Title: INCB-50465-204: A phase 2, open-label,

2-cohort study of INCB050465, a PI3KInhibitor, in subjects with relapsed orrefractory marginal zone lymphoma withor without prior exposure to a BTKinhibitor (CITADEL-204).

Source: IncyteRole: Institutional PI

Title: PrE0404: A phase I/II study of ixazomib

and ibrutinib in relapsed/refractorymantle cell lymphoma.

Source: PrECOGRole: Study Chair

6 / 59

Title: BMT-CTN 1703: A randomized,

multicenter, phase III trial oftacrolimus/methotrexate vs post-transplant cyclophosphamide/tacrolimus/mycophenolate mofetil inmon-myeloablative/reduced intensityconditioning allogeneic peripheral bloodtransplantation.

Source: NHLBIRole: Protocol Officer

Title: CYTEIR-CYT-0851-01-REFMAL639:

A multicenter, open label phase 1/2study of Cyt-0851, an oral Rad51inhibitor, in patients withrelapsed/refractory B-cell malignanciesand advanced solid tumors.

Source: CyteirRole: Institutional PI

Title: IIT Hamadani FLU-MEL-TBI: A phase

II, open-label, study of propylene glycol-free melphalan HCl (EVOMELA®) incombination with fludarabine and totalbody irradiation based reduced intensityconditioning for haploidenticaltransplantation.

Source: SpectrumRole: Principal Investigator

Title: WVU-11310: Once daily intravenous

Busulfex as part of reduced toxicityconditioning for patients withrelapsed/refractory Hodgkin and non-Hodgkin lymphomas undergoingallogeneic hematopoietic celltransplantation - A multicenter phase IIstudy.

Source: OPDC Inc.Role: Principal Investigator

PriorPeer Review

Title: A multi-center phase II trial of oncedaily intravenous Busulfex® as part ofreduced intensity conditioning forpatients with relapsed/refractoryHodgkin and non-Hodgkin lymphomas.

Source: Otsuka Pharmaceutical Development &Commercialization, Inc.


Title: Atorvastatin for the prophylaxis of acute

7 / 59

graft-versus-host-disease in patientsundergoing allogeneic stem celltransplantation

Source: American Cancer Society116837-IRG-09-061-01

Role: Principal InvestigatorDates: 04/13/2010 - 12/31/2011Direct Funds: $30,000 (Per Year)

Title: Morphologic, immunophenotypic and

molecular subtyping of high-grade largeB-cell lymphomas: A clinicopathologicevaluation targeting myc, bcl2, bcl6status and gene expression profiling aspotential diagnostic and prognosticmarkers in large B-cell lymphomas withaggressive features

Source: WVU MBRCC Pilot Project GrantRole: Co-InvestigatorPI: Jeffrey A. Vos, MDDates: 04/13/2010 - 12/31/2011Direct Funds: $30,000 (Per Year)

Title: Relative importance of intravenous

Busulfex’s dose-intensity in twoFlu/Bu/ATG based reduced intensityconditioning regimens

Source: Otsuka Pharmaceutical Development &Commercialization, Inc.



graft-versus-host-disease in patientsundergoing matched sibling allogeneictransplantation.

Source: Conquer Cancer Foundation of ASCOCareer Development Award



graft-versus-host-disease in patientsundergoing matched sibling allogeneictransplantation

Source: ASBMT & Millennium NewInvestigator Award


Title: Assessment of micro-RNA 155

expression in acute graft-versus-hostdisease

Source: WVCTSI & Ohio State CCTS

8 / 59

Collaboration Pilot AwardRole: Principal InvestigatorDates: 05/01/2012 - 04/30/2013Direct Funds: $50,000 (Per Year)

Title: MLN9708 for the prophylaxis of chronic

graft-versus-host disease in patientundergoing allogeneic transplantation.

Source: Millennium: The Takeda OncologyCompany

Role: Principal InvestigatorDates: 01/10/2014 - 01/29/2017

Title: CP-204: An open-label, phase 1/2 study

of MEDI-551, a humanized monoclonalantibody directed against CD19, inrelapsed or refractory advanced B-cellmalignancies

Source: Medimmune, LLCRole: Institutional PIDates: 07/17/2014 - 02/11/2020Direct Funds: $145,596

Title: A multi-center, randomized, double-

blind, placebo-controlled phase III trialof the FLT3 inhibitor gilteritinib.

Source: Astellas Pharma US Inc.Role: Principal InvestigatorDates: 03/01/2015 - 01/29/2017Direct Funds: $1,532,581

Title: ADCT-301-001: ADCT-301 in patients

with relapsed or refractory Hodgkinlymphoma and non-Hodgkin lymphoma

Source: ADCT TherapeuticsRole: Institutional PIDates: 06/2015 - 06/2019Direct Funds: $315,721

Title: SGN19A-003: Randomized open-label

phase 2 SGN-CD19A plus RICE vs.RICE for relapsed or refractory diffuseDLBCL.

Role: Institutional PIDates: 10/2015 - 06/2017

Title: Merck-MK-3475-170: A phase II study

of pembrolizumab in subjects withrelapsed or refractory primarymediastinal large B-cell lymphoma orrelapsed or refractory Richter Syndrome.

Source: Merck Sharp & Dohme Corp.Role: Institutional PIDates: 11/2015 - 02/2018

Title: Merck-MK-3475-013: A Phase Ib Multi-

Cohort Trial of MK-3475

9 / 59

(pembrolizumab) in Subjects withHematologic Malignancies

Source: Merck Sharp & Dohme Corp.Role: Institutional PIDates: 01/12/2016 - 10/24/2019Direct Funds: $222,649

Title: ADCT-402-101: A Phase 1 adaptive

dose-escalation study to evaluate thetolerability, safety, pharmacokinetics,and antitumor activity of ADCT-402 inpatients with relapsed or refractory B-cell lineage non Hodgkin lymphoma.

Source: Pharmaceutical Research Associates,Inc.

Role: Institutional PIDates: 06/07/2016 - 04/29/2020Direct Funds: $673,676

Title: SGN19A-003: A randomized, open-label

phase 2 study of SGN-CD19A plusrituximab, ifosfamide, carboplatin, andetoposide (19A+RICE) chemotherapy vsRICE in the treatment of patients withrelapsed or refractory diffuse large B-Cell lymphoma who are candidates forautologous stem cell transplant.

Source: Seattle Genetics, Inc.Role: Institutional PIDates: 06/14/2016 - 08/01/2018Direct Funds: $68,664

Title: BMT-CTN 1501: A randomized phase II

multi-center open label study comparingsirolimus to prednisone in patients withrefined Minnesota standard risk, AnnArbor 1/2 Confirmed acute GVHD.

Source: NCI/NIHRole: Protocol Officer/Institutional PIDates: 09/2016 - 09/2019

Title: MedImmune D4190C00023: A phase 1b

study to evaluate the safety and efficacyof MEDI4736 as monotherapy and incombination with tremelimumab orAZD9150 in subjects with relapsed orrefractory diffuse large B-celllymphoma.

Source: MedImmune LLCRole: Institutional PIDates: 12/27/2016 - 03/15/2019Direct Funds: $27,416

Title: SC17-03 - A multi-center, prospective,

observational long-term study of the useof TEPADINA in Canadian and AmericaPatients.

10 / 59

Source: ADIENNE SARole: Principal InvestigatorDates: 07/10/2017 - 07/09/2019Direct Funds: $1,896,295

Title: BMT-CTN 1506: A multicenter,

randomized, double-blind placebo-controlled phase III trial of the FLT3inhibitor gilteritinib administered asmaintenance therapy followingallogeneic transplant for patients withFLT3-ITD AML.

Source: NHLBIRole: Protocol OfficerDates: 10/01/2017 - 09/30/2025

Title: INCB-50465-102: An open-label, dose-

finding, and cohort-expansion phase 1study evaluating safety and efficacy ofthe study drug in combination withbendamustine and obinutuzumab insubjects with relapsed or refractoryfollicular lymphoma.

Source: Incyte CorporationRole: Institutional PIDates: 11/10/2017 - 05/20/2019Direct Funds: $96,592

Title: A Phase 2, Multicenter, International,

Open-Label, Safety and Efficacy Studyof INCB050465 in Subjects withRelapsed or Refractory Diffuse Large B-Cell Lymphoma.

Source: Incyte CorporationRole: Site PIDates: 11/29/2017 - 11/28/2020

Title: BMT-CTN 1802: An open-label, single-

arm, multicenter study, of combinationanti-CD3/CD7 immunotoxin (T-Guard)for steroid-refractory acute graft-versus-host disease.

Source: NHLBIRole: Protocol OfficerDates: 2020 - Present

Title: E2408: A 3-arm randomized phase II

trial of bendamustine-rituximab (BR)followed by rituximab vs. bortezomib-BR (BVR) followed by rituximab vs. BRFollowed by lenalidomide/rituximab inhigh risk follicular lymphoma

Source: ECOGRole: Institutional PI

Title: Phase 1/2 open-label, multiple-dose,

dose-escalation study to evaluate the

11 / 59

safety and tolerability of SNS01-Tadministered by intravenous infusion inpatients with relapsed or refractorymultiple myeloma

Source: SenescoRole: Institutional PI

Title: CALGB 50303: Phase III randomized

study of R-CHOP v. dose-adjustedEPOCH-R with molecular profiling inuntreated de novo diffuse large B-celllymphomas

Source: CALGBRole: Institutional PI

Title: BMT-CTN 0702: A trial of single

autologous transplant with or withoutconsolidation therapy versus tandemautologous transplant with lenalidomidemaintenance for patients with multiplemyeloma

Source: NHLBIRole: Institutional PI

Title: CP204-II: An open-label, phase 1/2

study of MEDI-551, a humanizedmonoclonal antibody directed againstCD19, in adult subjects with relapsed orrefractory advanced B-cell malignancies

Source: MedImmuneRole: Institutional PI

Title: C25003: A randomized, phase 3 trial of

A+AVD versus ABVD as frontlinetherapy in patients with advancedclassical Hodgkin lymphoma

Source: MillenniumRole: Institutional PI

Title: Merck-MK-3475-013: A phase Ib multi-

cohort trial of MK-3475(pembrolizumab) in subjects withhematologic malignancies

Source: MerckRole: Institutional PI

Title: ECOG 1411: Intergroup randomized,

four arm phase II study in patients ?60with previously untreated MCL

Source: ECOGRole: Institutional PI

Title: C16006: An open-label, dose-escalation,

phase 1/2 study of the oral form ofMLN9708, a second-generationproteasome inhibitor, administered incombination with lenalidomide and low-

12 / 59

dose dexamethasone in patients withnewly diagnosed multiple myelomarequiring systemic treatment


Title: MEDI-551-1088: A phase 2 randomized

open-label study of MEDI-551 in adultswith relapsed or refractory DLBCL


Title: Gilead 218-1502: Phase 2b randomized,

double-blind, placebo-controlled multi-center study GS-5806 in HCT recipientswith RSV lower respiratory tract.

Source: GileadRole: Institutional PI

Title: A phase II study of oral single agent

panobinostat in patients with refractoryde-novo or secondary acutemyelogenous leukemia

Source: Novartis CorpRole: Institutional PI

Title: PCI- 32765CLL3001: Randomized,

double-blind, placebo-controlled phase 3Study of Ibrutinib, in Combination withbendamustine and rituximab in subjectswith relapsed or refractory chroniclymphocytic leukemia/smalllymphocytic lymphoma

Source: Janssen R&DRole: Institutional PI

Title: Gilead 218-0108: Phase 2b randomized,

double-blind, placebo-controlled multi-center study GS-5806 in HCT recipientswith RSV upper respiratory tract

Source: GileadRole: Institutional PI

Title: MEDI-551-1088: A phase 2 randomized

open-label study of MEDI-551 in adultswith relapsed or refractory DLBCL


Title: A randomized phase II trial of R-Hyper-

CVAD induction followed byconsolidation with an autologoustransplant versus R-bendamustineinduction followed by an autologoustransplant for patients ?65 years withpreviously untreated mantle celllymphoma

13 / 59

Source: SWOGRole: Institutional PI

Title: A phase II trial of PET-directed therapy

for limited stage diffuse large B-celllymphoma


Title: PANORAMA 1: A multicenter,

randomized double-blind, placebocontrolled phase III study ofpanobinostat in combination withbortezomib and dexamethasone inpatients with relapsed multiple myeloma


Title: C16005: An open label, dose escalation,

phase I/II study of the oral form ofMLN9708, a second generationproteasome inhibitor administered incombination with lenalidomide and lowdose dexamethasone in patients withnewly diagnosed multiple myelomarequiring systemic treatment


Title: Phase II study to evaluate the efficacy

and safety of ibrutinib in subjects withmantle cell lymphoma who progressafter bortezimib therapy

Source: Janssen R&DRole: Institutional PI

Title: Complement A/B: A randomized, open

label study of ofatumumab andbendamustine combination therapycompared with bendamustinemonotherapy in indolent B-cell non-Hodgkin's lymphoma unresponsive torituximab or a rituximab-containingregimen during or within six months oftreatment

Source: GlaxoSmithKlineRole: Institutional PI

Title: BMT-CTN 0701: Phase II trial of non-

myeloablative allogeneic hematopoieticcell transplantation for patients withrelapsed follicular non-Hodgkin'slymphoma beyond first completeresponse

Source: NHLBIRole: Institutional PI

14 / 59

Title: ADCT-402-201-DLBCL: A phase 2open-label single-arm study to evaluatethe efficacy and safety of loncastuximabtesirine in patients with relapsed orrefractory DLBCL.

Source: ADCT TherapeuticsRole: Institutional PI

Title: NU 14H09: A phase I-II trial of DA-

EPOCH-R plus ixazomib as frontlinetherapy for patients with MYC-aberrantlymphoid malignancies: TheDACIPHOR regimen.

Source: TakedaRole: Institutional PI

Title: UNUM-ATTCK-20-03-BCL: Phase 1

study of ACTR707, an autologous T cellproduct, in combination with rituximab,in subjects with relapsed or refractoryCD20+ B cell lymphoma.

Source: Unum TherapeuticsRole: Institutional PI

Title: IISR X16034: MLN9708 for the

prophylaxis of chronic graft-versus-hostdisease in patient undergoing allogeneictransplantation. A phase I/II study.

Role: Principal Investigator

Title: A phase II study of ATRA, arsenictrioxide and gemtuzumab ozogamicin inpatients with previously untreated high-risk acute promyelocytic leukemia


Title: PLEX-09: A phase II study evaluating

the safety and efficacy of subcutaneousplerixafor for the mobilization andtransplantation of HLA-matched siblingdonor hematopoietic stem cells inrecipients with hematologicalmalignancies

Source: RCI-BMTRole: Institutional PI

Title: MEDI-551-1019: A phase 2 open-label

study of MEDI-551-1019 andbendamustine vs. rituximab andbendamistine in adults with relapsed orrefractory CL


Title: ARD12130: A Phase 2 study of

SAR245409 in patients with relapsed or

15 / 59

refractory mantle cell lymphoma,follicular lymphoma, or chroniclymphocytic leukemia/smalllymphocytic lymphoma

Source: Sanofi AventisRole: Institutional PI

Title: A phase I/II study of the tolerability of

lenalidomide and low dosedexamethasone in previously treatedmultiple myeloma patients with impairedrenal function

Source: PrEOCGRole: Institutional PI

Title: MEDI D2852C00004: A Phase 1b/2

open-label study to evaluate thesafety/efficacy of MEDI-551 incombination with immunomodulatingtherapy in subjects with relapsed orrefractory aggressive B-cell lymphomas


Title: C16012: A phase 3, randomized, two-

arm, open label, multicenter,international trial of alisertib orinvestigator choice in patients withrelapsed or refractory peripheral T-celllymphoma


Title: A randomized, open-label, multi-Center,

phase 2 study of zevalin(I90Y-ibritumumob tiuxetan) versus zevalinand motexafin gadolinium in patientswith rituxan-refractory low-grade orfollicular B-cell non-Hodgkin lymphoma

Source: SPIRole: Institutional PI

Title: CLBH589E2301: A phase III

randomized double blind, placebocontrolled multi-center study ofpanobinostat for maintenance ofresponse in patients with Hodgkin’slymphoma who are at risk for relapseafter high dose chemotherapy andautologous stem cell transplant


Title: Assessment of micro-RNA 155

expression in acute graft-versus-hostdisease.

Source: WVUCTSI/OSU-CCTS

16 / 59

Role: Co-Principal Investigator

Title: MCW & WVU-011012: Phase II studyof atorvastatin, micro-dose methotrexateand tacrolimus administered only totransplant recipients for the prophylaxisof acute graft-versus-host diseasefollowing matched sibling and unrelateddonor allogeneic hematopoietic celltransplantation.

Source: CCF of ASCORole: Principal Investigator

Title: JUNO-JCAR017-017006: A phase 2

study of lisocabragene maraleucel(JCAR017) as second-line therapy inadult patients with agressive B-cellNHL.

Source: Celgene CorporationRole: Institutional PI

Title: Phase II study evaluating the safety and

efficacy of atorvastatin for theprophylaxis of acute graft-versus-hostdisease in patients undergoing matchedsibling hematopoietic stem celltransplantation.

Source: ASC-IRG; ASCO, ASMBTRole: Principal Investigator

INVITED LECTURES/WORKSHOPS/PRESENTATIONS: LocalAllogeneic transplantation for chronic lymphocytic leukemia - From bedside to bench, Comprehensive

Transplant Center Seminar, The Ohio State University Medical Center and Arthur G. JamesComprehensive Cancer Center, Columbus, OH, 02/25/2009

CD103 deficiency Separates GVHD from GVL effects - Implications of murine solid organ & BMT modelsfor stem cell transplantation in humans, Medicine Grand Rounds, West Virginia University,Morgantown, WV, 01/15/2010

T-cell trafficking and modulation of Graft-versus-Host Disease, Osborn Program Meeting, West VirginiaUniversity, Morgantown, WV, 02/12/2010

A clinical trial taken to the lab, First Annual Osborn Program Retreat, Morgantown, WV, 08/20/2010Mary Babb Randolph Cancer Center initiative to increase patient accrual on therapeutic clinical trials, Cancer

Clinical Trials 101 Meeting, West Virginia University, Morgantown, WV, 02/09/2011Atorvastatin for the prophylaxis of acute Graft-versus-Host Disease, Osborn Program Meeting, Westvaco

NRC, WV, 08/05/2011Follicular lymphoma: The key to the cure is clinical trials, Medicine Grand Rounds, Morgantown, WV,

01/20/2012Management of Transplant Eligible Myeloma Patients: West Virginia & 2013, Medicine Grand Rounds, West

Virginia University, Morgantown, WV, 05/24/2013Graft-versus-Host Disease. Ixazomib for chronic GvHD prophylaxis., Division of Hematology/Oncology

Research Meeting, Milwaukee, WI, 07/17/2014Planning observational research in Hematology & Oncology Fellowship., Hematology/Oncology Fellowship

Program Research Day, Medical College of Wisconsin, Milwaukee, WI, 08/19/2016Meet the Professor: Management of diffuse large B-cell lymphoma., Division of Hematology and Oncology,

University of Cincinnati, Cincinnati, OH, 09/30/2016Role of targeted therapies in the management of chronic lymphocytic leukemia: From clinical data to

17 / 59

individualized care., CME, Brookfield, WI, 11/02/2016Transplant and non-Hodgkin lymphoma., University of Illinois at Chicago Group Meeting, San Diego, CA,

12/04/2016Mobilizing autologous stem cells: Is there on best method?, APP & RN Education Session, Medical College

of Wisconsin, Milwaukee, WI, 08/10/2017Allogeneic transplantation at advanced age., Research Seminar at the Division of Geriatrics/Gerontology,

Zablocki VA Medical Center, Milwaukee, WI, 09/01/2017Patient-specific overview of Hodgkin and non-Hodgkin lymphomas., Ask the Doctor Program by Lymphoma

Research Foundation, Wisconsin Room, Hilton, Milwaukee, WI, 11/01/2017Transplant and non-Hodgkin lymphoma. HSCT in select NHL subtypes., Advocate Lutheran General

Hospital, Chicago, IL, 11/08/2017Role of autologous stem cell transplantation in the treatment of non-Hodgkin lymphoma subtypes., Oak

Brook, IL, 12/12/2018ASCT for non-Hodgkin lymphomas., Dallas, TX, 08/21/2019Changing landscape of cell therapies in B-cell NHL., BMT Conference at the Colorado Blood Cancer,

Denver, CO, 08/30/2019Mobilizing autologous stem cells: Is there on best method?, BMT & Cellular Therapy Program Education

Session, Medical College of WI, Milwaukee, WI, 11/14/2019Evolving paradigms in the diagnosis and management of chronic lymphocytic leukemia., Brookfield, WI,

12/03/2019Diagnosis and management of CLL., Janesville, WI, 03/03/2020Mantle cell lymphoma. Pathogenesis, management and future directions., Virtual Milwaukee Regional

Practice Outreach Event., Milwaukee, WI, 12/16/2020

RegionalGVHD-Hydra against allogeneic stem cell transplantation, Hematology & Oncology Grand Rounds Feist-

Weiller Cancer Center, LSU Health Sciences Center, Shreveport, LA, 06/13/2008The role of revlimid® (lenalidomide) in multiple myeloma, CSB Promotional Program, Logan Regional

Medical Center, Charleston, WV, 04/01/2010Blood and marrow transplantation for follicular lymphoma in the rituximab era, 20th Annual Fall Cancer

Center Conference, Morgantown, WV, 10/29/2010Clinical trial options for patients with lymphoid malignancies, WVOS Spring CME Membership Conference,

Roanoke, WV, 04/13/2012Immune Modulation for Preventing Graft-versus-Host Disease: Hope or Hype?, Case Western Reserve

University Comprehensive Cancer Center, Cleveland, OH, 04/19/2013Immune Modulation to Mitigate GVHD: The WV Experience, Medical College of Wisconsin Cancer Center,

Milwaukee, WI, 05/30/2013Classical Hodgkin lymphoma, Leukemia Lymphoma Society 2nd Annual Lymphoma Survivorship

Conference, Milwaukee, WI, 04/05/2014Therapeutic landscape of mantle cell lymphoma, Celgene District Meeting, Lake Geneva, WI, 06/09/2014An update on transplantation for lymphoid malignancies, Fourth Annual Controversies in Hematologic

Malignancies Symposium, Milwaukee, WI, 03/07/2015Hodgkin lymphoma, Leukemia Lymphoma Society 3rd Annual Lymphoma Survivorship Conference,

Madison, WI, 05/09/2015Advancing quality healthcare metrics through the personalization of treatment for the patients with chronic

lymphocytic leukemia., Hospital Grand Rounds, Mount Sinai Hosptial, Chicago, IL, 02/25/2016Networking and research collaboration for hematologists/oncologists of Pakistani origin., 1st APPNA Hem-

Onc Chapter ASCO Annual Meeting, Chicago, IL, 06/04/2016Role of targeted therapies in the management of chronic lymphocytic leukemia: From clinical data to

individualized care., Internal Medicine Grand Rounds, Mount Sinai Hosptial, Chicago, IL, 08/17/2016Non-Hodgkin lymphoma (NHL) - Low grade., Leukemia & Lymphoma Society, Blood Cancer Conference,

Milwaukee, WI, 09/24/2016Transplantation in advanced lymphomas: Indications in targeted therapy era., University of Cincinnati Grand

Rounds, The Vontz Center for Molecular Studies, Cincinnati, OH, 09/30/2016Transplantation for lymphoid malignancies: Relevance in 2016 and beyond., 26th Annual Fall Cancer

Conference, at the West Virginia University, Morgantown, WV, 10/07/2016Current role of autologous transplantation for non-Hodgkin lymphomas., Fox Valley Hematology &

18 / 59

Oncology Grand Rounds, Appleton, WI, 02/08/2017Basics of lymphoma for a statistician., CIBMTR Bi-Campus Statistician Meeting, Milwaukee, WI &

Minneapolis, MN, 04/21/2017Non-Hodgkin lymphoma (NHL) – High grade and Hodgkin lymphoma., Leukemia & Lymphoma Society,

Blood Cancer Conference, Hayat Regency, Milwaukee, WI, 09/23/2017Transplantation for B-cell NHL: Relevance in 2018 and beyond., Blood & Marrow Transplant and Cellular

Immunotherapy Grand Rounds, Moffitt Cancer Center and Research Institute, 04/10/2018Autologous transplantation for non-Hodgkin lymphomas., Methodist Hospital, Houston, TX, 06/28/2018Transplantation for lymphoid malignancies: Breaking barriers, M.D. Anderson Cancer Center Apheresis Unit,

Houston, TX, 06/29/2018Transplantation for B-cell NHL: A registry researcher’s perspective., Hematology Grand Rounds, Levine

Cancer Institutue, Charlotte, NC, 08/02/2018Should Hodgkin lymphoma patients that fail autologous transplantation still undergo allogeneic transplant?,

8th Annual Controversies in Hematologic Malignancies Symposium, Milwaukee, WI, 03/09/2019Allogeneic stem cell transplant still has a role in Hodgkin lymphoma. (Debate Moderator), 16th International

Ultmann Chicago Lymphoma Symposium, Chicago, IL, 04/13/2019ADCs in Hodgkin and non-Hodgkin Lymphomas: Here to stay!, OncLive State of the Science Summit:

Treatment of Hematological Malignancies, Brookfield, WI, 04/23/2019 - 08/22/2019Transplant and cell therapy in B-cell NHL: Informing practice from a CIBMTR perspective., Special

Hematological Malignancy Seminar at the Harold C. Simmons Comprehensive Cancer Center, UTSouthwestern, Dallas, TX, 08/22/2019

Understanding mantle cell lymphoma (MCL): Current challenges and emerging treatment options, ArizonaOncology, Scottsdale, AZ, 11/20/2019

Evolving paradigms in the diagnosis and management of chronic lymphocytic leukemia., Mercy WalworthOncology, Lake Geneva, WI, 03/03/2020

Transplant & cell therapies in B-NHL: Insights from CIBMTR data., Virtual Houston Methodist CancerCenter Oncology Grand Rounds, Houston, TX, 08/04/2020

Lymphoma: High grade., Virtual Leukemia & Lymphoma Society Blood Cancer Conference, Milwaukee,WI, 10/17/2020

NationalEvaluation of rabbit antithymocyte globulin dose-intensity in patients undergoing allogeneic stem cell

transplantation following reduced intensity conditioning with fludarabine, busulfan and rATG,American Society for Bone Marrow Transplantation Tandem Meetings, Tampa, FL, 02/11/2009

Impact of conditioning regimen intensity on the outcomes of allogeneic hematopoietic cell transplantation forrefractory grade-III follicular and diffuse large B-cell lymphomas, American Society of HematologyAnnual Meeting, Atlanta, GA, 12/10/2012

Effect of graft source and transplant conditioning regimen intensity on the outcomes of allogeneichematopoietic cell transplantation for refractory mantle cell lymphoma, American Society ofHematology Annual Meeting, Atlanta, GA, 12/10/2012

Prospective evaluation of a 'two-pronged' strategy of atorvastatin administration as acute graft-versus-hostdisease prophylaxis to both donors and recipients of matched related donor allogeneic hematopoieticcell transplantation, American Society for Bone Marrow Transplantation Tandem Meetings, Salt LakeCity, UT, 02/14/2013

Association of reduced intensity conditioning allograft as the first transplant approach in relapsed/refractorygrade 3 follicular lymphoma with improved outcomes in long-term survivors., American Society ofClinical Oncology Annual Meetings, Chicago, IL, 05/30/2015

Prospective, multicenter clinical trial of atorvastatin-based acute graft-versus-host-disease prophylaxis inrecipients of HLA-matched related donor and matched unrelated donor allogeneic hematopoietic celltransplantation., American Society for Blood and Marrow Transplantation Tandem Meetings,Honolulu, HI, 02/19/2016

Beyond matched donors: Current options for allogeneic stem cell transplantation in lymphomas., 13thInternational Ultmann Chicago Lymphoma Symposium, Chicago, IL, 05/07/2016

Transplantation basics: Follicular lymphoma and DLBCL., Transplant Symposium for North AmericaEducational Forum on Lymphoma, Chicago, IL, 10/29/2016

Barriers for autologous transplantation in non-Hodgkin lymphomas., Annual APPNA Hematology &Oncology Chapter meeting, Orlando, FL, 02/24/2017

19 / 59

Transplant and non-Hodgkin lymphoma: HSCT in select NHL subtypes., 2nd Annual APPNA Hematology &Oncology Chapter meeting, Salt Lake City, UT, 02/23/2018

Maintenance therapy after autologous HCT for Hodgkin lymphoma., 4th International Workshop on Biology,Prevention and Treatment of Relapse after Hematopoietic Cell Transplantation,, Chicago, IL,09/21/2018

Precision medicine: incorporating into BMT CTN clinical trials., BMT CTN Coordinators, Transplantationand Cellular Therapy Meeting, Houston, TX, 02/20/2019 - 02/24/2019

Transplant and non-Hodgkin lymphoma: HSCT in select NHL subtypes., 3rd Annual APPNA Hematology &Oncology Chapter meeting, Houston, TX, 02/20/2019 - 02/24/2019

Transplant and non-Hodgkin lymphoma: HSCT in select NHL subtypes., 3rd Annual APPNA Hematology &Oncology Chapter meeting, Houston, TX, 02/22/2019

Current treatment approaches in follicular lymphoma., Lymphoma Rounds, Coronado, CA, 06/11/2019Autologous transplantation in lymphomas., 4th Annual Pakistan BMT & Cell Therapy Physician Meeting,

Orlando, FL, 02/20/2020Debate: How best to manage patients with relapsed mantle cell lymphoma? Cell-based therapies with

AlloSCT or CAR-T?, Great Debates & Updates in Hematological Malignancies, Los Angeles, CA,03/07/2020

MCW BMT & CT program’s experience and recovery plan in COVID-19 epidemic, BMT CTN SteeringCommittee Meeting,, Virtual, 06/19/2020

Debate: How best to manage patients with relapsed mantle cell lymphoma? Cell-based therapies withAlloSCT or CAR-T?, Virtual Great Debates & Updates in Hematological Malignancies, Chicago, IL,08/29/2020

Fresh or cryopreserved: The impact of cryopreservation on post-transplant cyclophosphamide-basedtransplant outcomes., Virtual Be the Match One Forum, 11/06/2020

Autologous transplantation and patient selection in DLBCL, Virtual Midwest Cellular Conference,11/14/2020

Changing landscape of transplantation in B-cell lymphomas., Virtual HCP-led Education on HCT & role inMM & NHL, 12/11/2020

InternationalDiffuse large B-cell lymphoma, APPNA MERIT (Medical Education & Research International Training &

Transfer of Technology) Initiative Webinar, Karachi & Lahore, Pakistan, 06/10/2011Lymphoma and plasma cell disorders: Invited faculty for poster discussion session, American Society of

Clinical Oncology Annual Meetings, Chicago, IL, 06/03/2013Clinical allogeneic and autologous transplantation - results: allogeneic transplantation, American Society of

Hematology Annual Meetings, New Orleans, LA, 12/10/2013Moving the needle: Potential effects of novel drug combinations on care in lymphoma, American Society of

Clinical Oncology Annual Meetings, Chicago, IL, 05/31/2015Clinical autologous transplantation - results: clinical autologous transplantation in myeloma I., American

Society of Hematology, San Diego, CA, 12/05/2016Establishing a curriculum for training in HCT: Roundtable discussion., WBMT, Riyadh, Saudi Arabia,

01/16/2017Transplantation for DLBCL and follicular lymphoma., WBMT, Riyadh, Saudi Arabia, 01/17/2017Are haploidentical transplants ready for prime time in lymphomas?, 43rd Annual Meeting of the European

Society for Blood and Marrow Transplantation, Marseille, France, 03/29/2017Clinical autologous transplantation: Modern indications and post-transplantation check point inhibitors in

lymphomas and myeloma., American Society of Hematology Annual Meeting, Atlanta, GA,12/10/2017

Palliative/supportive care and histocompatibility., ASBMT & CIBMTR BMT Tandem Meetings., Salt LakeCity, UT, 02/22/2018

Phase 1 study of ADCT-301 (camidanlumab tesirine), a novel pyrrolobenzodiazepine-based antibody drugdonjugate, in relapsed/refractory classical Hodgkin lymphoma., American Society of HematologyAnnual Meeting, San Diego, CA, 12/03/2018

Allogeneic hematopoietic cell transplantation in elderly (?65 years) non-Hodgkin lymphoma patients: A timetrends analysis from the CIBMTR., 45th Annual Meeting of the European Society for Blood andMarrow Transplantation, Frankfurt, Germany, 03/26/2019

? Meet the Professors: When do I consider stem cell transplant in relapsed FL? The role of autologous versus

20 / 59

allogeneic transplant., American Society of Clinical Oncology Annual Meetings, Chicago, IL,06/03/2019

Health Service Research – Malignant conditions (lymphoid disease): Treatment-based outcomes, AmericanSociety of Hematology, Orlando, FL, 12/07/2019

Higher TBI dose-intensity in Flu/TBI-based reduced-intensity conditioning regimen is associated withinferior survival in non-Hodgkin lymphoma patients undergoing allogeneic transplantation., TCTMeetings, Orlando, FL, 02/2020

? Clinical autologous transplantation: Building better transplant platforms in lymphoid malignancies, VirtualAmerican Society of Hematology Annual Meetings, San Diego, CA, 12/07/2020

ASTCT Practice Guidelines Update, Session Chair, 2021 Virtual TCT Meetings of ASTCT and CIBMTR,02/05/2021

CAR T-cell therapy, current status and future, Saudi Society of Blood and Marrow Transplantation, WebinarSeries, 02/06/2021

Transplantation and cell therapy in B-cell lymphomas., Society of Medical Oncology Pakistan, 2nd AnnualHematology Conference, Pakistan, 02/06/2021

DLBCL – A hard nut to crack, 8th Pakistan Society of Hematology Webinar, Karachi, Pakistan, 03/05/2021How to sequence cell-based therapies in Mantle Cell Lymphoma, for 47th Annual Meeting of the European

Society for Blood and Marrow Transplantation, Virtual, 03/16/2021

PEER REVIEWED WORKSHOPS/PRESENTATIONS: RegionalZaidi A, Hamadani M, Zahra K, Muazzam I, Shujaat A, Etiological Factors of Hepatocellular Carcinoma in

South East Asia., Sixth Shaukat Khanum Memorial Cancer Hospital and Research Center Symposium,Dubai, 04/2003

Rehman S, Hamadani M, Awab A, Venkatappa S, Eichner ER, Fondaparinux as an alternative anticoagulantin Heparin induced thrombocytopenia. Report of two cases., American College of PhysiciansOklahoma Chapter Scientific Meeting, 2004

Hamadani M, Awab A, Ali T, Granulocytic Sarcoma Presenting as Multiple Skeletal Lesions: A Case Reportand Review of the Literature., American College of Physicians Oklahoma Chapter Scientific Meeting,2004

Awab A, Hamadani M, Brown B, Peyton M, Bronchioloalveolar carcinoma with negative Positron EmissionTomography scan: A Case report and Review of the literature., American College of PhysiciansOklahoma Chapter Scientific Meeting, 2004

Hamadani M, Benjamin M, Holla P, Selby G, Scofield H, Impact of Hyperglycemia on the Outcome of BoneMarrow Transplantation. A Retrospective Chart Review, American College of Physicians OklahomaChapter Scientific Meeting, 2004

Hamadani M, Kharfan-Dabaja M, Kamble R, Awab A, Kern W, Ozer H, Marginal Zone B-Cell Lymphomaof the Uterus: A Case Report and Review of the Literature., American College of PhysiciansOklahoma Chapter Scientific Meeting, 2005

Hamadani M, Kamble R, Sethi S, Kharfan-Dabaja M, Kern W, Ozer H, Selby G, Elevated Mean CorpuscularVolume (MCV) following Autologous Hematopoietic Stem Cell Transplantation: Incidence andSignificance., Stuart Wolf Day (Residents’ Research Presentation Day), 2005

Hamadani M, Hays K, Patel S, Awab A, Tfayli A, McCune-Albright Syndrome presenting as Massive Pleuraleffusion. A Case Report and Review of the Literature., American College of Physicians OklahomaChapter Scientific Meeting, 2005

Hamadani M, Tfayli A, Kojouri K, Awab A, Comparison of Ondansetron, Granisetron, and Dolasetron withDexamethasone in the prevention of Acute Nausea and Vomiting associated with Platinum-basedtherapy., Stuart Wolf Day (Residents’ Research Presentation Day), 2005

Hamadani M, Lightfoot S, Voskuhl G, Left Atrial Myxoma infected with Histoplasma., Stuart Wolf Day(Residents’ Research Presentation Day), 2006

Hamadani M, Liu K, Anthony BA, Gaughan A, Wang JJ, Shana’ah A, Johnson AJ, Byrd JC, Devine SM,Hadley GA, CD103 deficiency separates GVHD and GVL effects mediated by effector T-cells., OSUComprehensive Cancer Center 11th Annual Scientific Meeting, 2009

Davanzo L, Awan F, Hamadani M, Benson DM, Devine SM, Stem cell transplantation for peripheral T-celllymphomas: Single-institution experience and outcomes., OSU Comprehensive Cancer Center 11thAnnual Scientific Meeting, 2009

21 / 59

MEDICAL COLLEGE TEACHING ACTIVITIES: Postdoctoral Fellow Education

2018 - 2020 Manoj Khanal, PhD Candidate. Member Doctoral Examination Committee

EXTRAMURAL TEACHING: Medical Student Education

2010 - Present Medical Students in Hematology/BMT clinic

Resident and Fellow Education2009 - Present Continuity Fellows in Hematology/BMT clinic2009 - Present Hematology/BMT Fellow and Resident teaching2009 - Present Ambulatory Residents and Fellows in Hematology clinic2010 - 2013 Internal Medicine Resident Noon Lecture Series, Acute and Chronic Leukemias for Medicine

Residents.2010 - 2011 Internal Medicine Resident Noon Lecture Series, Hypereosinophilic syndrome: What an

internist needs to know.2010 - 2013 Cancer Pharmacology & Therapeutics Lecture Series for Cancer Cell Biology Graduate

Students, Leukemia and lymphoma: Treatment options.2011 - 2013 Hematology & Oncology Fellows’ Core Lecture Series, Current concepts in diagnosis and

management of follicular lymphoma.2011 - 2013 Preceptor: Physical diagnosis and clinical integration I/II2011 - 2013 Internal Medicine Resident Noon Lecture Series, Basics of hematology for internal medicine

boards.2011 - 2013 Hematology & Oncology Fellows’ Core Lecture Series, Current concepts in diagnosis and

management of multiple myeloma.2011 - 2013 Internal Medicine Resident Noon Lecture Series, Myeloma and related disorders.2011 - 2013 Hematology & Oncology Fellows’ Core Lecture Series, Current concepts in diagnosis and

management of chronic lymphocytic leukemia.2011 - Present Hematology & Oncology Fellows’ Core Lecture Series, Aggressive non-Hodgkin

lymphomas.2012 - Present Hematology & Oncology Fellows’ Core Lecture Series, Classical Hodgkin lymphoma.2014 - Present M1/M2 Clinical Apprenticeship Preceptor

EXTRAMURAL STUDENTS, FACULTY, RESIDENTS, AND CLINICAL/RESEARCH FELLOWSMENTORED:

Postdoctoral StudentsYing Zhang, 2014 Member Dissertation CommitteeNatasha Sahr, 2016 - 2017 Doctoral Examination Committee

Clinical/Research Fellows

Salman Osman, MD, 2010 ASBMT Travel GrantLubna Chaudhary, 2013 Conquer Cancer Foundation of the ASCO Merit AwardSean Truong, 2013 1st Place WVU-HSC GME Original Research CompetitionSean Truong, 2013 Margaret J. Albrink research AwardBinod Dhakal, 2014 Conquer Cancer Foundation of the ASCO Merit AwardNarendranath Epperla, MD, MS, 2014 - 2016 Supervisor & MS Thesis Committee MemberShamsudin Virani, MD, MS, 2014 - 2016 Supervisor & MS Thesis Committee MemberGuru Murthy, MD, MS, 2016 - 2018 Supervisor & MS Thesis Committee MemberAbraham Kanate, Stanford Univeristy, Blood & Marrow Transplantation Fellowship

Faculty

Carla Casulo, MD, University of Rochester, Rochester, NY, 2016 - 2017 KL2 and Career Development,Award for Clinical and Translational Research

22 / 59

ELECTRONIC AND MEDIA: 05/31/2012 Advancing the care of myeloma and lymphoma patients and promoting access to clinical trials in

the state of West Virginia. WBOY Channel 12 News. Morgantown, WV. http:// www.wboy.com /story/18670393/wvu-hospitals-begins-new-service-for-blood-cancer-patients

06/30/2013 Ibrutinib: Pill could make chemotherapy a thing of the past. FOX Channel 10 News. Clarksburg,WV. http://www.wdtv.com/wdtv.cfm?func=view§ion=Fox-10&item=Pill-Could-Make-Chemotherapy-A-Thing-Of-The-Past10508

2016 Classical Hodgkin lymphoma. Practical Medical Education and Science. 2016.http://mededscience.com/presentations

2016 Aggressive non-Hodgkin lymphoma. Practical Medical Education and Science.http://mededscience.com/presentations

2016 Role of transplantation in follicular and DLBCL. Practical Medical Education and Science.https://youtu.be/lQX3HMoyU0w

2016 Bone marrow transplant: A refresher. http://bit.ly/2fAfXLd2017 How I manage: Hematopoietic cell transplantation in follicular lymphoma. 2017. http://www.clinicalonc

ology.com/Hematologic-Malignancies/Article/09-17/How-I-Manage-Hematopoietic-Cell-Transplantation-in-Follicular-Lymphoma/44492

06/10/2018 Hematopoietic cell transplantation for follicular lymphoma. A conversion with Mehdi Hamadani,MD. The ASCO Post. http://www.ascopost.com/issues/june-10-2018/hematopoietic-cell-transplantation-for-follicular-lymphoma/

12/2018 What to expect at the 60th ASH Annual Meeting with Drs. Hamadani, Sekeres, and Sola-Visne. TheHematologist 2018 ASH Podcast. https://soundcloud.com/ash_hematology/what-to-expect-at-the-60th-ash-annual-meeting-with-drs-hamadani-sekeres-and-sola-visner

01/2019 - 02/2019 60th ASH Annual Meeting wrap-up: A game changer in San Diego. The Hematologist.January-February 2019, Volume 16, Issue 1. https://buff.ly/2sapu22

04/06/2020 COVID-19 & Stem Cell Graft Cryopreservation: What’s the Fuss About? https://nucleus.astct.org/Full-Article/ArtMID/393/ArticleID/56/COVID-19-and-Stem-Cell-Graft-Cryopreservation-What%e2%80%99s-the-Fuss-About

04/15/2020 COVID-19 Effect on Transplantation for Patients with Hematologic Malignancies.https://www.oncnet.com/videos/covid-19-effect-transplantation-patients-hematologic-malignancies

04/21/2020 COVID-19 and Cancer Care. The ASCO Post. https://www.ascopost.com/videos/covid-19-and-cancer-care/mehdi-hamadani-on-delaying-autologous-transplant-in-patients-with-dlbcl-during-the-pandemic/

04/28/2020 Benefits and Risks of Cell Therapies for Relapsed/Refractory MCL. Oncology Learning Network.https://www.oncnet.com/videos/benefits-and-risks-cell-therapies-relapsedrefractory-mcl

03/18/2021 What are the options for cell-based therapies in mantle cell lymphoma? LymphomaHub. https://lymphomahub.com/medical-information/what-are-the-options-for-cell-based-therapies-in-mantle-cell-lymphoma

GRANT REVIEWER: 2010 - Present Thrasher Research Fund2011 - Present FDA Orphan Products Research Project Grant (RO1)

BIBLIOGRAPHYRefereed Journal Publications/Original Papers1. Hamadani M, Kharfan-Dabaja M, Kamble R, Awab A, William K, Ozer H Primary Malignant Lymphoma of

the Uterus. An Extranodal Lymphoma with an Ominous Five Year Survival. Pakistan Journal ofRadiology. 2004 October-December;15(4):11-17

2. Hamadani M, Tfayli A, Sethi S, Awab A, Hamdani N. Granulocytic sarcoma manifesting as multiple skeletallesions. Am J Med Sci. 2005 Sep;330(3):139-43.

3. Kamble RT, Hamadani M, Selby GB. Increased mean corpuscular volume after autologous hematopoieticstem cell transplantation: incidence and significance. Biol Blood Marrow Transplant. 2006Jan;12(1):111-2.

4. Kamble RT, Hamadani M, Selby GB. Delayed myeloid engraftment due to vancomycin in allogeneic

23 / 59

haematopoietic stem cell transplant recipients. J Antimicrob Chemother. 2006 Apr;57(4):795-6. 5. Hamadani M, Kharfan-Dabaja M, Kamble R, Kern W, Ozer H. Marginal zone B-cell lymphoma of the

uterus: a case report and review of the literature. J Okla State Med Assoc. 2006 Apr;99(4):154-6. 6. Hamadani M, Awab A, Rashid A, Ali T, Brown B. Fibrous dysplasia protuberans in a patient with McCune-

Albright syndrome. J Coll Physicians Surg Pak. 2006 May;16(5):376-7. 7. Hamadani M, Awab A, Chaudhary L, Tfayli A. Relative efficacy of ondansetron, granisetron, dolasetron and

palonosetron in controlling acute nausea and vomiting associated with platinum-based chemotherapy. JOncol Pharm Pract. 2006 Jun;12(2):67-8.

8. Awab A, Hamadani M, Sud B, Voskuhl GW. Infected atrial myxoma. Med J Aust. 2006 Sep 18;185(6):332. 9. Awab A, Hamadani M, Saya S, Whitsett T. Early detection of digitalis-induced nonocclusive mesenteric

ischemia using Doppler ultrasonography. South Med J. 2006 Oct;99(10):1142. 10. Hamadani M, Awan F. Role of thiamine in managing ifosfamide-induced encephalopathy. J Oncol Pharm

Pract. 2006 Dec;12(4):237-9. 11. Tfayli A, Selby G, Maqbool F, Bierbaum W, Hamadani M. Role of intra-arterial steroid administration in

the management of steroid-refractory acute gastrointestinal graft-versus-host disease. Am J Hematol.2006 Dec;81(12):959-62.

12. Hamadani M, Chaudhary L. McCune-Albright syndrome. Med J Aust. 2006 Dec 4-18;185(11-12):597. 13. Hamadani M, Martin LK, Benson DM, Copelan EA, Devine SM, Hofmeister CC. Central nervous system

post-transplant lymphoproliferative disorder despite negative serum and spinal fluid Epstein-Barr virusDNA PCR. Bone Marrow Transplant. 2007 Feb;39(4):249-51.

14. Ali T, Hasan M, Hamadani M, Harty RF. Gastroparesis. South Med J. 2007 Mar;100(3):281-6. 15. Awan F, Hamadani M. Gastrointestinal chronic graft-versus-host disease: management options. J Oncol

Pharm Pract. 2007 Mar;13(1):49-51. 16. Hamadani M, Benson DM Jr, Copelan EA. Thalidomide-induced fulminant hepatic failure. Mayo Clin Proc.

2007 May;82(5):638. 17. Hamadani M, Chaudhary L, Awan FT, Khan JK, Kojouri K, Ozer H, Tfayli A. Management of platinum-

based chemotherapy-induced acute nausea and vomiting: is there a superior serotonin receptorantagonist? J Oncol Pharm Pract. 2007 Jun;13(2):69-75.

18. Awan F, Hamadani M, Devine S. Paraneoplastic Sweet's syndrome and the pathergy phenomenon. AnnHematol. 2007 Aug;86(8):613-4.

19. Rashid A, Afaq A, Hamadani M, Warraich J, Hennebry T. An unusual etiology of chest pain. J Okla StateMed Assoc. 2007 Sep;100(9):352-3.

20. Awab A, Hamadani M, Peyton M, Brown B. False-negative PET scan with bronchioloalveolar carcinoma:an important diagnostic caveat. Am J Med Sci. 2007 Oct;334(4):311-3.

21. Vrindavanam N, Hamadani M, Steele B, Awan F, Suster S, Benson DM Jr. Dramatic response to single-agent rituximab in a patient with intravascular lymphoma. Am J Hematol. 2007 Dec;82(12):1120-1.

22. Hamadani M, Magro CM, Porcu P. CD4+ CD56+ haematodermic tumour (plasmacytoid dendritic cellneoplasm). Br J Haematol. 2008 Jan;140(2):122.

23. Hamadani M, Benson DM Jr, Blum W, Garzon R, Devine SM. Pulmonary Nocardia and Aspergillus co-infection in a patient with chronic graft-versus-host disease. Transpl Infect Dis. 2008 Feb;10(1):24-6.

24. Hamadani M, Hade E, Benson DM Jr, Hofmeister CC. The effect of statin use at the time of autologoustransplant on response and survival in multiple myeloma. Biol Blood Marrow Transplant. 2008Mar;14(3):351-2.

25. Hamadani M, Kraut EH. Review: isolated skeletal involvement in hairy cell leukemia. Clin Adv HematolOncol. 2008 Apr;6(4):294-6.

26. Hamadani M, Awan FT, Elder P, Lin TS, Porcu P, Blum KA, Devine SM. Allogeneic hematopoietic stemcell transplantation for peripheral T cell lymphomas; evidence of graft-versus-T cell lymphoma effect.Biol Blood Marrow Transplant. 2008 Apr;14(4):480-3.

27. Hamadani M, Awan FT, Devine SM. The impact of HMG-CoA reductase inhibition on the incidence andseverity of graft-versus-host disease in patients with acute leukemia undergoing allogeneictransplantation. Blood. 2008 Apr 01;111(7):3901-2.

28. Hamadani M, Awan FT, Copelan EA. Hematopoietic stem cell transplantation in adults with acute myeloidleukemia. Biol Blood Marrow Transplant. 2008 May;14(5):556-67.

29. Hamadani M, Hofmeister CC, Jansak B, Phillips G, Elder P, Blum W, Penza S, Lin TS, Klisovic R,Marcucci G, Farag SS, Devine SM. Addition of infliximab to standard acute graft-versus-host diseaseprophylaxis following allogeneic peripheral blood cell transplantation. Biol Blood Marrow Transplant.

24 / 59

2008 Jul;14(7):783-9. PMCID: PMC410072230. Hamadani M, Awan FT, Elder P, Lin TS, Porcu P, Benson DM, Blum KA, Devine SM. Feasibility of

allogeneic hematopoietic stem cell transplantation for follicular lymphoma undergoing transformationto diffuse large B-cell lymphoma. Leuk Lymphoma. 2008 Oct;49(10):1893-8.

31. Ferreri AJ, Dognini GP, Govi S, Crocchiolo R, Bouzani M, Bollinger CR, D'Incan M, Delaporte E, Hamadani M, Jardin F, Martusewicz-Boros M, Montanari M, Szomor A, Zucca E, Cavalli F, PonzoniM. Can rituximab change the usually dismal prognosis of patients with intravascular large B-celllymphoma? J Clin Oncol. 2008 Nov 01;26(31):5134-6; author reply 5136-7.

32. Hamadani M, Benson DM Jr, Lin TS, Porcu P, Blum KA, Devine SM. High-dose therapy and autologousstem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-celllymphoma. Eur J Haematol. 2008 Dec;81(6):425-31.

33. Hamadani M, Blum W Role of hematopoietic stem cell transplantation in adults with acute myeloidleukemia. Clinical Leukemia. Hamadani M., Blum W.: “Role of hematopoietic stem celltransplantation in adults with acute myeloid leukemia.” Clinical Leukemia. 2009 February;3(1):47-57

34. Blum KA, Hamadani M, Phillips GS, Lozanski G, Johnson AJ, Lucas DM, Smith LL, Baiocchi R, Lin TS,Porcu P, Devine SM, Byrd JC. Prolonged myelosuppression with clofarabine in the treatment ofpatients with relapsed or refractory, aggressive non-Hodgkin lymphoma. Leuk Lymphoma. 2009Mar;50(3):349-56. PMCID: PMC3695225

35. Hamadani M, Benson DM Jr, Hofmeister CC, Elder P, Blum W, Porcu P, Garzon R, Blum KA, Lin TS,Marcucci G, Devine SM. Allogeneic stem cell transplantation for patients with relapsedchemorefractory aggressive non-hodgkin lymphomas. Biol Blood Marrow Transplant. 2009May;15(5):547-53. PMCID: PMC3953134

36. Hamadani M, Devine SM. Reduced-intensity conditioning allogeneic stem cell transplantation in HIVpatients with hematologic malignancies: yes, we can. Blood. 2009 Sep 17;114(12):2564-6.

37. Hamadani M, Blum W, Phillips G, Elder P, Andritsos L, Hofmeister C, O'Donnell L, Klisovic R, Penza S,Garzon R, Krugh D, Lin T, Bechtel T, Benson DM, Byrd JC, Marcucci G, Devine SM. Improvednonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patientsundergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies.Biol Blood Marrow Transplant. 2009 Nov;15(11):1422-30. PMCID: PMC3953136

38. Pant S, Hamadani M, Dodds AJ, Szer J, Crilley PA, Stevenson D, Phillips G, Elder P, Nivison-Smith I,Avalos BR, Penza S, Topolsky D, Sobecks R, Kalaycio M, Bolwell BJ, Copelan EA. Incidence andreasons for late failure after allogeneic haematopoietic cell transplantation following BuCy2 in acutemyeloid leukaemia. Br J Haematol. 2010 Feb;148(4):623-6.

39. Benson DM Jr, Panzner K, Hamadani M, Hofmeister CC, Bakan CE, Smith MK, Elder P, Krugh D,O'Donnell L, Devine SM. Effects of induction with novel agents versus conventional chemotherapy onmobilization and autologous stem cell transplant outcomes in multiple myeloma. Leuk Lymphoma.2010 Feb;51(2):243-51. PMCID: PMC3557809

40. Hamadani M, Awan F, Villalona-Calero MA. Malignant thymoma with immunodeficiency (Goodsyndrome) associated with mucormycosis. Am J Clin Oncol. 2010 Feb;33(1):109.

41. Hamadani M, Awan FT. Remission induction, consolidation and novel agents in development for adultswith acute myeloid leukaemia. Hematol Oncol. 2010 Mar;28(1):3-12.

42. Hamadani M, Craig M, Awan FT, Devine SM. How we approach patient evaluation for hematopoietic stemcell transplantation. Bone Marrow Transplant. 2010 Aug;45(8):1259-68.

43. Christian B, Zhao W, Hamadani M, Sotomayor EM, Navarro W, Devine SM, Racke F, Blum KA. Mantlecell lymphoma 12 years after allogeneic bone marrow transplantation occurring simultaneously inrecipient and donor. J Clin Oncol. 2010 Nov 01;28(31):e629-32.

44. Hamadani M, Craig MD, Gibson LF, Remick SC. The evolving role of statins in hematopoietic stem andprogenitor cell transplantation. Am J Blood Res. 2011;1(1):57-64. PMCID: PMC3301410

45. Kanate AS, Craig M, Cumpston A, Saad A, Hobbs G, Leadmon S, Bunner P, Watkins K, Bulian D, GibsonL, Abraham J, Remick SC, Hamadani M. Higher infused CD34+ cell dose and overall survival inpatients undergoing in vivo T-cell depleted, but not t-cell repleted, allogeneic peripheral bloodhematopoietic cell transplantation. Hematol Oncol Stem Cell Ther. 2011;4(4):149-56.

46. Liu K, Anthony BA, Yearsly MM, Hamadani M, Gaughan A, Wang JJ, Devine SM, Hadley GA. CD103deficiency prevents graft-versus-host disease but spares graft-versus-tumor effects mediated byalloreactive CD8 T cells. PLoS One. 2011;6(7):e21968. PMCID: PMC3136479

47. Kumar S, Zhang MJ, Li P, Dispenzieri A, Milone GA, Lonial S, Krishnan A, Maiolino A, Wirk B, Weiss B,Freytes CO, Vogl DT, Vesole DH, Lazarus HM, Meehan KR, Hamadani M, Lill M, Callander NS,

25 / 59

Majhail NS, Wiernik PH, Nath R, Kamble RT, Vij R, Kyle RA, Gale RP, Hari PN. Trends inallogeneic stem cell transplantation for multiple myeloma: a CIBMTR analysis. Blood. 2011 Aug18;118(7):1979-88. PMCID: PMC3158724

48. Hamadani M, Mohty M, Kharfan-Dabaja MA. Reduced-intensity conditioning allogeneic hematopoietic celltransplantation in adults with acute myeloid leukemia. Cancer Control. 2011 Oct;18(4):237-45.

49. Hamadani M, Craig M, Phillips GS, Abraham J, Tse W, Cumpston A, Gibson L, Remick SC, Bunner P,Leadmon S, Elder P, Hofmeister C, Penza S, Efebera Y, Andritsos L, Garzon R, Benson DM Jr, BlumW, Devine SM. Higher busulfan dose intensity does not improve outcomes of patients undergoingallogeneic haematopoietic cell transplantation following fludarabine, busulfan-based reduced toxicityconditioning. Hematol Oncol. 2011 Dec;29(4):202-10. PMCID: PMC3557914

50. Chaudhary L, Hamadani M Management strategies for follicular lymphoma patients in remission aftermodern frontline chemoimmunotherapies. Journal of Blood Disorders & Transfusion. Chaudhary L, Hamadani M (2012) Management Strategies for Follicular Lymphoma patients in Remission afterModern Frontline Chemoimmunotherapies. J Blood Disorders Transf 3:e105

51. Kanate AS, Kharfan-Dabaja MA, Hamadani M. Controversies and recent advances in hematopoietic celltransplantation for follicular non-hodgkin lymphoma. Bone Marrow Res. 2012;2012:897215. PMCID:PMC3477524

52. Awan FT, Kochuparambil ST, Deremer D, Cumpston A, Craig M, Jillella A, Hamadani M. PlerixaforSalvage Is Safe and Effective in Hard-to-Mobilize Patients Undergoing Chemotherapy and Filgrastim-Based Peripheral Blood Progenitor Cell Mobilization. J Oncol. 2012;2012:931071. PMCID:PMC3335320

53. Awan FT, Osman S, Kochuparambil ST, Gibson L, Remick SC, Abraham J, Craig M, Jillella A, HamadaniM. Impact of response to thalidomide-, lenalidomide- or bortezomib- containing induction therapy onthe outcomes of multiple myeloma patients undergoing autologous transplantation. Bone MarrowTransplant. 2012 Jan;47(1):146-8.

54. Ranganathan P, Heaphy CE, Costinean S, Stauffer N, Na C, Hamadani M, Santhanam R, Mao C, TaylorPA, Sandhu S, He G, Shana'ah A, Nuovo GJ, Lagana A, Cascione L, Obad S, Broom O, Kauppinen S,Byrd JC, Caligiuri M, Perrotti D, Hadley GA, Marcucci G, Devine SM, Blazar BR, Croce CM, GarzonR. Regulation of acute graft-versus-host disease by microRNA-155. Blood. 2012 May17;119(20):4786-97. PMCID: PMC3367879

55. Hamadani M, Kochuparambil ST, Osman S, Cumpston A, Leadmon S, Bunner P, Watkins K, Morrison D,Speir E, Deremer D, Kota V, Jillella A, Craig M, Awan F. Intermediate-dose versus low-dosecyclophosphamide and granulocyte colony-stimulating factor for peripheral blood stem cellmobilization in patients with multiple myeloma treated with novel induction therapies. Biol BloodMarrow Transplant. 2012 Jul;18(7):1128-35.

56. Ballen KK, Woolfrey AE, Zhu X, Ahn KW, Wirk B, Arora M, George B, Savani BN, Bolwell B, Porter DL,Copelan E, Hale G, Schouten HC, Lewis I, Cahn JY, Halter J, Cortes J, Kalaycio ME, Antin J, AljurfMD, Carabasi MH, Hamadani M, McCarthy P, Pavletic S, Gupta V, Deeg HJ, Maziarz RT, HorowitzMM, Saber W. Allogeneic hematopoietic cell transplantation for advanced polycythemia vera andessential thrombocythemia. Biol Blood Marrow Transplant. 2012 Sep;18(9):1446-54. PMCID:PMC3499973

57. Ross AL, Slain D, Cumpston A, Bryant AM, Hamadani M, Craig M. Evaluation of an alternativeposaconazole prophylaxis regimen in haematological malignancy patients receiving concomitant stressulcer prophylaxis. Int J Antimicrob Agents. 2012 Dec;40(6):557-61.

58. Sweet MA, Cumpston A, Briggs F, Craig M, Hamadani M. Impact of alcohol-impregnated port protectorsand needleless neutral pressure connectors on central line-associated bloodstream infections andcontamination of blood cultures in an inpatient oncology unit. Am J Infect Control. 2012Dec;40(10):931-4.

59. Kharfan-Dabaja MA, Hamadani M, Reljic T, Nishihori T, Bensinger W, Djulbegovic B, Kumar A.Comparative efficacy of tandem autologous versus autologous followed by allogeneic hematopoieticcell transplantation in patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. J Hematol Oncol. 2013 Jan 04;6:2. PMCID: PMC3548722

60. Veltri L, Regier M, Cumpston A, Leadmon S, Tse W, Craig M, Hamadani M. Incidence and Pattern ofGraft-versus-Host Disease in Patients Undergoing Allogeneic Transplantation after NonmyeloablativeConditioning with Total Lymphoid Irradiation and Antithymocyte Globulin. Bone Marrow Res.2013;2013:414959. PMCID: PMC3652129

61. Maramattom LV, Hari PN, Burns LJ, Carreras J, Arcese W, Cairo MS, Costa LJ, Fenske TS, Lill M, Freytes

26 / 59

CO, Gale RP, Gross TG, Hale GA, Hamadani M, Holmberg LA, Hsu JW, Inwards DJ, Lazarus HM,Marks DI, Maloney DG, Maziarz RT, Montoto S, Rizzieri DA, Wirk B, Gajewski JL. Autologous andallogeneic transplantation for burkitt lymphoma outcomes and changes in utilization: a report from thecenter for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2013Feb;19(2):173-9. PMCID: PMC3553321

62. Cumpston A, Craig M, Hamadani M, Abraham J, Hobbs GR, Sarwari AR. Extended follow-up of anantibiotic cycling program for the management of febrile neutropenia in a hematologic malignancy andhematopoietic cell transplantation unit. Transpl Infect Dis. 2013 Apr;15(2):142-9.

63. Hamadani M, Saber W, Ahn KW, Carreras J, Cairo MS, Fenske TS, Gale RP, Gibson J, Hale GA, Hari PN,Hsu JW, Inwards DJ, Kamble RT, Klein A, Maharaj D, Marks DI, Rizzieri DA, Savani BN, SchoutenHC, Waller EK, Wirk B, Lazarus HM. Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: a cohort analysis from the center for international blood andmarrow transplant research. Biol Blood Marrow Transplant. 2013 Apr;19(4):625-31. PMCID:PMC3640440

64. Hamadani M, Saber W, Ahn KW, Carreras J, Cairo MS, Fenske TS, Gale RP, Gibson J, Hale GA, Hari PN,Hsu JW, Inwards DJ, Kamble RT, Klein A, Maharaj D, Marks DI, Rizzieri DA, Savani BN, SchoutenHC, Waller EK, Wirk B, Laport GG, Montoto S, Maloney DG, Lazarus HM. Impact ofpretransplantation conditioning regimens on outcomes of allogeneic transplantation for chemotherapy-unresponsive diffuse large B cell lymphoma and grade III follicular lymphoma. Biol Blood MarrowTransplant. 2013 May;19(5):746-53. PMCID: PMC3650915

65. Kharfan-Dabaja MA, Lazarus HM, Nishihori T, Mahfouz RA, Hamadani M. Diagnostic and therapeuticadvances in blastic plasmacytoid dendritic cell neoplasm: a focus on hematopoietic celltransplantation. Biol Blood Marrow Transplant. 2013 Jul;19(7):1006-12.

66. Kanate AS, Watkins K, Cumpston A, Craig M, Hamadani M. Salvage bone marrow harvest in patientsfailing plerixafor-based stem cell mobilization attempt: feasibility and autologous transplantationoutcomes. Biol Blood Marrow Transplant. 2013 Jul;19(7):1133-5.

67. Hamadani M. Reappraising the role of autologous transplantation for indolent B-cell lymphomas in thechemoimmunotherapy era: is it still relevant? Bone Marrow Transplant. 2013 Aug;48(8):1013-21.

68. Kharfan-Dabaja MA, Nishihori T, Otrock ZK, Haidar N, Mohty M, Hamadani M. Monoclonal antibodies inconditioning regimens for hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2013Sep;19(9):1288-300.

69. Hamadani M, Kanate AS Dawn of a new era: targeting the B-cell receptor signaling pathway to conquer B-cell lymphomas. Community Oncology. Hamadani M., Kanate AS.: “Dawn of a new era: targetingthe B-cell receptor signaling pathway to conquer B-cell lymphomas.” Community Oncology. 2013October;10(10):279-281

70. Awan F, Kochuparambil ST, Falconer DE, Cumpston A, Leadmon S, Watkins K, Deremer D, Jillella A,Craig M, Hamadani M. Comparable efficacy and lower cost of PBSC mobilization with intermediate-dose cyclophosphamide and G-CSF compared with plerixafor and G-CSF in patients with multiplemyeloma treated with novel therapies. Bone Marrow Transplant. 2013 Oct;48(10):1279-84.

71. Chaudhary L, Awan F, Cumpston A, Leadmon S, Watkins K, Tse W, Craig M, Hamadani M. Peripheralblood stem cell mobilization in multiple myeloma patients treat in the novel therapy-era with plerixaforand G-CSF has superior efficacy but significantly higher costs compared to mobilization with low-dose cyclophosphamide and G-CSF. J Clin Apher. 2013 Oct;28(5):359-67.

72. Chaudhary L, Kharfan-Dabaja MA, Hari P, Hamadani M. Is hematopoietic cell transplantation still a validoption for mantle cell lymphoma in first remission in the chemoimmunotherapy-era? Bone MarrowTransplant. 2013 Nov;48(12):1489-96.

73. Kharfan-Dabaja MA, Hamadani M, Reljic T, Pyngolil R, Komrokji RS, Lancet JE, Fernandez HF,Djulbegovic B, Kumar A. Gemtuzumab ozogamicin for treatment of newly diagnosed acute myeloidleukaemia: a systematic review and meta-analysis. Br J Haematol. 2013 Nov;163(3):315-25.

74. Palla AR, Hamadani M. Rituximab maintenance versus retreatment in follicular lymphoma. Hematol Oncol.2013 Dec;31(4):171-8.

75. Copelan EA, Hamilton BK, Avalos B, Ahn KW, Bolwell BJ, Zhu X, Aljurf M, van Besien K, Bredeson C,Cahn JY, Costa LJ, de Lima M, Gale RP, Hale GA, Halter J, Hamadani M, Inamoto Y, Kamble RT,Litzow MR, Loren AW, Marks DI, Olavarria E, Roy V, Sabloff M, Savani BN, Seftel M, SchoutenHC, Ustun C, Waller EK, Weisdorf DJ, Wirk B, Horowitz MM, Arora M, Szer J, Cortes J, KalaycioME, Maziarz RT, Saber W. Better leukemia-free and overall survival in AML in first remissionfollowing cyclophosphamide in combination with busulfan compared with TBI. Blood. 2013 Dec

27 / 59

05;122(24):3863-70. PMCID: PMC385410876. Hamadani M, Gibson LF, Remick SC, Wen S, Petros W, Tse W, Brundage KM, Vos JA, Cumpston A,

Bunner P, Craig MD. Sibling donor and recipient immune modulation with atorvastatin for theprophylaxis of acute graft-versus-host disease. J Clin Oncol. 2013 Dec 10;31(35):4416-23. PMCID:PMC3842909

77. Gupta V, Malone AK, Hari PN, Ahn KW, Hu ZH, Gale RP, Ballen KK, Hamadani M, Olavarria E, GerdsAT, Waller EK, Costa LJ, Antin JH, Kamble RT, van Besien KM, Savani BN, Schouten HC, Szer J,Cahn JY, de Lima MJ, Wirk B, Aljurf MD, Popat U, Bejanyan N, Litzow MR, Norkin M, Lewis ID,Hale GA, Woolfrey AE, Miller AM, Ustun C, Jagasia MH, Lill M, Maziarz RT, Cortes J, KalaycioME, Saber W. Reduced-intensity hematopoietic cell transplantation for patients with primarymyelofibrosis: a cohort analysis from the center for international blood and marrow transplantresearch. Biol Blood Marrow Transplant. 2014 Jan;20(1):89-97. PMCID: PMC3886623

78. Hamadani M, Abu Kar SM, Usmani SZ, Savani BN, Ayala E, Kharfan-Dabaja MA. Management ofrelapses after hematopoietic cell transplantation in T-cell non-Hodgkin lymphomas. Semin Hematol.2014 Jan;51(1):73-86.

79. Truong Q, Shah N, Knestrick M, Curley B, Hu Y, Craig M, Hamadani M. Limited utility of surveillanceimaging for detecting disease relapse in patients with non-Hodgkin lymphoma in first completeremission. Clin Lymphoma Myeloma Leuk. 2014 Feb;14(1):50-5.

80. Truong Q, Shah N, Knestrick M, Curley B, Hu Y, Craig M, Hamadani M. Limited utility of surveillanceimaging for detecting disease relapse in patients with non-Hodgkin lymphoma in first completeremission. Clin Lymphoma Myeloma Leuk. 2014 Feb;14(1):50-5.

81. Fenske TS, Zhang MJ, Carreras J, Ayala E, Burns LJ, Cashen A, Costa LJ, Freytes CO, Gale RP, HamadaniM, Holmberg LA, Inwards DJ, Lazarus HM, Maziarz RT, Munker R, Perales MA, Rizzieri DA,Schouten HC, Smith SM, Waller EK, Wirk BM, Laport GG, Maloney DG, Montoto S, Hari PN.Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation forchemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality. J ClinOncol. 2014 Feb 01;32(4):273-81. PMCID: PMC3897255

82. Hamadani M. Antithymocyte globulin in reduced-intensity conditioning allografting: is the benefit simplyin the eyes of the transplanter? Biol Blood Marrow Transplant. 2014 Mar;20(3):292-4.

83. Rauenzahn S, Truong Q, Cumpston A, Goff L, Leadmon S, Evans K, Zhang J, Wen S, Craig M, HamadaniM, Kanate AS. Predictors and impact of thirty-day readmission on patient outcomes and health carecosts after reduced-toxicity conditioning allogeneic hematopoietic cell transplantation. Biol BloodMarrow Transplant. 2014 Mar;20(3):415-20. PMCID: PMC4557764

84. Truong Q, Veltri L, Kanate AS, Hu Y, Craig M, Hamadani M, Cumpston A. Impact of the duration ofantiviral prophylaxis on rates of varicella-zoster virus reactivation disease in autologous hematopoieticcell transplantation recipients. Ann Hematol. 2014 Apr;93(4):677-82.

85. Kanate AS, Pasquini MC, Hari PN, Hamadani M. Allogeneic hematopoietic cell transplant for acutemyeloid leukemia: Current state in 2013 and future directions. World J Stem Cells. 2014 Apr26;6(2):69-81. PMCID: PMC3999783

86. Kharfan-Dabaja MA, Hamadani M, Sibai H, Savani BN. Managing Hodgkin lymphoma relapsing afterautologous hematopoietic cell transplantation: a not-so-good cancer after all! Bone Marrow Transplant.2014 May;49(5):599-606.

87. Duléry R, Mohty M, Duhamel A, Robin M, Beguin Y, Michallet M, Vigouroux S, Lioure B, Garnier A, ElCheikh J, Bulabois CE, Huynh A, Bay JO, Daguindau E, Ceballos P, Clément L, Dauriac C, MaillardN, Legrand F, Cornillon J, Guillerm G, François S, Lapusan S, Chevallier P, Damaj G, Yakoub-AghaI. Antithymocyte globulin before allogeneic stem cell transplantation for progressive myelodysplasticsyndrome: a study from the French Society of Bone Marrow Transplantation and Cellular Therapy.Biol Blood Marrow Transplant. 2014 May;20(5):646-54.

88. Michaelis LC, Hamadani M, Hari PN. Hematopoietic stem cell transplantation in older persons: respectingthe heterogeneity of age. Expert Rev Hematol. 2014 Jun;7(3):321-4.

89. Hamadani M, Vos JA, Craig MD. Reply to S. Fuji et al. J Clin Oncol. 2014 Jun 10;32(17):1860-1. 90. Wirk B, Fenske TS, Hamadani M, Zhang MJ, Hu ZH, Akpek G, Aljurf MD, Armand P, Ayala E,

Bachanova V, Bolwell B, Cairo MS, Cashen A, Chen YB, Costa LJ, Farhan S, Freytes CO, GajewskiJL, Gibson J, Hale GA, Holmberg LA, Hsu JW, Inwards DJ, Kamble RT, Maharaj D, Maziarz RT,Munker R, Nath R, Reddy NM, Reeder CB, Rizzieri DA, Sauter CS, Savani BN, Schouten HC, SuredaA, Vose JM, Waller EK, Wiernik PH, Gale RP, Burns LJ, Saber W. Outcomes of hematopoietic celltransplantation for diffuse large B cell lymphoma transformed from follicular lymphoma. Biol Blood

28 / 59

Marrow Transplant. 2014 Jul;20(7):951-9. PMCID: PMC406043691. McClune BL, Ahn KW, Wang HL, Antin JH, Artz AS, Cahn JY, Deol A, Freytes CO, Hamadani M,

Holmberg LA, Jagasia MH, Jakubowski AA, Kharfan-Dabaja MA, Lazarus HM, Miller AM, OlssonR, Pedersen TL, Pidala J, Pulsipher MA, Rowe JM, Saber W, van Besien KW, Waller EK, Aljurf MD,Akpek G, Bacher U, Chao NJ, Chen YB, Cooper BW, Dehn J, de Lima MJ, Hsu JW, Lewis ID, MarksDI, McGuirk J, Cairo MS, Schouten HC, Szer J, Ramanathan M, Savani BN, Seftel M, Socie G, Vij R,Warlick ED, Weisdorf DJ. Allotransplantation for patients age ?40 years with non-Hodgkinlymphoma: encouraging progression-free survival. Biol Blood Marrow Transplant. 2014Jul;20(7):960-8. PMCID: PMC4057955

92. Hamadani M, Hari PN, Zhang Y, Carreras J, Akpek G, Aljurf MD, Ayala E, Bachanova V, Chen AI, ChenYB, Costa LJ, Fenske TS, Freytes CO, Ganguly S, Hertzberg MS, Holmberg LA, Inwards DJ, KambleRT, Kanfer EJ, Lazarus HM, Marks DI, Nishihori T, Olsson R, Reddy NM, Rizzieri DA, Savani BN,Solh M, Vose JM, Wirk B, Maloney DG, Smith SM, Montoto S, Saber W, Alpdogan O, Cashen A,Dandoy C, Finke R, Gale R, Gibson J, Hsu JW, Janakiraman N, Laughlin MJ, Lill M, Cairo MS,Munker R, Rowlings PA, Schouten HC, Shea TC, Stiff PJ, Waller EK. Early failure of frontlinerituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futilityof autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2014Nov;20(11):1729-36. PMCID: PMC4194275

93. Kumar SK, Berdeja JG, Niesvizky R, Lonial S, Laubach JP, Hamadani M, Stewart AK, Hari P, Roy V,Vescio R, Kaufman JL, Berg D, Liao E, Di Bacco A, Estevam J, Gupta N, Hui AM, Rajkumar V,Richardson PG. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination withlenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. Lancet Oncol. 2014 Dec;15(13):1503-1512.

94. Dhakal B, Strouse C, D'Souza A, Arce-Lara C, Esselman J, Eastwood D, Pasquini M, Saber W, Drobyski W,Rizzo JD, Hari PN, Hamadani M. Plerixafor and abbreviated-course granulocyte colony-stimulatingfactor for mobilizing hematopoietic progenitor cells in light chain amyloidosis. Biol Blood MarrowTransplant. 2014 Dec;20(12):1926-31.

95. Hamadani M. Autologous hematopoietic cell transplantation: an update for clinicians. Ann Med. 2014Dec;46(8):619-32.

96. Copelan EA, Avalos BR, Ahn KW, Zhu X, Gale RP, Grunwald MR, Hamadani M, Hamilton BK, Hale GA,Marks DI, Waller EK, Savani BN, Costa LJ, Ramanathan M, Cahn JY, Khoury HJ, Weisdorf DJ,Inamoto Y, Kamble RT, Schouten HC, Wirk B, Litzow MR, Aljurf MD, van Besien KW, Ustun C,Bolwell BJ, Bredeson CN, Fasan O, Ghosh N, Horowitz MM, Arora M, Szer J, Loren AW, Alyea EP,Cortes J, Maziarz RT, Kalaycio ME, Saber W. Comparison of outcomes of allogeneic transplantationfor chronic myeloid leukemia with cyclophosphamide in combination with intravenous busulfan, oralbusulfan, or total body irradiation. Biol Blood Marrow Transplant. 2015 Mar;21(3):552-8. PMCID:PMC4329042

97. Dhakal B, Singavi A, Cohen EP, Dangal M, Palmer J, Dall A, D'Souza A, Hamadani M, Hari PN. ChronicGVHD and concurrent new-onset nephrotic syndrome in allogeneic transplant recipients. Incidence,pattern and therapeutic outcomes. Bone Marrow Transplant. 2015 Mar;50(3):449-51.

98. Police RL, Trask PC, Wang J, Olivares R, Khan S, Abbe A, Colosia A, Njue A, Sherrill B, Ruiz-Soto R,Kaye JA, Hamadani M. Randomized controlled trials in relapsed/refractory chronic lymphocyticleukemia: a systematic review and meta-analysis. Clin Lymphoma Myeloma Leuk. 2015Apr;15(4):199-207.

99. Dhakal B, D'Souza A, Arce-Lara C, Pasquini M, Saber W, Falvo F, Esselman J, Zellner K, Fenske T, HariPN, Hamadani M. Superior efficacy but higher cost of plerixafor and abbreviated-course G-CSF formobilizing hematopoietic progenitor cells (HPC) in AL amyloidosis. Bone Marrow Transplant. 2015Apr;50(4):610-2.

100. Cooper BW, Kindwall-Keller TL, Craig MD, Creger RJ, Hamadani M, Tse WW, Lazarus HM. A phase Istudy of midostaurin and azacitidine in relapsed and elderly AML patients. Clin Lymphoma MyelomaLeuk. 2015 Jul;15(7):428-432.e2. PMCID: PMC4484305

101. Shah N, Callander N, Ganguly S, Gul Z, Hamadani M, Costa L, Sengsayadeth S, Abidi M, Hari P, MohtyM, Chen YB, Koreth J, Landau H, Lazarus H, Leather H, Majhail N, Nath R, Osman K, Perales MA,Schriber J, Shaughnessy P, Vesole D, Vij R, Wingard J, Giralt S, Savani BN, American Society forBlood and Marrow Transplantation. Hematopoietic Stem Cell Transplantation for Multiple Myeloma:Guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood MarrowTransplant. 2015 Jul;21(7):1155-66.

29 / 59

102. Inamoto Y, Shah NN, Savani BN, Shaw BE, Abraham AA, Ahmed IA, Akpek G, Atsuta Y, Baker KS,Basak GW, Bitan M, DeFilipp Z, Gregory TK, Greinix HT, Hamadani M, Hamilton BK, Hayashi RJ,Jacobsohn DA, Kamble RT, Kasow KA, Khera N, Lazarus HM, Malone AK, Lupo-Stanghellini MT,Margossian SP, Muffly LS, Norkin M, Ramanathan M, Salooja N, Schoemans H, Wingard JR, WirkB, Wood WA, Yong A, Duncan CN, Flowers ME, Majhail NS. Secondary solid cancer screeningfollowing hematopoietic cell transplantation. Bone Marrow Transplant. 2015 Aug;50(8):1013-23.PMCID: PMC4989866

103. Goyal SD, Zhang MJ, Wang HL, Akpek G, Copelan EA, Freytes C, Gale RP, Hamadani M, Inamoto Y,Kamble RT, Lazarus HM, Marks DI, Nishihori T, Olsson RF, Reshef R, Ritchie DS, Saber W, SavaniBN, Seber A, Shea TC, Tallman MS, Wirk B, Bunjes DW, Devine SM, de Lima M, Weisdorf DJ, UyGL. Allogeneic hematopoietic cell transplant for AML: no impact of pre-transplant extramedullarydisease on outcome. Bone Marrow Transplant. 2015 Aug;50(8):1057-62. PMCID: PMC4527880

104. Cumpston A, Caddell R, Shillingburg A, Lu X, Wen S, Hamadani M, Craig M, Kanate AS. SuperiorSerum Concentrations with Posaconazole Delayed-Release Tablets Compared to SuspensionFormulation in Hematological Malignancies. Antimicrob Agents Chemother. 2015 Aug;59(8):4424-8.PMCID: PMC4505228

105. Bachanova V, Burns LJ, Ahn KW, Laport GG, Akpek G, Kharfan-Dabaja MA, Nishihori T, Agura E,Armand P, Jaglowski SM, Cairo MS, Cashen AF, Cohen JB, D'Souza A, Freytes CO, Gale RP,Ganguly S, Ghosh N, Holmberg LA, Inwards DJ, Kanate AS, Lazarus HM, Malone AK, Munker R,Mussetti A, Norkin M, Prestidge TD, Rowe JM, Satwani P, Siddiqi T, Stiff PJ, William BM, Wirk B,Maloney DG, Smith SM, Sureda AM, Carreras J, Hamadani M, Center for International Blood andMarrow Transplant Research Lymphoma Working Committee. Impact of Pretransplantation (18)F-fluorodeoxy Glucose-Positron Emission Tomography Status on Outcomes after AllogeneicHematopoietic Cell Transplantation for Non-Hodgkin Lymphoma. Biol Blood Marrow Transplant.2015 Sep;21(9):1605-11. PMCID: PMC4558181

106. Epperla N, Fenske TS, Hari PN, Hamadani M. Recent advances in post autologous transplantationmaintenance therapies in B-cell non-Hodgkin lymphomas. World J Transplant. 2015 Sep 24;5(3):81-8.PMCID: PMC4580930

107. Urbano-Ispizua A, Pavletic SZ, Flowers ME, Klein JP, Zhang MJ, Carreras J, Montoto S, Perales MA,Aljurf MD, Akpek G, Bredeson CN, Costa LJ, Dandoy C, Freytes CO, Fung HC, Gale RP, Gibson J, Hamadani M, Hayashi RJ, Inamoto Y, Inwards DJ, Lazarus HM, Maloney DG, Martino R, MunkerR, Nishihori T, Olsson RF, Rizzieri DA, Reshef R, Saad A, Savani BN, Schouten HC, Smith SM,Socié G, Wirk B, Yu LC, Saber W. The Impact of Graft-versus-Host Disease on the Relapse Rate inPatients with Lymphoma Depends on the Histological Subtype and the Intensity of the ConditioningRegimen. Biol Blood Marrow Transplant. 2015 Oct;21(10):1746-53. PMCID: PMC4568162

108. Hamadani M, Balasubramanian S, Hari PN. Ibrutinib in Refractory Classic Hodgkin's Lymphoma. N EnglJ Med. 2015 Oct;373(14):1381-2.

109. Epperla N, Fenske TS, Lazarus HM, Hamadani M. Post-autologous transplant maintenance therapies inlymphoid malignancies: are we there yet? Bone Marrow Transplant. 2015 Nov;50(11):1393-404.

110. Satwani P, Ahn KW, Carreras J, Abdel-Azim H, Cairo MS, Cashen A, Chen AI, Cohen JB, Costa LJ,Dandoy C, Fenske TS, Freytes CO, Ganguly S, Gale RP, Ghosh N, Hertzberg MS, Hayashi RJ,Kamble RT, Kanate AS, Keating A, Kharfan-Dabaja MA, Lazarus HM, Marks DI, Nishihori T, OlssonRF, Prestidge TD, Rolon JM, Savani BN, Vose JM, Wood WA, Inwards DJ, Bachanova V, Smith SM,Maloney DG, Sureda A, Hamadani M. A prognostic model predicting autologous transplantationoutcomes in children, adolescents and young adults with Hodgkin lymphoma. Bone MarrowTransplant. 2015 Nov;50(11):1416-23. PMCID: PMC4633349

111. Hussain AS, Hari P, Brazauskas R, Arce-Lara C, Pasquini M, Hamadani M, D'Souza A. Changes incardiac biomarkers with bortezomib treatment in patients with advanced cardiac amyloidosis. Am JHematol. 2015 Nov;90(11):E212-3. PMCID: PMC4618044

112. Veltri L, Cumpston A, Shillingburg A, Wen S, Luo J, Leadmon S, Watkins K, Craig M, Hamadani M,Kanate AS. Hematopoietic progenitor cell mobilization with "just-in-time" plerixafor approach is acost-effective alternative to routine plerixafor use. Cytotherapy. 2015 Dec;17(12):1785-92. PMCID:PMC4700501

113. Klyuchnikov E, Bacher U, Kröger NM, Hari PN, Ahn KW, Carreras J, Bachanova V, Bashey A, Cohen JB,D'Souza A, Freytes CO, Gale RP, Ganguly S, Hertzberg MS, Holmberg LA, Kharfan-Dabaja MA,Klein A, Ku GH, Laport GG, Lazarus HM, Miller AM, Mussetti A, Olsson RF, Slavin S, Usmani SZ,Vij R, Wood WA, Maloney DG, Sureda AM, Smith SM, Hamadani M. Reduced-Intensity

30 / 59

Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two FollicularLymphoma Provides Improved Outcomes in Long-Term Survivors. Biol Blood Marrow Transplant.2015 Dec;21(12):2091-2099. PMCID: PMC4639453

114. Uy GL, Costa LJ, Hari PN, Zhang MJ, Huang JX, Anderson KC, Bredeson CN, Callander NS, Cornell RF,Perez MA, Dispenzieri A, Freytes CO, Gale RP, Garfall A, Gertz MA, Gibson J, Hamadani M,Lazarus HM, Kalaycio ME, Kamble RT, Kharfan-Dabaja MA, Krishnan AY, Kumar SK, Kyle RA,Landau HJ, Lee CH, Maiolino A, Marks DI, Mark TM, Munker R, Nishihori T, Olsson RF,Ramanathan M, Rodriguez TE, Saad AA, Savani BN, Schiller GJ, Schouten HC, Schriber JR, Scott E,Seo S, Sharma M, Ganguly S, Stadtmauer EA, Tay J, To LB, Vesole DH, Vogl DT, Wagner JL, WirkB, Wood WA, D'Souza A. Contribution of chemotherapy mobilization to disease control in multiplemyeloma treated with autologous hematopoietic cell transplantation. Bone Marrow Transplant. 2015Dec;50(12):1513-8. PMCID: PMC4548821

115. Nishihori T, Al-Kadhimi Z, Hamadani M, Kharfan-Dabaja MA. Antithymocyte globulin in allogeneichematopoietic cell transplantation: benefits and limitations. Immunotherapy. 2016;8(4):435-47.

116. Turner RB, Cumpston A, Sweet M, Briggs F, Slain D, Wen S, Craig M, Hamadani M, Petros W.Prospective, Controlled Study of Acyclovir Pharmacokinetics in Obese Patients. Antimicrob AgentsChemother. 2016 Jan 11;60(3):1830-3. PMCID: PMC4775958

117. Klyuchnikov E, Bacher U, Woo Ahn K, Carreras J, Kröger NM, Hari PN, Ku GH, Ayala E, Chen AI, ChenYB, Cohen JB, Freytes CO, Gale RP, Kamble RT, Kharfan-Dabaja MA, Lazarus HM, Martino R,Mussetti A, Savani BN, Schouten HC, Usmani SZ, Wiernik PH, Wirk B, Smith SM, Sureda A, Hamadani M. Long-term survival outcomes of reduced-intensity allogeneic or autologoustransplantation in relapsed grade 3 follicular lymphoma. Bone Marrow Transplant. 2016Jan;51(1):58-66. PMCID: PMC4703480

118. Nelson AA, Harrington AM, Kroft S, Dahar MA, Hamadani M, Dhakal B. Presentation and managementof post-allogeneic transplantation EBV-positive mucocutaneous ulcer. Bone Marrow Transplant. 2016Feb;51(2):300-2.

119. Kanate AS, Mussetti A, Kharfan-Dabaja MA, Ahn KW, DiGilio A, Beitinjaneh A, Chhabra S, Fenske TS,Freytes C, Gale RP, Ganguly S, Hertzberg M, Klyuchnikov E, Lazarus HM, Olsson R, Perales MA,Rezvani A, Riches M, Saad A, Slavin S, Smith SM, Sureda A, Yared J, Ciurea S, Armand P, Salit R,Bolaños-Meade J, Hamadani M. Reduced-intensity transplantation for lymphomas usinghaploidentical related donors vs HLA-matched unrelated donors. Blood. 2016 Feb 18;127(7):938-47.PMCID: PMC4760094

120. Kharfan-Dabaja MA, El-Asmar J, Awan FT, Hamadani M, Ayala E. Current state of hematopoietic celltransplantation in CLL as smart therapies emerge. Best Pract Res Clin Haematol. 201603;29(1):54-66.

121. Seftel MD, Neuberg D, Zhang MJ, Wang HL, Ballen KK, Bergeron J, Couban S, Freytes CO, HamadaniM, Kharfan-Dabaja MA, Lazarus HM, Nishihori T, Paulson K, Saber W, Sallan SE, Soiffer R,Tallman MS, Woolfrey AE, DeAngelo DJ, Weisdorf DJ, Acute Leukemia Committee of the CIBMTRand the Dana Farber ALL Consortium. Pediatric-inspired therapy compared to allografting forPhiladelphia chromosome-negative adult ALL in first complete remission. Am J Hematol. 2016Mar;91(3):322-9. PMCID: PMC4764423

122. El-Asmar J, Reljic T, Ayala E, Hamadani M, Nishihori T, Kumar A, Kharfan-Dabaja MA. Efficacy ofHigh-Dose Therapy and Autologous Hematopoietic Cell Transplantation in Peripheral T CellLymphomas as Front-Line Consolidation or in the Relapsed/Refractory Setting: A SystematicReview/Meta-Analysis. Biol Blood Marrow Transplant. 2016 May;22(5):802-14.

123. Chaudhury S, Sparapani R, Hu ZH, Nishihori T, Abdel-Azim H, Malone A, Olsson R, Hamadani M, DalyA, Bacher U, Wirk BM, Kamble RT, Gale RP, Wood WA, Hale G, Wiernik PH, Hashmi SK, Marks D,Ustun C, Munker R, Savani BN, Alyea E, Popat U, Sobecks R, Kalaycio M, Maziarz R, Hijiya N,Saber W. Outcomes of Allogeneic Hematopoietic Cell Transplantation in Children and Young Adultswith Chronic Myeloid Leukemia: A CIBMTR Cohort Analysis. Biol Blood Marrow Transplant. 201606;22(6):1056-1064. PMCID: PMC4877686

124. Dhakal B, D'Souza A, Martens M, Kapke J, Harrington AM, Pasquini M, Saber W, Drobyski WR, ZhangMJ, Hamadani M, Hari PN. Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma:Impact of Disease Risk and Post Allograft Minimal Residual Disease on Survival. Clin LymphomaMyeloma Leuk. 2016 07;16(7):379-86.

125. Fenske TS, Ahn KW, Graff TM, DiGilio A, Bashir Q, Kamble RT, Ayala E, Bacher U, Brammer JE, CairoM, Chen A, Chen YB, Chhabra S, D'Souza A, Farooq U, Freytes C, Ganguly S, Hertzberg M, Inwards

31 / 59

D, Jaglowski S, Kharfan-Dabaja MA, Lazarus HM, Nathan S, Pawarode A, Perales MA, Reddy N, SeoS, Sureda A, Smith SM, Hamadani M. Allogeneic transplantation provides durable remission in asubset of DLBCL patients relapsing after autologous transplantation. Br J Haematol. 201607;174(2):235-48. PMCID: PMC4940282

126. DeFilipp Z, Duarte RF, Snowden JA, Majhail NS, Greenfield DM, Miranda JL, Arat M, Baker KS, BurnsLJ, Duncan CN, Gilleece M, Hale GA, Hamadani M, Hamilton BK, Hogan WJ, Hsu JW, Inamoto Y,Kamble RT, Lupo-Stanghellini MT, Malone AK, McCarthy P, Mohty M, Norkin M, Paplham P,Ramanathan M, Richart JM, Salooja N, Schouten HC, Schoemans H, Seber A, Steinberg A, Wirk BM,Wood WA, Battiwalla M, Flowers MED, Savani BN, Shaw BE, CIBMTR Late Effects and Quality ofLife Working Committee, EBMT Complications and Quality of Life Working Party. MetabolicSyndrome and Cardiovascular Disease after Hematopoietic Cell Transplantation: Screening andPreventive Practice Recommendations from the CIBMTR and EBMT. Biol Blood Marrow Transplant.2016 08;22(8):1493-1503. PMCID: PMC4949101

127. Fenske TS, Hamadani M, Cohen JB, Costa LJ, Kahl BS, Evens AM, Hamlin PA, Lazarus HM, PetersdorfE, Bredeson C. Allogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients withNon-Hodgkin Lymphoma: Increasingly Successful Application to Older Patients. Biol Blood MarrowTransplant. 2016 09;22(9):1543-1551. PMCID: PMC4981559

128. Ghosh N, Karmali R, Rocha V, Ahn KW, DiGilio A, Hari PN, Bachanova V, Bacher U, Dahi P, de LimaM, D'Souza A, Fenske TS, Ganguly S, Kharfan-Dabaja MA, Prestidge TD, Savani BN, Smith SM,Sureda AM, Waller EK, Jaglowski S, Herrera AF, Armand P, Salit RB, Wagner-Johnston ND, FuchsE, Bolaños-Meade J, Hamadani M. Reduced-Intensity Transplantation for Lymphomas UsingHaploidentical Related Donors Versus HLA-Matched Sibling Donors: A Center for InternationalBlood and Marrow Transplant Research Analysis. J Clin Oncol. 2016 09 10;34(26):3141-9. PMCID:PMC5012706

129. Police RL, Trask PC, Wang J, Olivares R, Khan S, Abbe A, Colosia A, Njue A, Sherril B, Ruiz-Soto R,Kaye JA, Hamadani M. Randomized controlled trials in relapsed/refractory follicular lymphoma: asystematic review and meta-analysis. J Oncol Pharm Pract. 2016 Oct;22(5):666-78.

130. Dhakal B, Veltri LW, Fenske TS, Eastwood D, Craig MD, Cumpston A, Shillingburg A, Esselman J,Watkins K, Pasquini MC, D'Souza A, Hari P, Kanate AS, Hamadani M. Hematopoietic ProgenitorCell Mobilization with Ifosfamide, Carboplatin, and Etoposide Chemotherapy versus Plerixafor-BasedStrategies in Patients with Hodgkin and Non-Hodgkin Lymphoma. Biol Blood Marrow Transplant.2016 10;22(10):1773-1780.

131. Snyder M, Shillingburg A, Newton M, Hamadani M, Kanate AS, Craig M, Cumpston A. Impact ofintravenous magnesium infusion rate during ambulatory replacements on serum magnesiumconcentrations after allogeneic stem cell transplant. Support Care Cancer. 2016 10;24(10):4237-40.

132. Deol A, Sengsayadeth S, Ahn KW, Wang HL, Aljurf M, Antin JH, Battiwalla M, Bornhauser M, Cahn JY,Camitta B, Chen YB, Cutler CS, Gale RP, Ganguly S, Hamadani M, Inamoto Y, Jagasia M, KambleR, Koreth J, Lazarus HM, Liesveld J, Litzow MR, Marks DI, Nishihori T, Olsson RF, Reshef R, RoweJM, Saad AA, Sabloff M, Schouten HC, Shea TC, Soiffer RJ, Uy GL, Waller EK, Wiernik PH, WirkB, Woolfrey AE, Bunjes D, Devine S, de Lima M, Sandmaier BM, Weisdorf D, Khoury HJ, Saber W.Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloidleukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis.Cancer. 2016 10;122(19):3005-3014. PMCID: PMC5030151

133. Kharfan-Dabaja MA, Reljic T, El-Asmar J, Nishihori T, Ayala E, Hamadani M, Kumar A. Reduced-intensity or myeloablative allogeneic hematopoietic cell transplantation for mantle cell lymphoma: asystematic review. Future Oncol. 2016 Nov;12(22):2631-2642.

134. Epperla N, Shah N, Hamadani M, Richardson K, Kapke JT, Patel A, Teegavarapu SP, Carrum G, Hari PN,Pingali SR, Karmali R, Fenske TS. Impact of Routine Surveillance Imaging on Outcomes of PatientsWith Diffuse Large B-Cell Lymphoma After Autologous Hematopoietic Cell Transplantation. ClinLymphoma Myeloma Leuk. 2016 12;16(12):672-678.

135. Kharfan-Dabaja MA, Kumar A, Hamadani M, Stilgenbauer S, Ghia P, Anasetti C, Dreger P, Montserrat E,Perales MA, Alyea EP, Awan FT, Ayala E, Barrientos JC, Brown JR, Castro JE, Furman RR, GribbenJ, Hill BT, Mohty M, Moreno C, O'Brien S, Pavletic SZ, Pinilla-Ibarz J, Reddy NM, Sorror M,Bredeson C, Carpenter P, Savani BN. Clinical Practice Recommendations for Use of AllogeneicHematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the GuidelinesCommittee of the American Society for Blood and Marrow Transplantation. Biol Blood MarrowTransplant. 2016 12;22(12):2117-2125. PMCID: PMC5116249

32 / 59

136. Raj RV, Hari P, Pasquini M, Epperla N, D'Souza A, Fenske T, Shaw BE, Rizzo JD, Drobyski W, Hamadani M. Impact of haploidentical hematopoietic cell transplantation conditioning intensity onthe incidence and severity of post-transplantation viral infections. Bone Marrow Transplant. 201612;51(12):1602-1604.

137. Epperla N, Olteanu H, Hamadani M. Think outside the box: Acanthamoeba encephalitis followingautologous haematopoietic stem cell transplantation. Br J Haematol. 2016 12;175(5):758.

138. Cornell RF, Bachanova V, D'Souza A, Woo-Ahn K, Martens M, Huang J, Al-Homsi AS, Chhabra S,Copelan E, Diaz MA, Freytes CO, Gale RP, Ganguly S, Hamadani M, Hildebrandt G, Kamble RT,Kharfan-Dabaja M, Kindwall-Keller T, Lazarus HM, Marks DI, Nishihori T, Olsson RF, Saad A,Usmani S, Vesole DH, Yared J, Mark T, Nieto Y, Hari P. Allogeneic Transplantation for RelapsedWaldenström Macroglobulinemia and Lymphoplasmacytic Lymphoma. Biol Blood MarrowTransplant. 2017 01;23(1):60-66. PMCID: PMC5182098

139. Epperla N, Pasquini M, Pierce K, Drobyski WR, Rizzo JD, Horowitz MM, Saber W, Zellner K, Ramirez S,Bartz K, Raj RV, Hari PN, Hamadani M. Salvage haploidentical hematopoietic cell transplantationfor graft rejection following a prior haploidentical allograft. Bone Marrow Transplant. 201701;52(1):147-150.

140. Cornell RF, D'Souza A, Kassim AA, Costa LJ, Innis-Shelton RD, Zhang MJ, Huang J, Abidi M, Aiello J,Akpek G, Bashey A, Bashir Q, Cerny J, Comenzo R, Diaz MA, Freytes C, Gale RP, Ganguly S, Hamadani M, Hashmi S, Holmberg L, Hossain N, Kamble RT, Kharfan-Dabaja M, Kindwall-KellerT, Kyle R, Kumar S, Lazarus H, Lee C, Maiolino A, Marks DI, Meehan K, Mikhael J, Nath R,Nishihori T, Olsson RF, Ramanathan M, Saad A, Seo S, Usmani S, Vesole D, Vij R, Vogl D, WirkBM, Yared J, Krishnan A, Mark T, Nieto Y, Hari P. Maintenance versus Induction Therapy Choice onOutcomes after Autologous Transplantation for Multiple Myeloma. Biol Blood Marrow Transplant.2017 Feb;23(2):269-277. PMCID: PMC5346183

141. DeFilipp Z, Duarte RF, Snowden JA, Majhail NS, Greenfield DM, Miranda JL, Arat M, Baker KS, BurnsLJ, Duncan CN, Gilleece M, Hale GA, Hamadani M, Hamilton BK, Hogan WJ, Hsu JW, Inamoto Y,Kamble RT, Lupo-Stanghellini MT, Malone AK, McCarthy P, Mohty M, Norkin M, Paplham P,Ramanathan M, Richart JM, Salooja N, Schouten HC, Schoemans H, Seber A, Steinberg A, Wirk BM,Wood WA, Battiwalla M, Flowers ME, Savani BN, Shaw BE. Metabolic syndrome and cardiovasculardisease following hematopoietic cell transplantation: screening and preventive practicerecommendations from CIBMTR and EBMT. Bone Marrow Transplant. 2017 Feb;52(2):173-182.PMCID: PMC5288134

142. Shah N, Rauenzahn S, Veltri L, Wen S, Craig M, Hamadani M, Kanate AS, Cumpston A. Long-termoutcomes after thiotepa-based high-dose therapy (HDT) and autologous hematopoietic celltransplantation (auto-HCT) in non-Hodgkin lymphoma (NHL). Bone Marrow Transplant. 201702;52(2):321-322.

143. Costa LJ, Maddocks K, Epperla N, Reddy NM, Karmali R, Umyarova E, Bachanova V, Costa C, Glenn MJ,Chavez JC, Calzada O, Lansigan F, Nasheed H, Barta SK, Zhou Z, Jaglal M, Chhabra S, Hernandez-Ilizaliturri F, Xavier AC, Mehta A, Peker D, Forero-Torres A, Al-Mansour Z, Evens AM, Cohen JB,Flowers CR, Fenske TS, Hamadani M. Diffuse large B-cell lymphoma with primary treatment failure:Ultra-high risk features and benchmarking for experimental therapies. Am J Hematol. 2017Feb;92(2):161-170. PMCID: PMC5549936

144. Dhakal B, Nelson A, Guru Murthy GS, Fraser R, Eastwood D, Hamadani M, Pasquini M, D'Souza A, HariP. Autologous Hematopoietic Cell Transplantation in Patients With Multiple Myeloma: Effect of Age.Clin Lymphoma Myeloma Leuk. 2017 03;17(3):165-172.

145. Guru Murthy GS, Hamadani M, Bhatt VR, Dhakal I, Mehta P. Systemic Anaplastic Lymphoma Kinase-positive Anaplastic Large Cell Lymphoma: A Population-based Analysis of Incidence and Survival.Clin Lymphoma Myeloma Leuk. 2017 04;17(4):201-206.

146. Scott BL, Pasquini MC, Logan BR, Wu J, Devine SM, Porter DL, Maziarz RT, Warlick ED, Fernandez HF,Alyea EP, Hamadani M, Bashey A, Giralt S, Geller NL, Leifer E, Le-Rademacher J, Mendizabal AM,Horowitz MM, Deeg HJ, Horwitz ME. Myeloablative Versus Reduced-Intensity Hematopoietic CellTransplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes. J Clin Oncol. 2017 Apr10;35(11):1154-1161. PMCID: PMC5455603

147. Epperla N, Hamadani M, Fenske TS, Costa LJ. Incidence and survival trends in mantle cell lymphoma. BrJ Haematol. 2018 06;181(5):703-706.

148. Dhakal B, Fenske TS, Ramalingam S, Shuff J, Epperla N, Hosking P, Rein L, Banerjee A, Hari P, D'SouzaA, Shah N, Siker M, Griepentrog GJ, Harris GJ, Wells TS, Erickson BA, Hamadani M. Local Disease

33 / 59

Control in Ocular Adnexal Lymphoproliferative Disorders: Comparative Outcomes of MALT VersusNon-MALT Histologies. Clin Lymphoma Myeloma Leuk. 2017 05;17(5):305-311.e2.

149. Liu HD, Ahn KW, Hu ZH, Hamadani M, Nishihori T, Wirk B, Beitinjaneh A, Rizzieri D, Grunwald MR,Sabloff M, Olsson RF, Bajel A, Bredeson C, Daly A, Inamoto Y, Majhail N, Saad A, Gupta V, GerdsA, Malone A, Tallman M, Reshef R, Marks DI, Copelan E, Gergis U, Savoie ML, Ustun C, LitzowMR, Cahn JY, Kindwall-Keller T, Akpek G, Savani BN, Aljurf M, Rowe JM, Wiernik PH, Hsu JW,Cortes J, Kalaycio M, Maziarz R, Sobecks R, Popat U, Alyea E, Saber W. Allogeneic HematopoieticCell Transplantation for Adult Chronic Myelomonocytic Leukemia. Biol Blood Marrow Transplant.2017 May;23(5):767-775. PMCID: PMC5590102

150. Hamadani M, Kanate AS, DiGilio A, Ahn KW, Smith SM, Lee JW, Ayala E, Chao N, Hari P, Bolaños-Meade J, Gress R, Smedegaard Anderson N, Chen YB, Farooq U, Schiller G, Yared J, Sureda A,Fenske TS, Olteanu H. Allogeneic Hematopoietic Cell Transplantation for Aggressive NK CellLeukemia. A Center for International Blood and Marrow Transplant Research Analysis. Biol BloodMarrow Transplant. 2017 May;23(5):853-856. PMCID: PMC5410937

151. Jethava Y, Guru Murthy GS, Hamadani M. Relapse of Hodgkin lymphoma after autologoustransplantation: Time to rethink treatment? Hematol Oncol Stem Cell Ther. 2017 Jun;10(2):47-56.

152. Weil E, Zook F, Oxencis C, Canadeo A, Urmanski A, Waggoner M, Eastwood D, Pasquini M, HamadaniM, Hari P. Evaluation of the Pharmacokinetics and Efficacy of a Busulfan Test Dose in Adult PatientsUndergoing Myeloablative Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2017Jun;23(6):952-957.

153. Epperla N, Ahn KW, Ahmed S, Jagasia M, DiGilio A, Devine SM, Jaglowski S, Kennedy V, Rezvani AR,Smith SM, Sureda A, Fenske TS, Kharfan-Dabaja MA, Armand P, Hamadani M. Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneictransplantation in B cell non-Hodgkin lymphoma. J Hematol Oncol. 2017 06 12;10(1):117. PMCID:PMC5469142

154. Shillingburg A, Kanate AS, Hamadani M, Wen S, Craig M, Cumpston A. Treatment of severe mucositispain with oral ketamine mouthwash. Support Care Cancer. 2017 07;25(7):2215-2219. PMCID:PMC5500907

155. Kapke JT, Epperla N, Shah N, Richardson K, Carrum G, Hari PN, Pingali SR, Hamadani M, Karmali R,Fenske TS. Effect of Routine Surveillance Imaging on the Outcomes of Patients With ClassicalHodgkin Lymphoma After Autologous Hematopoietic Cell Transplantation. Clin LymphomaMyeloma Leuk. 2017 07;17(7):408-414.

156. Haverkos BM, Abbott D, Hamadani M, Armand P, Flowers ME, Merryman R, Kamdar M, Kanate AS,Saad A, Mehta A, Ganguly S, Fenske TS, Hari P, Lowsky R, Andritsos L, Jagasia M, Bashey A,Brown S, Bachanova V, Stephens D, Mineishi S, Nakamura R, Chen YB, Blazar BR, Gutman J,Devine SM. PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: highresponse rate but frequent GVHD. Blood. 2017 07 13;130(2):221-228. PMCID: PMC5510790

157. Kanate AS, Hari PN, Pasquini MC, Visotcky A, Ahn KW, Boyd J, Guru Murthy GS, Rizzo JD, Saber W,Drobyski W, Michaelis L, Atallah E, Carlson KS, D'Souza A, Fenske TS, Cumpston A, Bunner P,Craig M, Horowitz MM, Hamadani M. Recipient Immune Modulation with Atorvastatin for AcuteGraft-versus-Host Disease Prophylaxis after Allogeneic Transplantation. Biol Blood MarrowTransplant. 2017 Aug;23(8):1295-1302.

158. Kanate AS, DiGilio A, Ahn KW, Al Malki M, Jacobsen E, Steinberg A, Hamerschlak N, Kharfan-DabajaM, Salit R, Ball E, Bashir Q, Cashen A, Couriel D, Diez-Martin J, Katsanis E, Linhares Y, Mori S,Nash R, Pawarode A, Perales MA, Phipps CD, Richman C, Savani BN, Shapira MY, Stiff P, Strair R,Fenske TS, Smith SM, Sureda A, Olteanu H, Hamadani M. Allogeneic haematopoietic celltransplantation for extranodal natural killer/T-cell lymphoma, nasal type: a CIBMTR analysis. Br JHaematol. 2018 09;182(6):916-920. PMCID: PMC5796874

159. Hammons L, Brazauskas R, Pasquini M, Hamadani M, Hari P, D'Souza A. Presence of fluorescent in situhybridization abnormalities is associated with plasma cell burden in light chain amyloidosis. HematolOncol Stem Cell Ther. 2018 Jun;11(2):105-111.

160. D'Souza A, Zhang MJ, Huang J, Fei M, Pasquini M, Hamadani M, Hari P. Trends in pre- and post-transplant therapies with first autologous hematopoietic cell transplantation among patients withmultiple myeloma in the United States, 2004-2014. Leukemia. 2017 09;31(9):1998-2000. PMCID:PMC5587375

161. Levin A, Kleman A, Rein L, Tarima S, Michaelis LC, Carlson KS, Hamadani M, Fenske TS, Hari P,Atallah E, Dhakal B. Early mortality in patients with acute myelogenous leukemia treated in teaching

34 / 59

versus non-teaching hospitals: A large database analysis. Am J Hematol. 2017 Sep;92(9):E563-E565. 162. Bashey A, Zhang MJ, McCurdy SR, St Martin A, Argall T, Anasetti C, Ciurea SO, Fasan O, Gaballa S,

Hamadani M, Munshi P, Al Malki MM, Nakamura R, O'Donnell PV, Perales MA, Raj K, Romee R,Rowley S, Rocha V, Salit RB, Solh M, Soiffer RJ, Fuchs EJ, Eapen M. Mobilized Peripheral BloodStem Cells Versus Unstimulated Bone Marrow As a Graft Source for T-Cell-Replete HaploidenticalDonor Transplantation Using Post-Transplant Cyclophosphamide. J Clin Oncol. 2017 Sep10;35(26):3002-3009. PMCID: PMC5590802

163. Jerkins JH, Hamadani M, Zook F, Epperla N, Shaw BE, Saber W, Rizzo JD, Pasquini M, Chhabra S,Drobyski WR, Hari PN, Shah NN. Alpha-1-antitrypsin for the treatment of steroid-refractory acutegastrointestinal graft-versus-host disease. Am J Hematol. 2017 Oct;92(10):E610-E611.

164. Mateos MV, Masszi T, Grzasko N, Hansson M, Sandhu I, Pour L, Viterbo L, Jackson SR, Stoppa AM,Gimsing P, Hamadani M, Borsaru G, Berg D, Lin J, Di Bacco A, van de Velde H, Richardson PG,Moreau P. Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone <i>vs</i>. placebo-lenalidomide-dexamethasone in patients with relapsed/refractorymultiple myeloma in TOURMALINE-MM1. Haematologica. 2017 10;102(10):1767-1775. PMCID:PMC5622861

165. Kharfan-Dabaja MA, Kumar A, Ayala E, Hamadani M, Reimer P, Gisselbrecht C, d'Amore F, Jantunen E,Ishida T, Bazarbachi A, Foss F, Advani R, Fenske TS, Lazarus HM, Friedberg JW, Aljurf M, Sokol L,Tobinai K, Tse E, Burns LJ, Chavez JC, Reddy NM, Suzuki R, Ahmed S, Nademanee A, Mohty M,Gopal AK, Fanale MA, Pro B, Moskowitz AJ, Sureda A, Perales MA, Carpenter PA, Savani BN.Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantationin Mature T Cell and NK/T Cell Lymphomas: An International Collaborative Effort on Behalf of theGuidelines Committee of the American Society for Blood and Marrow Transplantation. Biol BloodMarrow Transplant. 2017 Nov;23(11):1826-1838.

166. Epperla N, Hemauer K, Hamadani M, Friedman KD, Kreuziger LB. Impact of treatment and outcomes forpatients with posttransplant drug-associated thrombotic microangiopathy. Transfusion. 201711;57(11):2775-2781.

167. Thompson J, Yin Z, D'Souza A, Fenske T, Hamadani M, Hari P, Rizzo JD, Pasquini M, Saber W, Shah N,Shaw BE, Shahir K, Banerjee A, Drobyski WR. Etanercept and Corticosteroid Therapy for theTreatment of Late-Onset Idiopathic Pneumonia Syndrome. Biol Blood Marrow Transplant. 2017Nov;23(11):1955-1960.

168. Kharfan-Dabaja MA, El-Jurdi N, Ayala E, Kanate AS, Savani BN, Hamadani M. Is myeloablative doseintensity necessary in allogeneic hematopoietic cell transplantation for lymphomas? Bone MarrowTransplant. 2017 Nov;52(11):1487-1494.

169. Wang M, Schuster SJ, Phillips T, Lossos IS, Goy A, Rule S, Hamadani M, Ghosh N, Reeder CB, BarnettE, Bravo MC, Martin P. Observational study of lenalidomide in patients with mantle cell lymphomawho relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004). J Hematol Oncol.2017 11 02;10(1):171. PMCID: PMC5668956

170. Epperla N, Maddocks KJ, Salhab M, Chavez JC, Reddy N, Karmali R, Umyarova E, Bachanova V, CostaC, Glenn M, Calzada O, Xavier AC, Zhou Z, Hossain NM, Hernandez-Ilizaliturri FJ, Al-Mansour Z,Barta SK, Chhabra S, Lansigan F, Mehta A, Jaglal MV, Evens AM, Flowers CR, Cohen JB, FenskeTS, Hamadani M, Costa LJ. C-MYC-positive relapsed and refractory, diffuse large B-cell lymphoma:Impact of additional "hits" and outcomes with subsequent therapy. Cancer. 2017 1115;123(22):4411-4418.

171. D'Souza A, Flynn K, Chhabra S, Dhakal B, Hamadani M, Jacobsen K, Pasquini M, Weihrauch D, Hari P.Rationale and design of DUAL study: Doxycycline to Upgrade response in light chain (AL)amyloidosis (DUAL): A phase 2 pilot study of a two-pronged approach of prolonged doxycycline withplasma cell-directed therapy in the treatment of AL amyloidosis. Contemp Clin Trials Commun. 2017Dec;8:33-38. PMCID: PMC5898504

172. Epperla N, Hamadani M. Hematopoietic cell transplantation for diffuse large B-cell and follicularlymphoma: Current controversies and advances. Hematol Oncol Stem Cell Ther. 2017Dec;10(4):277-284.

173. Hamadani M, Horowitz MM. Allogeneic Transplantation for Follicular Lymphoma: Does One Size FitAll? J Oncol Pract. 2017 12;13(12):798-806. PMCID: PMC5728364

174. Epperla N, Hamadani M, Cashen AF, Ahn KW, Oak E, Kanate AS, Calzada O, Cohen JB, Farmer L,Ghosh N, Tallarico M, Nabhan C, Costa LJ, Kenkre VP, Hari PN, Fenske TS. Predictive factors andoutcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma-a "real world" study.

35 / 59

Hematol Oncol. 2017 Dec;35(4):528-535. 175. Kharfan-Dabaja MA, Al Malki MM, Deotare U, Raj RV, El-Jurdi N, Majhail N, Cherry MA, Bashir Q,

Darrah J, Nishihori T, Sibai H, Hamadani M, de Lima M, Gerds AT, Selby G, Qazilbash MH,Forman SJ, Ayala E, Lipton JH, Hari PN, Muzzafar T, Zhang L, Olteanu H, Perkins J, Sokol L, KumarA, Ahmed S. Haematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: aNorth American multicentre collaborative study. Br J Haematol. 2017 12;179(5):781-789.

176. Epperla N, Ahn KW, Armand P, Jaglowski S, Ahmed S, Kenkre VP, Savani B, Jagasia M, Shah NN,Fenske TS, Sureda A, Smith SM, Hamadani M. Fludarabine and Busulfan versus Fludarabine,Cyclophosphamide, and Rituximab as Reduced-Intensity Conditioning for Allogeneic Transplantationin Follicular Lymphoma. Biol Blood Marrow Transplant. 2018 01;24(1):78-85. PMCID: PMC5743624

177. Shah NN, Szabo A, Huntington SF, Epperla N, Reddy N, Ganguly S, Vose J, Obiozor C, Faruqi F, KovachAE, Costa LJ, Xavier AC, Okal R, Kanate AS, Ghosh N, Kharfan-Dabaja MA, Strelec L, HamadaniM, Fenske TS, Calzada O, Cohen JB, Chavez J, Svoboda J. R-CHOP versus dose-adjusted R-EPOCHin frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis. Br JHaematol. 2018 02;180(4):534-544.

178. Kelly DL, Buchbinder D, Duarte RF, Auletta JJ, Bhatt N, Byrne M, DeFilipp Z, Gabriel M, Mahindra A,Norkin M, Schoemans H, Shah AJ, Ahmed I, Atsuta Y, Basak GW, Beattie S, Bhella S, Bredeson C,Bunin N, Dalal J, Daly A, Gajewski J, Gale RP, Galvin J, Hamadani M, Hayashi RJ, Adekola K, LawJ, Lee CJ, Liesveld J, Malone AK, Nagler A, Naik S, Nishihori T, Parsons SK, Scherwath A, SchofieldHL, Soiffer R, Szer J, Twist I, Warwick A, Wirk BM, Yi J, Battiwalla M, Flowers ME, Savani B,Shaw BE. Neurocognitive Dysfunction in Hematopoietic Cell Transplant Recipients: Expert Reviewfrom the Late Effects and Quality of Life Working Committee of the Center for International Bloodand Marrow Transplant Research and Complications and Quality of Life Working Party of theEuropean Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 201802;24(2):228-241. PMCID: PMC5768142

179. McCurdy SR, Zhang MJ, St Martin A, Al Malki MM, Bashey A, Gaballa S, Keesler DA, Hamadani M,Norkin M, Perales MA, Reshef R, Rocha V, Romee R, Solh M, Urbano-Ispizua A, Waller EK, FuchsEJ, Eapen M. Effect of donor characteristics on haploidentical transplantation with posttransplantationcyclophosphamide. Blood Adv. 2018 02 13;2(3):299-307. PMCID: PMC5812334

180. Myers RM, Hill BT, Shaw BE, Kim S, Millard HR, Battiwalla M, Majhail NS, Buchbinder D, Lazarus HM,Savani BN, Flowers MED, D'Souza A, Ehrhardt MJ, Langston A, Yared JA, Hayashi RJ, Daly A,Olsson RF, Inamoto Y, Malone AK, DeFilipp Z, Margossian SP, Warwick AB, Jaglowski S,Beitinjaneh A, Fung H, Kasow KA, Marks DI, Reynolds J, Stockerl-Goldstein K, Wirk B, Wood WA, Hamadani M, Satwani P. Long-term outcomes among 2-year survivors of autologous hematopoieticcell transplantation for Hodgkin and diffuse large b-cell lymphoma. Cancer. 2018 0215;124(4):816-825. PMCID: PMC5871233

181. Htut M, D'Souza A, Krishnan A, Bruno B, Zhang MJ, Fei M, Diaz MA, Copelan E, Ganguly S, HamadaniM, Kharfan-Dabaja M, Lazarus H, Lee C, Meehan K, Nishihori T, Saad A, Seo S, Ramanathan M,Usmani SZ, Gasparetto C, Mark TM, Nieto Y, Hari P. Autologous/Allogeneic Hematopoietic CellTransplantation versus Tandem Autologous Transplantation for Multiple Myeloma: Comparison ofLong-Term Postrelapse Survival. Biol Blood Marrow Transplant. 2018 03;24(3):478-485. PMCID:PMC5826888

182. Kharfan-Dabaja MA, Raj R, Nikolaenko L, Ahmed S, Reddy N, Nathan S, Cherry M, El-Jurdi N, ObiozorC, Fenske TS, Song J, Muzzafar T, Ayala E, Savani B, Khawandanah M, Caimi PF, Hamadani M,Forman SJ, Hussaini M, de Lima M, Olteanu H, Shah B, Chavez JC, Al Malki M, Kumar A, GangulyS. Efficacy of High-Dose Therapy and Autologous Hematopoietic Cell Transplantation in Gray ZoneLymphoma: A US Multicenter Collaborative Study. Biol Blood Marrow Transplant. 201803;24(3):486-493.

183. Dhakal B, Szabo A, Chhabra S, Hamadani M, D'Souza A, Usmani SZ, Sieracki R, Gyawali B, Jackson JL,Asimakopoulos F, Hari PN. Autologous Transplantation for Newly Diagnosed Multiple Myeloma inthe Era of Novel Agent Induction: A Systematic Review and Meta-analysis. JAMA Oncol. 2018 Mar01;4(3):343-350. PMCID: PMC5885822

184. Shah NN, Fenske TS, Hamadani M, Svoboda J. What is the standard of care for primary mediastinal B celllymphoma; R-CHOP or DA-EPOCH-R? - Response to Melani et al. Br J Haematol. 201903;184(5):838-840.

185. Brown JR, Hamadani M, Hayslip J, Janssens A, Wagner-Johnston N, Ottmann O, Arnason J, Tilly H,Millenson M, Offner F, Gabrail NY, Ganguly S, Ailawadhi S, Kasar S, Kater AP, Doorduijn JK, Gao

36 / 59

L, Lager JJ, Wu B, Egile C, Kersten MJ. Voxtalisib (XL765) in patients with relapsed or refractorynon-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial. LancetHaematol. 2018 Apr;5(4):e170-e180. PMCID: PMC7029813

186. Drobyski WR, Szabo A, Zhu F, Keever-Taylor C, Hebert KM, Dunn R, Yim S, Johnson B, D'Souza A,Eapen M, Fenske TS, Hari P, Hamadani M, Horowitz MM, Rizzo JD, Saber W, Shah N, Shaw B,Pasquini M. Tocilizumab, tacrolimus and methotrexate for the prevention of acutegraft-<i>versus</i>-host disease: low incidence of lower gastrointestinal tract disease. Haematologica.2018 04;103(4):717-727. PMCID: PMC5865423

187. Sureda A, Zhang MJ, Dreger P, Carreras J, Fenske T, Finel H, Schouten H, Montoto S, Robinson S, SmithSM, Boumedil A, Hamadani M, Pasquini MC. Allogeneic hematopoietic stem cell transplantation forrelapsed follicular lymphoma: A combined analysis on behalf of the Lymphoma Working Party of theEBMT and the Lymphoma Committee of the CIBMTR. Cancer. 2018 04 15;124(8):1733-1742.PMCID: PMC5946312

188. Shah NN, Ahn KW, Litovich C, Fenske TS, Ahmed S, Battiwalla M, Bejanyan N, Dahi PB, Bolaños-Meade J, Chen AI, Ciurea SO, Bachanova V, DeFilipp Z, Epperla N, Farhadfar N, Herrera AF,Haverkos BM, Holmberg L, Hossain NM, Kharfan-Dabaja MA, Kenkre VP, Lazarus HM, Murthy HS,Nishihori T, Rezvani AR, D'Souza A, Savani BN, Ulrickson ML, Waller EK, Sureda A, Smith SM, Hamadani M. Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneictransplantation: a CIBMTR analysis. Blood Adv. 2018 04 24;2(8):933-940. PMCID: PMC5916010

189. Epperla N, Hamadani M, Ahn KW, He F, Kodali D, Kleman A, Hari PN, Pasquini M, Fenske TS, CraigMD, Kanate AS, Bachanova V. Survival of Lymphoma Patients Experiencing Relapse or Progressionafter an Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 201805;24(5):983-988.

190. Buchbinder D, Kelly DL, Duarte RF, Auletta JJ, Bhatt N, Byrne M, DeFilipp Z, Gabriel M, Mahindra A,Norkin M, Schoemans H, Shah AJ, Ahmed I, Atsuta Y, Basak GW, Beattie S, Bhella S, Bredeson C,Bunin N, Dalal J, Daly A, Gajewski J, Gale RP, Galvin J, Hamadani M, Hayashi RJ, Adekola K, LawJ, Lee CJ, Liesveld J, Malone AK, Nagler A, Naik S, Nishihori T, Parsons SK, Scherwath A, SchofieldHL, Soiffer R, Szer J, Twist I, Warwick AB, Wirk BM, Yi J, Battiwalla M, Flowers MDE, Savani B,Shaw BE. Neurocognitive dysfunction in hematopoietic cell transplant recipients: expert review fromthe late effects and Quality of Life Working Committee of the CIBMTR and complications andQuality of Life Working Party of the EBMT. Bone Marrow Transplant. 2018 05;53(5):535-555.PMCID: PMC5985976

191. Rezahosseini O, Hanaei S, Hamadani M, Keshavarz-Fathi M, Rezaei N. The promising role of monoclonalantibodies for immunotherapy of the HIV-associated cancer, non-Hodgkin lymphoma. Int RevImmunol. 2018 05 04;37(3):165-173.

192. Knight JM, Kerswill SA, Hari P, Cole SW, Logan BR, D'Souza A, Shah NN, Horowitz MM, Stolley MR,Sloan EK, Giles KE, Costanzo ES, Hamadani M, Chhabra S, Dhakal B, Rizzo JD. Repurposingexisting medications as cancer therapy: design and feasibility of a randomized pilot investigatingpropranolol administration in patients receiving hematopoietic cell transplantation. BMC Cancer. 2018May 24;18(1):593. PMCID: PMC5968588

193. Hashmi SK, Lee SJ, Savani BN, Burns L, Wingard JR, Perales MA, Palmer J, Chow E, Meyer E, Marks D,Mohty M, Inamoto Y, Rodriguez C, Nagler A, Sauter C, Komanduri KV, Pidala J, Hamadani M,Johnston L, Shah N, Shaughnessy P, Hamilton BK, Majhail N, Kharfan-Dabaja MA, Schriber J,DeFilipp Z, Tarlock KG, Fanning S, Curtin P, Rizzo JD, Carpenter PA. ASBMT Practice GuidelinesCommittee Survey on Long-Term Follow-Up Clinics for Hematopoietic Cell Transplant Survivors.Biol Blood Marrow Transplant. 2018 06;24(6):1119-1124.

194. Casulo C, Friedberg JW, Ahn KW, Flowers C, DiGilio A, Smith SM, Ahmed S, Inwards D, Aljurf M, ChenAI, Choe H, Cohen J, Copelan E, Farooq U, Fenske TS, Freytes C, Gaballa S, Ganguly S, Jethava Y,Kamble RT, Kenkre VP, Lazarus H, Lazaryan A, Olsson RF, Rezvani AR, Rizzieri D, Seo S, ShahGL, Shah N, Solh M, Sureda A, William B, Cumpston A, Zelenetz AD, Link BK, Hamadani M.Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A NationalLymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis.Biol Blood Marrow Transplant. 2018 06;24(6):1163-1171. PMCID: PMC5993598

195. Greenwell IB, Staton AD, Lee MJ, Switchenko JM, Saxe DF, Maly JJ, Blum KA, Grover NS, Mathews SP,Gordon MJ, Danilov AV, Epperla N, Fenske TS, Hamadani M, Park SI, Flowers CR, Cohen JB.Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor responseto intensive induction therapy. Cancer. 2018 06 01;124(11):2306-2315. PMCID: PMC5992038

37 / 59

196. Smith SM, Godfrey J, Ahn KW, DiGilio A, Ahmed S, Agrawal V, Bachanova V, Bacher U, Bashey A,Bolaños-Meade J, Cairo M, Chen A, Chhabra S, Copelan E, Dahi PB, Aljurf M, Farooq U, Ganguly S,Hertzberg M, Holmberg L, Inwards D, Kanate AS, Karmali R, Kenkre VP, Kharfan-Dabaja MA, KleinA, Lazarus HM, Mei M, Mussetti A, Nishihori T, Ramakrishnan Geethakumari P, Saad A, Savani BN,Schouten HC, Shah N, Urbano-Ispizua A, Vij R, Vose J, Sureda A, Hamadani M. Autologoustransplantation versus allogeneic transplantation in patients with follicular lymphoma experiencingearly treatment failure. Cancer. 2018 06 15;124(12):2541-2551. PMCID: PMC5990449

197. Costa LJ, Landau HJ, Chhabra S, Hari P, Innis-Shelton R, Godby KN, Hamadani M, Tamari R, AndertonK, Dixon P, Giralt SA. Phase 1/2 Trial of Carfilzomib Plus High-Dose Melphalan PreparativeRegimen for Salvage Autologous Hematopoietic Cell Transplantation Followed by MaintenanceCarfilzomib in Patients with Relapsed/Refractory Multiple Myeloma. Biol Blood Marrow Transplant.2018 07;24(7):1379-1385. PMCID: PMC7590532

198. Dhakal B, D'Souza A, Lakshman A, Hamadani M, Chhabra S, Thompson R, Shah N, Pasquini M, Hari P.Pharmacokinetics of High-Dose Propylene Glycol-Free Melphalan in Multiple Myeloma PatientsUndergoing Autologous Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 201808;24(8):1610-1614.

199. Raj RV, Hamadani M, Szabo A, Pasquini MC, Shah NN, Drobyski WR, Shaw BE, Saber W, Rizzo JD,Jerkins J, Fenske TS, D'Souza A, Dhakal B, Zhang C, Konings S, Hari PN, Chhabra S. PeripheralBlood Grafts for T Cell-Replete Haploidentical Transplantation Increase the Incidence and Severity ofCytokine Release Syndrome. Biol Blood Marrow Transplant. 2018 08;24(8):1664-1670.

200. Guru Murthy GS, Hamadani M, Dhakal B, Hari P, Atallah E. Incidence and survival of therapy relatedmyeloid neoplasm in United States. Leuk Res. 2018 08;71:95-99.

201. Sureda A, Montoto S, Dreger P, Hamadani M, Pasquini MC. Reply to the persistent uncertainty of when torecommend allogeneic stem cell transplantation in follicular iymphoma. Cancer. 201808;124(16):3455-3456.

202. Badar T, Hari P, Chhabra S, Dhakal B, Drobyski WR, Fenske TS, Hamadani M, Pasquini M, Saber W,Shah NN, Shaw BE, D'Souza A. Use of propylene glycol-free melphalan conditioning in light-chainamyloidosis patients undergoing autologous hematopoietic cell transplantation is well tolerated andeffective. Bone Marrow Transplant. 2018 09;53(9):1210-1213.

203. Hashmi H, Hamadani M, Awan FT. Choosing the appropriate salvage therapy for B-cell non-Hodgkinlymphoma. Expert Opin Pharmacother. 2018 10;19(15):1631-1634.

204. Hamadani M. Advances in Transplantation for Lymphomas Resulting from CIBMTR LymphomaWorking Committee's Research Portfolio: A Five-Year Report (2013-2018). Adv Cell Gene Ther.2018 Nov;1(3). PMCID: PMC7946113

205. Radivoyevitch T, Dean RM, Shaw BE, Brazauskas R, Tecca HR, Molenaar RJ, Battiwalla M, Savani BN,Flowers MED, Cooke KR, Hamilton BK, Kalaycio M, Maciejewski JP, Ahmed I, Akpek G, Bajel A,Buchbinder D, Cahn JY, D'Souza A, Daly A, DeFilipp Z, Ganguly S, Hamadani M, Hayashi RJ,Hematti P, Inamoto Y, Khera N, Kindwall-Keller T, Landau H, Lazarus H, Majhail NS, Marks DI,Olsson RF, Seo S, Steinberg A, William BM, Wirk B, Yared JA, Aljurf M, Abidi MH, Allewelt H,Beitinjaneh A, Cook R, Cornell RF, Fay JW, Hale G, Chakrabarty JH, Jodele S, Kasow KA, MahindraA, Malone AK, Popat U, Rizzo JD, Schouten HC, Warwick AB, Wood WA, Sekeres MA, Litzow MR,Gale RP, Hashmi SK. Risk of acute myeloid leukemia and myelodysplastic syndrome afterautotransplants for lymphomas and plasma cell myeloma. Leuk Res. 2018 11;74:130-136. PMCID:PMC6219911

206. Calzada O, Switchenko JM, Maly JJ, Blum KA, Grover N, Mathews S, Park SI, Gordon M, Danilov A,Epperla N, Fenske TS, Hamadani M, Flowers CR, Cohen JB. Deferred treatment is a safe and viableoption for selected patients with mantle cell lymphoma. Leuk Lymphoma. 2018 12;59(12):2862-2870.PMCID: PMC6360945

207. Voshtina E, Szabo A, Hamadani M, Fenske TS, D'Souza A, Chhabra S, Saber W, Drobyski WR, Hari P,Shah NN. Impact of Obesity on Clinical Outcomes of Elderly Patients Undergoing AllogeneicHematopoietic Cell Transplantation for Myeloid Malignancies. Biol Blood Marrow Transplant. 201901;25(1):e33-e38.

208. Epperla N, Ahn KW, Litovich C, Ahmed S, Battiwalla M, Cohen JB, Dahi P, Farhadfar N, Farooq U,Freytes CO, Ghosh N, Haverkos B, Herrera A, Hertzberg M, Hildebrandt G, Inwards D, Kharfan-Dabaja MA, Khimani F, Lazarus H, Lazaryan A, Lekakis L, Murthy H, Nathan S, Nishihori T,Pawarode A, Prestidge T, Ramakrishnan P, Rezvani AR, Romee R, Shah NN, Sureda A, Fenske TS, Hamadani M. Allogeneic hematopoietic cell transplantation provides effective salvage despite

38 / 59

refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: aCIBMTR analysis. J Hematol Oncol. 2019 01 10;12(1):6. PMCID: PMC6329157

209. Shah NN, Szabo A, Saba R, Strelec L, Kodali D, Vaughn JL, Esan O, Yang DT, Mato AR, Kanate AS,Olteanu H, Hamadani M, Fenske TS, Kenkre VP, Svoboda J, Cashen AF, Epperla N. MulticenterAnalysis of Advanced Stage Grade 3A Follicular Lymphoma Outcomes by Frontline TreatmentRegimen. Clin Lymphoma Myeloma Leuk. 2019 02;19(2):95-102.

210. Dreger P, Sureda A, Ahn KW, Eapen M, Litovich C, Finel H, Boumendil A, Gopal A, Herrera AF, SchmidC, Diez-Martin JL, Fuchs E, Bolaños-Meade J, Gooptu M, Al Malki MM, Castagna L, Ciurea SO,Dominietto A, Blaise D, Ciceri F, Tischer J, Corradini P, Montoto S, Robinson S, Gülbas Z, Hamadani M. PTCy-based haploidentical vs matched related or unrelated donor reduced-intensityconditioning transplant for DLBCL. Blood Adv. 2019 02 12;3(3):360-369. PMCID: PMC6373757

211. Chen YB, Le-Rademacher J, Brazauskas R, Kiefer DM, Hamadani M, DiPersio JF, Litzow MR, Craig M,Horwitz ME, Artz AS, McClune BL, Fernandez HF, Duong HK, Kobusingye H, Proue M, Drexler RJ,Horowitz MM, Shaw BE, Miller JP, Hosoba S, Waller EK, Devine SM. Plerixafor alone for themobilization and transplantation of HLA-matched sibling donor hematopoietic stem cells. Blood Adv.2019 03 26;3(6):875-883. PMCID: PMC6436017

212. Guru Murthy GS, Hari PN, Szabo A, Pasquini M, Narra R, Khan M, Abedin S, Chhabra S, Dhakal B,D'Souza A, Drobyski WR, Rizzo JD, Runaas L, Shah NN, Shaw B, Saber W, Fenske T, Hamadani M.Outcomes of Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell TransplantationPerformed in the Inpatient versus Outpatient Setting. Biol Blood Marrow Transplant. 201904;25(4):827-833.

213. Badar T, Hamadani M, Bachanova V, Maddocks KJ, Umyarova E, Chavez JC, Epperla N, Chhabra S,Xavier AC, Karmali R, Salhab M, Reddy N, Glenn MJ, Hernandez-Ilizaliturri FJ, Flowers CR, EvensAM, Zhou Z, Lansigan F, Barta SK, Cohen JB, Fenske TS, Costa LJ. Efficacy of salvagechemotherapy in diffuse large B cell lymphoma with primary treatment failure according to putativecell of origin. Leuk Lymphoma. 2019 04;60(4):940-946.

214. Kanate AS, Kumar A, Dreger P, Dreyling M, Le Gouill S, Corradini P, Bredeson C, Fenske TS, Smith SM,Sureda A, Moskowitz A, Friedberg JW, Inwards DJ, Herrera AF, Kharfan-Dabaja MA, Reddy N,Montoto S, Robinson SP, Abutalib SA, Gisselbrecht C, Vose J, Gopal A, Shadman M, Perales MA,Carpenter P, Savani BN, Hamadani M. Maintenance Therapies for Hodgkin and Non-HodgkinLymphomas After Autologous Transplantation: A Consensus Project of ASBMT, CIBMTR, and theLymphoma Working Party of EBMT. JAMA Oncol. 2019 May 01;5(5):715-722. PMCID:PMC6988125

215. Epperla N, Badar T, Szabo A, Vaughn J, Borson S, Saini NY, Patel RD, Shah NN, Hamadani M, AhmedS, Cashen AF, Fenske TS. Postrelapse survival in diffuse large B-cell lymphoma after therapy failurefollowing autologous transplantation. Blood Adv. 2019 06 11;3(11):1661-1669. PMCID:PMC6560348

216. Rashidi A, Hamadani M, Zhang MJ, Wang HL, Abdel-Azim H, Aljurf M, Assal A, Bajel A, Bashey A,Battiwalla M, Beitinjaneh AM, Bejanyan N, Bhatt VR, Bolaños-Meade J, Byrne M, Cahn JY, CairoM, Ciurea S, Copelan E, Cutler C, Daly A, Diaz MA, Farhadfar N, Gale RP, Ganguly S, GrunwaldMR, Hahn T, Hashmi S, Hildebrandt GC, Holland HK, Hossain N, Kanakry CG, Kharfan-Dabaja MA,Khera N, Koc Y, Lazarus HM, Lee JW, Maertens J, Martino R, McGuirk J, Munker R, Murthy HS,Nakamura R, Nathan S, Nishihori T, Palmisiano N, Patel S, Pidala J, Olin R, Olsson RF, Oran B,Ringden O, Rizzieri D, Rowe J, Savoie ML, Schultz KR, Seo S, Shaffer BC, Singh A, Solh M,Stockerl-Goldstein K, Verdonck LF, Wagner J, Waller EK, De Lima M, Sandmaier BM, Litzow M,Weisdorf D, Romee R, Saber W. Outcomes of haploidentical vs matched sibling transplantation foracute myeloid leukemia in first complete remission. Blood Adv. 2019 06 25;3(12):1826-1836.PMCID: PMC6595262

217. Kanate AS, Szabo A, Raj RV, Bower K, Grulke R, Shah N, Ross KG, Cumpston A, Craig M, Pasquini MC,Shah N, Hari P, Hamadani M, Chhabra S. Comparison of Graft Acquisition and Early Direct Chargesof Haploidentical Related Donor Transplantation versus Umbilical Cord Blood Transplantation. BiolBlood Marrow Transplant. 2019 07;25(7):1456-1464.

218. Kumar SK, Berdeja JG, Niesvizky R, Lonial S, Laubach JP, Hamadani M, Stewart AK, Hari P, Roy V,Vescio R, Kaufman JL, Berg D, Liao E, Rajkumar SV, Richardson PG. Ixazomib, lenalidomide, anddexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up includingixazomib maintenance. Leukemia. 2019 07;33(7):1736-1746. PMCID: PMC6755968

219. Kumar A, Reljic T, Hamadani M, Mohty M, Kharfan-Dabaja MA. Antithymocyte globulin for graft-versus-

39 / 59

host disease prophylaxis: an updated systematic review and meta-analysis. Bone Marrow Transplant.2019 07;54(7):1094-1106.

220. Levis MJ, Chen YB, Hamadani M, Horowitz MM, Jones RJ, Blood and Marrow Transplant Clinical TrialsNetwork. FLT3 Inhibitor Maintenance After Allogeneic Transplantation: Is a Placebo-Controlled,Randomized Trial Ethical? J Clin Oncol. 2019 07 01;37(19):1604-1607. PMCID: PMC6804888

221. Dhakal B, Giri S, Levin A, Rein L, Fenske TS, Chhabra S, Shah NN, Szabo A, D'Souza A, Pasquini M,Hari P, Hamadani M. Factors Associated With Unplanned 30-Day Readmissions After HematopoieticCell Transplantation Among US Hospitals. JAMA Netw Open. 2019 07 03;2(7):e196476.

222. Dhakal B, D'Souza A, Hamadani M, Arce-Lara C, Schroeder K, Chhabra S, Shah NN, Gauger K, KeatonT, Pasquini M, Hari P. Phase I/II trial of bendamustine, ixazomib, and dexamethasone inrelapsed/refractory multiple myeloma. Blood Cancer J. 2019 07 29;9(8):56. PMCID: PMC6663939

223. D'Souza A, Hari P, Pasquini M, Braun T, Johnson B, Lundy S, Couriel D, Hamadani M, Magenau J,Dhakal B, Shah NN, Riwes M, Parkin B, Reddy P, Pawarode A. A Phase 2 Study of Pembrolizumabduring Lymphodepletion after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma.Biol Blood Marrow Transplant. 2019 08;25(8):1492-1497.

224. Abedin S, McKenna E, Chhabra S, Pasquini M, Shah NN, Jerkins J, Baim A, Runaas L, Longo W,Drobyski W, Hari PN, Hamadani M. Efficacy, Toxicity, and Infectious Complications in Ruxolitinib-Treated Patients with Corticosteroid-Refractory Graft-versus-Host Disease after Hematopoietic CellTransplantation. Biol Blood Marrow Transplant. 2019 08;25(8):1689-1694.

225. Kim HT, Ahn KW, Hu ZH, Davids MS, Volpe VO, Antin JH, Sorror ML, Shadman M, Press O, Pidala J,Hogan W, Negrin R, Devine S, Uberti J, Agura E, Nash R, Mehta J, McGuirk J, Forman S, LangstonA, Giralt SA, Perales MA, Battiwalla M, Hale GA, Gale RP, Marks DI, Hamadani M, Ganguly S,Bacher U, Lazarus H, Reshef R, Hildebrandt GC, Inamoto Y, Cahn JY, Solh M, Kharfan-Dabaja MA,Ghosh N, Saad A, Aljurf M, Schouten HC, Hill BT, Pawarode A, Kindwall-Keller T, Saba N, CopelanEA, Nathan S, Beitinjaneh A, Savani BN, Cerny J, Grunwald MR, Yared J, Wirk BM, Nishihori T,Chhabra S, Olsson RF, Bashey A, Gergis U, Popat U, Sobecks R, Alyea E, Saber W, Brown JR.Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients:Center for International Blood and Marrow Transplant Research Report. Clin Cancer Res. 2019 0815;25(16):5143-5155. PMCID: PMC6697588

226. Ahmed S, Kanakry JA, Ahn KW, Litovich C, Abdel-Azim H, Aljurf M, Bacher VU, Bejanyan N, CohenJB, Farooq U, Fuchs EJ, Bolaños-Meade J, Ghosh N, Herrera AF, Hossain NM, Inwards D, KanateAS, Martino R, Munshi PN, Murthy H, Mussetti A, Nieto Y, Perales MA, Romee R, Savani BN, SeoS, Wirk B, Yared JA, Sureda A, Fenske TS, Hamadani M. Lower Graft-versus-Host Disease andRelapse Risk in Post-Transplant Cyclophosphamide-Based Haploidentical versus Matched SiblingDonor Reduced-Intensity Conditioning Transplant for Hodgkin Lymphoma. Biol Blood MarrowTransplant. 2019 09;25(9):1859-1868. PMCID: PMC6755039

227. Meybodi MA, Cao W, Luznik L, Bashey A, Zhang X, Romee R, Saber W, Hamadani M, Weisdorf DJ,Chu H, Rashidi A. HLA-haploidentical vs matched-sibling hematopoietic cell transplantation: asystematic review and meta-analysis. Blood Adv. 2019 09 10;3(17):2581-2585. PMCID:PMC6737418

228. Zhao JC, Arnall JR, Martin AL, Atrash S, Bhutani M, Voorhees P, Avalos B, Copelan E, Ghosh N, Hamadani M, Usmani S, Ford P. A Review of Growth Factor Support in Bloodless AutologousHematopoietic Stem Cell Transplant. Biol Blood Marrow Transplant. 2019 10;25(10):e305-e309.

229. Solomon SR, St Martin A, Shah NN, Fatobene G, Al Malki MM, Ballen KK, Bashey A, Bejanyan N,Bolaños Meade J, Brunstein CG, DeFilipp Z, Champlin RE, Fuchs EJ, Hamadani M, Hematti P,Kanakry CG, McGuirk JP, McNiece IK, Ciurea SO, Pasquini MC, Rocha V, Romee R, Patel SS, VasuS, Waller EK, Wingard JR, Zhang MJ, Eapen M. Myeloablative vs reduced intensity T-cell-repletehaploidentical transplantation for hematologic malignancy. Blood Adv. 2019 10 08;3(19):2836-2844.PMCID: PMC6784523

230. Guru Murthy GS, Szabo A, Hamadani M, Fenske TS, Shah NN. Contemporary Outcomes for Advanced-Stage Classical Hodgkin Lymphoma in the U.S.: Analysis of Surveillance, Epidemiology, and EndResults Database. Oncologist. 2019 11;24(11):1488-1495. PMCID: PMC6853108

231. Jain T, Bar M, Kansagra AJ, Chong EA, Hashmi SK, Neelapu SS, Byrne M, Jacoby E, Lazaryan A,Jacobson CA, Ansell SM, Awan FT, Burns L, Bachanova V, Bollard CM, Carpenter PA, DiPersio JF, Hamadani M, Heslop HE, Hill JA, Komanduri KV, Kovitz CA, Lazarus HM, Serrette JM, Mohty M,Miklos D, Nagler A, Pavletic SZ, Savani BN, Schuster SJ, Kharfan-Dabaja MA, Perales MA, Lin Y.Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory

40 / 59

Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society forTransplantation and Cellular Therapy. Biol Blood Marrow Transplant. 2019 12;25(12):2305-2321.

232. Aljurf M, Weisdorf D, Hashmi S, Nassar A, Gluckman E, Mohty M, Rizzo D, Pasquini M, Hamadani M,Saber W, Hari P, Kharfan-Dabaja M, Majhail N, Gerges U, Hamidieh AA, Hussain F, Elhaddad A,Mahmoud HK, Tbakhi A, Othman TB, Hamladji RM, Bekadja MA, Ahmed P, Bazarbachi A, Adil S,Alkindi S, Ladeb S, Dennison D, Patel M, Lu P, Quessar AE, Okamoto S, Atsuta Y, Alhejazi A, AyasMF, Ahmed SO, Novitzky N, Srivastava A, Seber A, Solh HE, Ghavamzadeh A, Confer D, Kodera Y,Hildegard G, Szer J, Horowitz MM, Niederwieser D. Worldwide Network for Blood and MarrowTransplantation Recommendations for Establishing a Hematopoietic Stem Cell TransplantationProgram in Countries with Limited Resources, Part II: Clinical, Technical, and SocioeconomicConsiderations. Biol Blood Marrow Transplant. 2019 12;25(12):2330-2337.

233. Badar T, Khan MA, Szabo A, Drobyski W, Chhabra S, Dhakal B, Fenske TS, Hamadani M, Hari P,Jerkins JH, Shah NN, Shaw BE, D'Souza A. Incidence and characteristics of engraftment syndromeafter autologous hematopoietic cell transplantation in light chain amyloidosis. Amyloid. 2019Dec;26(4):210-215.

234. Badar T, Dhakal B, Szabo A, Padmanabhan A, Johnson BD, Heidtke S, Esselmann J, Chhabra S, Hamadani M, Hari P, D'Souza A. An updated single center experience with plerixafor andgranulocyte colony-stimulating factor for stem cell mobilization in light chain amyloidosis. J ClinApher. 2019 Dec;34(6):686-691. PMCID: PMC6957224

235. Kahl BS, Hamadani M, Radford J, Carlo-Stella C, Caimi P, Reid E, Feingold JM, Ardeshna KM, Solh M,Heffner LT, Ungar D, He S, Boni J, Havenith K, O'Connor OA. A Phase I Study of ADCT-402(Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, inRelapsed/Refractory B-Cell Non-Hodgkin Lymphoma. Clin Cancer Res. 2019 1201;25(23):6986-6994.

236. Epperla N, Hamadani M, Reljic T, Kharfan-Dabaja MA, Savani BN, Kumar A. Upfront autologoushematopoietic stem cell transplantation consolidation for patients with aggressive B-cell lymphomas infirst remission in the rituximab era: A systematic review and meta-analysis. Cancer. 2019 Dec15;125(24):4417-4425.

237. Shah NN, Ahn KW, Litovich C, Sureda A, Kharfan-Dabaja MA, Awan FT, Ganguly S, Gergis U, InwardsD, Karmali R, Lazaryan A, Lekakis L, Munshi P, Nathan S, Saad AA, Solh M, Steinberg A, Vij R,Wood WA, Fenske TS, Smith S, Hamadani M. Allogeneic transplantation in elderly patients ?65years with non-Hodgkin lymphoma: a time-trend analysis. Blood Cancer J. 2019 12 03;9(12):97.PMCID: PMC6890709

238. Abedin S, Hamadani M. Experimental Pharmaceuticals for Steroid-Refractory Acute Graft-versus-HostDisease. J Exp Pharmacol. 2020;12:549-557. PMCID: PMC7705269

239. Pidala J, Hamadani M, Dawson P, Martens M, Alousi AM, Jagasia M, Efebera YA, Chhabra S, Pusic I,Holtan SG, Ferrara JLM, Levine JE, Mielcarek M, Anasetti C, Antin JH, Bolaños-Meade J, Howard A,Logan BR, Leifer ES, Pritchard TS, Horowitz MM, MacMillan ML. Randomized multicenter trial ofsirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trial.Blood. 2020 01 09;135(2):97-107. PMCID: PMC6952830

240. Badar T, Epperla N, Szabo A, Borson S, Vaughn J, George G, Saini N, Shah AR, Patel RD, Ahmed S, ShahNN, Cashen AF, Hamadani M, Fenske TS. Trends in postrelapse survival in classic Hodgkinlymphoma patients after experiencing therapy failure following auto-HCT. Blood Adv. 2020 0114;4(1):47-54. PMCID: PMC6960457

241. Knight JM, Rizzo JD, Hari P, Pasquini MC, Giles KE, D'Souza A, Logan BR, Hamadani M, Chhabra S,Dhakal B, Shah N, Sriram D, Horowitz MM, Cole SW. Propranolol inhibits molecular risk markers inHCT recipients: a phase 2 randomized controlled biomarker trial. Blood Adv. 2020 0211;4(3):467-476. PMCID: PMC7013267

242. Aljurf M, Weisdorf D, Hashmi SK, Nassar A, Gluckman E, Mohty M, Rizzo D, Pasquini M, Hamadani M,Saber W, Hari P, Kharfan-Dabaja M, Majhail N, Gerges U, Hamidieh AA, Hussain F, Elhaddad A,Mahmoud HK, Tbakhi A, Othman TB, Hamladji RM, Bekadja MA, Ahmed P, Bazarbachi A, Adil S,Alkindi S, Ladeb S, Dennison D, Patel M, Lu P, Quessar AE, Okamoto S, Atsuta Y, Alhejazi A, AyasM, Ahmed SO, Novitzky N, Srivastava A, Seber A, Elsolh H, Ghavamzadeh A, Confer D, Kodera Y,Greinix H, Szer J, Horowitz M, Niederwieser D. Worldwide Network for Blood and MarrowTransplantation (WBMT) recommendations for establishing a hematopoietic stem cell transplantationprogram in countries with limited resources (Part II): Clinical, technical and socio-economicconsiderations. Hematol Oncol Stem Cell Ther. 2020 03;13(1):7-16.

41 / 59

243. DeFilipp Z, Ancheta R, Liu Y, Hu ZH, Gale RP, Snyder D, Schouten HC, Kalaycio M, Hildebrandt GC,Ustun C, Daly A, Ganguly S, Inamoto Y, Litzow M, Szer J, Savoie ML, Hossain N, Kharfan-DabajaMA, Hamadani M, Reshef R, Bajel A, Schultz KR, Gadalla S, Gerds A, Liesveld J, Juckett MB,Kamble R, Hashmi S, Abdel-Azim H, Solh M, Bacher U, Lazarus H, Olsson R, Cahn JY, GrunwaldMR, Savani BN, Yared J, Rowe JM, Cerny J, Chaudhri NA, Aljurf M, Beitinjaneh A, Seo S, NishihoriT, Hsu JW, Ramanathan M, Alyea E, Popat U, Sobecks R, Saber W. Maintenance Tyrosine KinaseInhibitors Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic MyelogenousLeukemia: A Center for International Blood and Marrow Transplant Research Study. Biol BloodMarrow Transplant. 2020 03;26(3):472-479. PMCID: PMC7358778

244. Dreger P, Fenske TS, Montoto S, Pasquini MC, Sureda A, Hamadani M, European Society for Blood andMarrow Transplantation (EBMT) and the Center for International Blood and Marrow TransplantResearch (CIBMTR). Cellular Immunotherapy for Refractory Diffuse Large B Cell Lymphoma in theChimeric Antigen Receptor-Engineered T Cell Era: Still a Role for Allogeneic Transplantation? BiolBlood Marrow Transplant. 2020 04;26(4):e77-e85. PMCID: PMC7207150

245. Hourigan CS, Dillon LW, Gui G, Logan BR, Fei M, Ghannam J, Li Y, Licon A, Alyea EP, Bashey A, DeegHJ, Devine SM, Fernandez HF, Giralt S, Hamadani M, Howard A, Maziarz RT, Porter DL, Scott BL,Warlick ED, Pasquini MC, Horwitz ME. Impact of Conditioning Intensity of AllogeneicTransplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease. J ClinOncol. 2020 04 20;38(12):1273-1283. PMCID: PMC7164487

246. Chhabra S, Jerkins JH, Conto JE, Zellner K, Shah NN, Hari PN, Hamadani M. Lifitegrast ophthalmicsolution for treatment of ocular chronic graft-versus-host disease. Leuk Lymphoma. 202004;61(4):869-874.

247. Kanate AS, Perales MA, Hamadani M. Eligibility Criteria for Patients Undergoing AllogeneicHematopoietic Cell Transplantation. J Natl Compr Canc Netw. 2020 05;18(5):635-643.

248. Chhabra S, Narra RK, Wu R, Szabo A, George G, Michaelis LC, D'Souza A, Dhakal B, Drobyski WR,Fenske TS, Jerkins JH, Pasquini MC, Rizzo RD, Saber W, Shah NN, Shaw BE, Hamadani M, HariPN. Fludarabine/Busulfan Conditioning-Based Allogeneic Hematopoietic Cell Transplantation forMyelofibrosis: Role of Ruxolitinib in Improving Survival Outcomes. Biol Blood Marrow Transplant.2020 05;26(5):893-901.

249. Abedin SM, Hamadani M. Ruxolitinib: a potential treatment for corticosteroid refractory acute graft-versus-host disease. Expert Opin Investig Drugs. 2020 May;29(5):423-427.

250. Fatobene G, Rocha V, St Martin A, Hamadani M, Robinson S, Bashey A, Boumendil A, Brunstein C,Castagna L, Dominietto A, Finel H, Chalandon Y, Kenzey C, Kharfan-Dabaja M, Labussière-WalletH, Moraleda JM, Pastano R, Perales MA, El Ayoubi HR, Ruggeri A, Sureda A, Volt F, Yakoub-AghaI, Zhang MJ, Gluckman E, Montoto S, Eapen M. Nonmyeloablative Alternative Donor Transplantationfor Hodgkin and Non-Hodgkin Lymphoma: From the LWP-EBMT, Eurocord, and CIBMTR. J ClinOncol. 2020 05 10;38(14):1518-1526. PMCID: PMC7213591

251. Jagadeesh D, Majhail NS, He Y, Ahn KW, Litovich C, Ahmed S, Aljurf M, Bacher U, Badawy SM,Bejanyan N, Cairo M, Cerny J, Epperla N, Farhadfar N, Freytes CO, Gale RP, Haverkos B, Hossain N,Inwards D, Kamble RT, Kenkre VP, Lazarus HM, Lazaryan A, Lekakis L, Mei M, Murthy HS,Mussetti A, Nathan S, Nishihori T, Olsson RF, Ramakrishnan Geethakumari P, Savani BN, Yared JA,Fenske TS, Kharfan-Dabaja MA, Sureda A, Hamadani M. Outcomes of rituximab-BEAM versusBEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologoustransplantation. Cancer. 2020 05 15;126(10):2279-2287. PMCID: PMC7190439

252. Rashidi A, Meybodi MA, Cao W, Chu H, Warlick ED, Devine S, Pasquini MC, Weisdorf DJ, HamadaniM. Myeloablative versus Reduced-Intensity Hematopoietic Cell Transplantation in MyelodysplasticSyndromes: Systematic Review and Meta-analysis. Biol Blood Marrow Transplant. 202006;26(6):e138-e141.

253. Hamadani M, Khanal M, Ahn KW, Litovich C, Chow VA, Eghtedar A, Karmali R, Winter A, Fenske TS,Sauter C, Kharfan-Dabaja MA, Awan FT. Higher Total Body Irradiation Dose Intensity inFludarabine/TBI-Based Reduced-Intensity Conditioning Regimen Is Associated with Inferior Survivalin Non-Hodgkin Lymphoma Patients Undergoing Allogeneic Transplantation. Biol Blood MarrowTransplant. 2020 06;26(6):1099-1105. PMCID: PMC7255948

254. Dhakal B, Narra RK, Giri S, Szabo A, Smunt TL, Ghose S, Pathak LK, Aryal M, Hamadani M, Chhabra S,Janz S, D'Souza A, Hari PN. Association of adverse events and associated cost with efficacy forapproved relapsed and/or refractory multiple myeloma regimens: A Bayesian network meta-analysis ofphase 3 randomized controlled trials. Cancer. 2020 06 15;126(12):2791-2801.

42 / 59

255. Chhabra S, Szabo A, Glisch C, George G, Narra RK, Harrington A, Jerkins JH, D'Souza A, Dhakal B,Pasquini MC, Hamadani M, Hari PN. Relapse after Allogeneic Hematopoietic Cell Transplantationfor Multiple Myeloma: Survival Outcomes and Factors Influencing Them. Biol Blood MarrowTransplant. 2020 07;26(7):1288-1297.

256. Eapen M, Zhang MJ, Tang XY, Lee SJ, Fei MW, Wang HL, Hebert KM, Arora M, Chhabra S, Devine SM, Hamadani M, D'Souza A, Pasquini MC, Phelan R, Rizzo JD, Saber W, Shaw BE, Weisdorf DJ,Horowitz MM. Hematopoietic Cell Transplantation with Cryopreserved Grafts for Severe AplasticAnemia. Biol Blood Marrow Transplant. 2020 07;26(7):e161-e166. PMCID: PMC7206419

257. Kanate AS, Majhail NS, Savani BN, Bredeson C, Champlin RE, Crawford S, Giralt SA, LeMaistre CF,Marks DI, Omel JL, Orchard PJ, Palmer J, Saber W, Veys PA, Carpenter PA, Hamadani M.Indications for Hematopoietic Cell Transplantation and Immune Effector Cell Therapy: Guidelinesfrom the American Society for Transplantation and Cellular Therapy. Biol Blood Marrow Transplant.2020 07;26(7):1247-1256.

258. Hamadani M, Zhang MJ, Tang XY, Fei M, Brunstein C, Chhabra S, D'Souza A, Milano F, Phelan R, SaberW, Shaw BE, Weisdorf D, Devine SM, Horowitz MM. Graft Cryopreservation Does Not ImpactOverall Survival after Allogeneic Hematopoietic Cell Transplantation Using Post-TransplantationCyclophosphamide for Graft-versus-Host Disease Prophylaxis. Biol Blood Marrow Transplant. 202007;26(7):1312-1317. PMCID: PMC7194895

259. Badar T, Astle J, Kakar IK, Zellner K, Hari PN, Hamadani M. Clinical activity of ibrutinib in classicalHodgkin lymphoma relapsing after allogeneic stem cell transplantation is independent of tumor BTKexpression. Br J Haematol. 2020 07;190(2):e98-e101.

260. Ghosh N, Ahmed S, Ahn KW, Khanal M, Litovich C, Aljurf M, Bacher VU, Bredeson C, Epperla N,Farhadfar N, Freytes CO, Ganguly S, Haverkos B, Inwards D, Kamble RT, Lazarus HM, Lekakis L,Murthy HS, Nishihori T, Ramakrishnan P, Rizzieri DA, Yared JA, Kharfan-Dabaja MA, Sureda A, Hamadani M. Association of Reduced-Intensity Conditioning Regimens With Overall SurvivalAmong Patients With Non-Hodgkin Lymphoma Undergoing Allogeneic Transplant. JAMA Oncol.2020 07 01;6(7):1011-1018. PMCID: PMC7273311

261. Zhou Z, Nath R, Cerny J, Wang HL, Zhang MJ, Abdel-Azim H, Agrawal V, Ahmed G, Al-Homsi AS,Aljurf M, Alkhateeb HB, Assal A, Bacher U, Bajel A, Bashir Q, Battiwalla M, Bhatt VR, Byrne M,Cahn JY, Cairo M, Choe H, Copelan E, Cutler C, Damlaj MB, DeFilipp Z, De Lima M, Diaz MA,Farhadfar N, Foran J, Freytes CO, Gerds AT, Gergis U, Grunwald MR, Gul Z, Hamadani M, HashmiS, Hertzberg M, Hildebrandt GC, Hossain N, Inamoto Y, Isola L, Jain T, Kamble RT, Khan MW,Kharfan-Dabaja MA, Kebriaei P, Kekre N, Khera N, Lazarus HM, Liesveld JL, Litzow M, Liu H,Marks DI, Martino R, Mathews V, Mishra A, Murthy HS, Nagler A, Nakamura R, Nathan S, NishihoriT, Olin R, Olsson RF, Palmisiano N, Patel SS, Patnaik MM, Pawarode A, Perales MA, Politikos I,Popat U, Rizzieri D, Sandmaier BM, Savani BN, Seo S, Shah NN, Uy GL, Valcárcel D, Verdonck LF,Waller EK, Wang Y, Weisdorf D, Wirk B, Wong E, Yared JA, Saber W. Reduced intensityconditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTRreport. Blood Adv. 2020 07 14;4(13):3180-3190. PMCID: PMC7362362

262. D'Souza A, Fretham C, Lee SJ, Arora M, Brunner J, Chhabra S, Devine S, Eapen M, Hamadani M, Hari P,Pasquini MC, Perez W, Phelan RA, Riches ML, Rizzo JD, Saber W, Shaw BE, Spellman SR, SteinertP, Weisdorf DJ, Horowitz MM. Current Use of and Trends in Hematopoietic Cell Transplantation inthe United States. Biol Blood Marrow Transplant. 2020 08;26(8):e177-e182. PMCID: PMC7404814

263. Dhakal B, Miller S, Rein L, Pathak LK, Gloria L, Szabo A, Giri S, Chhabra S, Hamadani M, Paner A,Padmanabhan A, Janz S, D'Souza A, Hari P. Trends in the use of therapeutic plasma exchange inmultiple myeloma. J Clin Apher. 2020 Aug;35(4):307-315.

264. Ahmed S, Ghosh N, Ahn KW, Khanal M, Litovich C, Mussetti A, Chhabra S, Cairo M, Mei M, William B,Nathan S, Bejanyan N, Olsson RF, Dahi PB, van der Poel M, Steinberg A, Kanakry J, Cerny J, FarooqU, Seo S, Kharfan-Dabaja MA, Sureda A, Fenske TS, Hamadani M. Impact of type of reduced-intensity conditioning regimen on the outcomes of allogeneic haematopoietic cell transplantation inclassical Hodgkin lymphoma. Br J Haematol. 2020 08;190(4):573-582. PMCID: PMC7575614

265. Thapa B, Caimi PF, Ardeshna KM, Solh M, Carlo-Stella C, Kahl BS, Hamadani M. CD19 antibody-drugconjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-celltherapy. Blood Adv. 2020 08 25;4(16):3850-3852. PMCID: PMC7448593

266. Abid MB, Hamadani M, Szabo A, Hari PN, Graham MB, Frank MO, Collier WS, Abedin S, Jerkins JH,Pasquini MC, Runaas L, Shah NN, Chhabra S. Severity of Cytokine Release Syndrome and ItsAssociation with Infections after T Cell-Replete Haploidentical Related Donor Transplantation. Biol

43 / 59

Blood Marrow Transplant. 2020 09;26(9):1670-1678. 267. Shah NN, Johnson BD, Schneider D, Zhu F, Szabo A, Keever-Taylor CA, Krueger W, Worden AA, Kadan

MJ, Yim S, Cunningham A, Hamadani M, Fenske TS, Dropuli? B, Orentas R, Hari P. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation andexpansion trial. Nat Med. 2020 10;26(10):1569-1575.

268. Chhabra S, Visotcky A, Pasquini MC, Zhu F, Tang X, Zhang MJ, Thompson R, Abedin S, D'Souza A,Dhakal B, Drobyski WR, Fenske TS, Jerkins JH, Douglas Rizzo J, Runaas L, Saber W, Shah NN,Shaw BE, Horowitz MM, Hari PN, Hamadani M. Ixazomib for Chronic Graft-versus-Host DiseaseProphylaxis following Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant.2020 10;26(10):1876-1885. PMCID: PMC7571859

269. Chhabra S, Thapa B, Szabo A, Konings S, D'Souza A, Dhakal B, Jerkins JH, Pasquini MC, Johnson BD,Hari PN, Hamadani M. Utilization and Cost Implications of Hematopoietic Progenitor Cells Storedfor a Future Salvage Autologous Transplantation or Stem Cell Boost in Myeloma Patients. Biol BloodMarrow Transplant. 2020 11;26(11):2011-2017.

270. Monahan K, Kleman A, Thapa B, Szabo A, D'Souza A, Dhakal B, Jerkins JH, Pasquini MC, Hamadani M,Hari PN, Chhabra S. Propylene Glycol-Free Melphalan versus PG-Melphalan as Conditioning forAutologous Hematopoietic Cell Transplantation for Myeloma. Biol Blood Marrow Transplant. 202012;26(12):2229-2236.

271. Hamadani M, Litovich C, Ahn KW. Allogeneic Transplant Conditioning Regimens for Patients With Non-Hodgkin Lymphoma-Reply. JAMA Oncol. 2020 12 01;6(12):1984.

272. Algwaiz G, Aljurf M, Koh M, Horowitz MM, Ljungman P, Weisdorf D, Saber W, Kodera Y, Szer J, JawdatD, Wood WA, Brazauskas R, Lehmann L, Pasquini MC, Seber A, Lu PH, Atsuta Y, Riches M, PeralesMA, Worel N, Okamoto S, Srivastava A, Chemaly RF, Cordonnier C, Dandoy CE, Wingard JR,Kharfan-Dabaja MA, Hamadani M, Majhail NS, Waghmare AA, Chao N, Kröger N, Shaw B, MohtyM, Niederwieser D, Greinix H, Hashmi SK, WBMT and the CIBMTR Health Services andInternational Studies Committee. Real-World Issues and Potential Solutions in Hematopoietic CellTransplantation during the COVID-19 Pandemic: Perspectives from the Worldwide Network for Bloodand Marrow Transplantation and Center for International Blood and Marrow Transplant ResearchHealth Services and International Studies Committee. Biol Blood Marrow Transplant. 202012;26(12):2181-2189. PMCID: PMC7380217

273. Bal S, Costa LJ, Sauter C, Litovich C, Hamadani M. Outcomes of Autologous Hematopoietic CellTransplantation in Diffuse Large B Cell Lymphoma Refractory to Firstline Chemoimmunotherapy.Transplant Cell Ther. 2021 01;27(1):55.e1-55.e7. PMCID: PMC7965782

274. Epperla N, Ahn KW, Khanal M, Litovich C, Ahmed S, Ghosh N, Fenske TS, Kharfan-Dabaja MA, SuredaA, Hamadani M. Impact of Reduced-Intensity Conditioning Regimens on Outcomes in Diffuse LargeB Cell Lymphoma Undergoing Allogeneic Transplantation. Transplant Cell Ther. 202101;27(1):58-66. PMCID: PMC7972998

275. Dholaria B, Savani BN, Hamilton BK, Oran B, Liu HD, Tallman MS, Ciurea SO, Holtzman NG, Ii GLP,Devine SM, Mannis G, Grunwald MR, Appelbaum F, Rodriguez C, El Chaer F, Shah N, Hashmi SK,Kharfan-Dabaja MA, DeFilipp Z, Aljurf M, AlShaibani A, Inamoto Y, Jain T, Majhail N, Perales MA,Mohty M, Hamadani M, Carpenter PA, Nagler A. Hematopoietic Cell Transplantation in theTreatment of Newly Diagnosed Adult Acute Myeloid Leukemia: An Evidence-Based Review from theAmerican Society of Transplantation and Cellular Therapy. Transplant Cell Ther. 2021 01;27(1):6-20.

276. Dillon LW, Gui G, Logan BR, Fei M, Ghannam J, Li Y, Licon A, Alyea EP, Bashey A, Devine SM,Fernandez HF, Giralt S, Hamadani M, Howard A, Maziarz RT, Porter DL, Warlick ED, Pasquini MC,Scott BL, Horwitz ME, Deeg HJ, Hourigan CS. Impact of Conditioning Intensity and Genomics onRelapse After Allogeneic Transplantation for Patients With Myelodysplastic Syndrome. JCO PrecisOncol. 2021;5. PMCID: PMC8140814

277. Dhakal B, Hari PN, Usmani SZ, Hamadani M. Chimeric antigen receptor T cell therapy in multiplemyeloma: promise and challenges. Bone Marrow Transplant. 2021 01;56(1):9-19.

278. Epperla N, Hamadani M. A New Target for Hodgkin Lymphoma - Camidanlumab Tesirine. Curr HematolMalig Rep. 2021 02;16(1):19-24.

279. Shah NN, Hamadani M. Is There Still a Role for Allogeneic Transplantation in the Management ofLymphoma? J Clin Oncol. 2021 02 10;39(5):487-498.

280. Alotaibi S, Hamadani M, Al-Mansour M, Aljurf M. Breast Implant-associated Anaplastic Large CellLymphoma. Clin Lymphoma Myeloma Leuk. 2021 03;21(3):e272-e276.

281. Abid MB, Chhabra S, Buchan B, Graham MB, Abedin S, Thapa B, D'Souza A, George B, Hamadani M.

44 / 59

Bronchoalveolar lavage-based COVID-19 testing in patients with cancer. Hematol Oncol Stem CellTher. 2021 Mar;14(1):65-70. PMCID: PMC7543702

282. Badar T, Johnson BD, Hamadani M. Delayed neurotoxicity after axicabtagene ciloleucel therapy inrelapsed refractory diffuse large B-cell lymphoma. Bone Marrow Transplant. 2021 03;56(3):683-685.

283. Shah NN, Ahn KW, Litovich C, He Y, Sauter C, Fenske TS, Hamadani M. Is autologous transplant inrelapsed DLBCL patients achieving only a PET+ PR appropriate in the CAR T-cell era? Blood. 202103 11;137(10):1416-1423. PMCID: PMC7955408

284. Al Somali Z, Hamadani M, Kharfan-Dabaja M, Sureda A, El Fakih R, Aljurf M. Enteropathy-Associated Tcell Lymphoma. Curr Hematol Malig Rep. 2021 04;16(2):140-147.

285. Sharma A, Badawy SM, Suelzer EM, Murthy HS, Prasad P, Eissa H, Carpenter PA, Hamadani M, LabopinM, Schoemans H, Tichelli A, Phelan R, Hamilton BK, Buchbinder D, Im A, Hunter R, Brazauskas R,Burns LJ. Systematic reviews in hematopoietic cell transplantation and cellular therapy: considerationsand guidance from the American Society for Transplantation and Cellular Therapy, European Societyfor Blood and Marrow Transplantation, and the Center for International Blood and Marrow TransplantResearch late effects and quality of life working committee. Bone Marrow Transplant. 202104;56(4):786-797. PMCID: PMC8168056

286. Shah NN, Ahn KW, Litovich C, Sureda A, Kharfan-Dabaja MA, Awan FT, Ganguly S, Gergis U, InwardsD, Karmali R, Lazaryan A, Lekakis L, Munshi P, Nathan S, Saad AA, Solh M, Steinberg A, Vij R,Wood WA, Fenske TS, Smith S, Hamadani M. Correction: Allogeneic transplantation in elderlypatients ?65 years with non-Hodgkin lymphoma: a time-trend analysis. Blood Cancer J. 2021 Apr29;11(4):82. PMCID: PMC8085088

287. Yassine F, Sandoval-Sus J, Ayala E, Chavez J, Hamadani M, Kharfan-Dabaja MA. Cellular Therapies forMantle Cell Lymphoma. Transplant Cell Ther. 2021 05;27(5):363-370.

288. Sharma A, Badawy SM, Suelzer EM, Murthy HS, Prasad P, Eissa H, Carpenter PA, Hamadani M, LabopinM, Schoemans H, Tichelli A, Phelan R, Hamilton BK, Buchbinder D, Im A, Hunter R, Brazauskas R,Burns LJ. Systematic Reviews in Hematopoietic Cell Transplantation and Cellular Therapy:Considerations and Guidance from the American Society for Transplantation and Cellular Therapy,European Society for Blood and Marrow Transplantation, and Center for International Blood andMarrow Transplant Research Late Effects and Quality of Life Working Committee. Transplant CellTher. 2021 05;27(5):380-388. PMCID: PMC8415092

289. Hamadani M, Radford J, Carlo-Stella C, Caimi PF, Reid E, O'Connor OA, Feingold JM, Ardeshna KM,Townsend W, Solh M, Heffner LT, Ungar D, Wang L, Boni J, Havenith K, Qin Y, Kahl BS. Finalresults of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkinlymphoma. Blood. 2021 05 13;137(19):2634-2645. PMCID: PMC8138546

290. Hamadani M, Collins GP, Caimi PF, Samaniego F, Spira A, Davies A, Radford J, Menne T, Karnad A,Zain JM, Fields P, Havenith K, Cruz HG, He S, Boni J, Feingold J, Wuerthner J, Horwitz S.Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label,multicentre, dose-escalation, dose-expansion study. Lancet Haematol. 2021 Jun;8(6):e433-e445.

291. Caimi PF, Ai W, Alderuccio JP, Ardeshna KM, Hamadani M, Hess B, Kahl BS, Radford J, Solh M,Stathis A, Zinzani PL, Havenith K, Feingold J, He S, Qin Y, Ungar D, Zhang X, Carlo-Stella C.Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): amulticentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2021 06;22(6):790-800.

292. Scott BL, Pasquini MC, Fei M, Fraser R, Wu J, Devine SM, Porter DL, Maziarz RT, Warlick E, FernandezHF, Soiffer RJ, Alyea E, Hamadani M, Bashey A, Giralt S, Geller NL, Leifer E, Hourigan CS, Gui G,Mendizabal A, Horowitz MM, Deeg HJ, Horwitz ME. Myeloablative versus Reduced-IntensityConditioning for Hematopoietic Cell Transplantation in Acute Myelogenous Leukemia andMyelodysplastic Syndromes-Long-Term Follow-Up of the BMT CTN 0901 Clinical Trial. TransplantCell Ther. 2021 06;27(6):483.e1-483.e6. PMCID: PMC8217373

293. Sharma A, Badawy SM, Suelzer EM, Murthy HS, Prasad P, Eissa H, Carpenter PA, Hamadani M, LabopinM, Schoemans H, Tichelli A, Phelan R, Hamilton BK, Buchbinder D, Im A, Hunter R, Brazauskas R,Burns LJ. Correction: Systematic reviews in hematopoietic cell transplantation and cellular therapy:considerations and guidance from the American Society for Transplantation and Cellular Therapy,European Society for Blood and Marrow Transplantation, and the Center for International Blood andMarrow Transplant Research late effects and quality of life working committee. Bone MarrowTransplant. 2021 Jun;56(6):1486.

294. Jella TK, Cwalina TB, Treisman J, Hamadani M. Risk Factors for Cost-Related Delays to Medical CareAmong Lymphoma Patients: A 22-Year Analysis of a Nationally Representative Sample. Clin

45 / 59

Lymphoma Myeloma Leuk. 2021 07;21(7):e619-e625. 295. Wieduwilt MJ, Stock W, Advani A, Luger S, Larson RA, Tallman M, Appelbaum F, Zhang MJ, Bo-Subait

K, Wang HL, Bhatt VR, Dholaria B, Eapen M, Hamadani M, Jamy O, Prestidge T, Pulsipher M,Ritchie D, Rizzieri D, Sharma A, Barba P, Sandmaier BM, de Lima M, Kebriaei P, Litzow M, SaberW, Weisdorf D. Superior survival with pediatric-style chemotherapy compared to myeloablativeallogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negativeacute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and theCIBMTR. Leukemia. 2021 07;35(7):2076-2085. PMCID: PMC8257494

296. Wieduwilt MJ, Stock W, Advani A, Luger S, Larson RA, Tallman M, Appelbaum F, Zhang MJ, Bo-SubaitK, Wang HL, Bhatt VR, Dholaria B, Eapen M, Hamadani M, Jamy O, Prestidge T, Pulsipher M,Ritchie D, Rizzieri D, Sharma A, Barba P, Sandmaier BM, de Lima M, Kebriaei P, Litzow M, SaberW, Weisdorf D. Correction: Superior survival with pediatric-style chemotherapy compared tomyeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults withPh-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403and the CIBMTR. Leukemia. 2021 Jul;35(7):2140. PMCID: PMC8329698

297. Scordo M, Wang TP, Ahn KW, Chen Y, Ahmed S, Awan FT, Beitinjaneh A, Chen A, Chow VA, DholariaB, Epperla N, Farooq U, Ghosh N, Grover N, Hamad N, Hildebrandt GC, Holmberg L, Hong S,Inwards DJ, Jimenez-Jimenez A, Karmali R, Kenkre VP, Khimani F, Klyuchnikov E, Krem MM,Munshi PN, Nieto Y, Prestidge T, Ramakrishnan Geethakumari P, Rezvani AR, Riedell PA, Seo S,Shah NN, Solh M, Yared JA, Kharfan-Dabaja MA, Herrera A, Hamadani M, Sauter CS. OutcomesAssociated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous SystemLymphoma After Autologous Hematopoietic Cell Transplant. JAMA Oncol. 2021 0701;7(7):993-1003. PMCID: PMC8283558

298. Abboud R, Wan F, Mariotti J, Arango M, Castagna L, Romee R, Hamadani M, Chhabra S. Cytokinerelease syndrome after haploidentical hematopoietic cell transplantation: an international multicenteranalysis. Bone Marrow Transplant. 2021 11;56(11):2763-2770.

299. Halahleh K, Al Rimawi D, Abu Ghosh A, Muradi I, Da'na W, Hamadani M. The impact of post-hematopoietic stem cell transplant tyrosine kinase inhibitors in Philadelphia-positive acutelymphoblastic leukemia. Hematol Oncol Stem Cell Ther. 2021 Jul 29.

300. Kharfan-Dabaja MA, Kumar A, Ayala E, Aljurf M, Nishihori T, Marsh R, Burroughs LM, Majhail N, Al-Homsi AS, Al-Kadhimi ZS, Bar M, Bertaina A, Boelens JJ, Champlin R, Chaudhury S, DeFilipp Z,Dholaria B, El-Jawahri A, Fanning S, Fraint E, Gergis U, Giralt S, Hamilton BK, Hashmi SK, Horn B,Inamoto Y, Jacobsohn DA, Jain T, Johnston L, Kanate AS, Kansagra A, Kassim A, Kean LS, KitkoCL, Knight-Perry J, Kurtzberg J, Liu H, MacMillan ML, Mahmoudjafari Z, Mielcarek M, Mohty M,Nagler A, Nemecek E, Olson TS, Oran B, Perales MA, Prockop SE, Pulsipher MA, Pusic I, RichesML, Rodriguez C, Romee R, Rondon G, Saad A, Shah N, Shaw PJ, Shenoy S, Sierra J, Talano J,Verneris MR, Veys P, Wagner JE, Savani BN, Hamadani M, Carpenter PA. Standardizing Definitionsof Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and DonorChimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the AmericanSociety for Transplantation and Cellular Therapy. Transplant Cell Ther. 2021 08;27(8):642-649.

301. Munshi PN, Hamadani M, Kumar A, Dreger P, Friedberg JW, Dreyling M, Kahl B, Jerkeman M, Kharfan-Dabaja MA, Locke FL, Shadman M, Hill BT, Ahmed S, Herrera AF, Sauter CS, Bachanova V, GhoshN, Lunning M, Kenkre VP, Aljurf M, Wang M, Maddocks KJ, Leonard JP, Kamdar M, Phillips T,Cashen AF, Inwards DJ, Sureda A, Cohen JB, Smith SM, Carlo-Stella C, Savani B, Robinson SP,Fenske TS. ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant andcellular therapies in mantle cell lymphoma. Bone Marrow Transplant. 2021 12;56(12):2911-2921.PMCID: PMC8639670

302. Riedell PA, Hamadani M, Ahn KW, Litovich C, Murthy GSG, Locke FL, Brunstein CG, Merryman RW,Stiff PJ, Pawarode A, Nishihori T, Kharfan-Dabaja MA, Herrera AF, Sauter CS, Smith SM. Outcomesand Utilization Trends of Front-Line Autologous Hematopoietic Cell Transplantation for Mantle CellLymphoma. Transplant Cell Ther. 2021 11;27(11):911.e1-911.e7. PMCID: PMC8556305

303. Heslop HE, Stadtmauer EA, Levine JE, Ballen KK, Chen YB, DeZern AE, Eapen M, Hamadani M,Hamilton BK, Hari P, Jones RJ, Logan BR, Kean LS, Leifer ES, Locke FL, Maziarz RT, Nemecek ER,Pasquini M, Phelan R, Riches ML, Shaw BE, Walters MC, Foley A, Devine SM, Horowitz MM.Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2021: LookingForward as the Network Celebrates its 20th Year. Transplant Cell Ther. 2021 11;27(11):885-907.PMCID: PMC8556300

46 / 59

304. Merryman RW, Castagna L, Giordano L, Ho VT, Corradini P, Guidetti A, Casadei B, Bond DA, JaglowskiS, Spinner MA, Arai S, Lowsky R, Shah GL, Perales MA, De Colella JMS, Blaise D, Herrera AF,Shouse G, Spilleboudt C, Ansell SM, Nieto Y, Badar T, Hamadani M, Feldman TA, Dahncke L,Singh AK, McGuirk JP, Nishihori T, Chavez J, Serritella AV, Kline J, Mohty M, Dulery R,Stamatoulas A, Houot R, Manson G, Moles-Moreau MP, Orvain C, Bouabdallah K, Modi D,Ramchandren R, Lekakis L, Beitinjaneh A, Frigault MJ, Chen YB, Lynch RC, Smith SD, Rao U,Byrne M, Romancik JT, Cohen JB, Nathan S, Phillips T, Joyce RM, Rahimian M, Bashey A, BallardHJ, Svoboda J, Torri V, Sollini M, De Philippis C, Magagnoli M, Santoro A, Armand P, Zinzani PL,Carlo-Stella C. Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma.Leukemia. 2021 09;35(9):2672-2683.

305. Munshi PN, Hamadani M, Kumar A, Dreger P, Friedberg JW, Dreyling M, Kahl B, Jerkeman M, Kharfan-Dabaja MA, Locke FL, Shadman M, Hill BT, Ahmed S, Herrera AF, Sauter CS, Bachanova V, GhoshN, Lunning M, Kenkre VP, Aljurf M, Wang M, Maddocks KJ, Leonard JP, Kamdar M, Phillips T,Cashen AF, Inwards DJ, Sureda A, Cohen JB, Smith SM, Carlo-Stella C, Savani B, Robinson SP,Fenske TS. American Society of Transplantation and Cellular Therapy, Center of International Bloodand Marrow Transplant Research, and European Society for Blood and Marrow TransplantationClinical Practice Recommendations for Transplantation and Cellular Therapies in Mantle CellLymphoma. Transplant Cell Ther. 2021 09;27(9):720-728. PMCID: PMC8447221

306. Shanmugasundaram K, Goyal S, Switchenko J, Calzada O, Churnetski MC, Kolla B, Bachanova V, GersonJN, Barta SK, Gordon MJ, Danilov AV, Grover NS, Mathews S, Burkart M, Karmali R, Sawalha Y,Hill BT, Ghosh N, Park SI, Epperla N, Bond DA, Badar T, Blum KA, Hamadani M, Fenske TS,Malecek M, Kahl BS, Martin P, Guo J, Flowers CR, Cohen JB. Intensive induction regimens afterdeferring initial therapy for mantle cell lymphoma are not associated with improved survival. Eur JHaematol. 2021 Sep;107(3):301-310. PMCID: PMC8338766

307. Bond DA, Switchenko JM, Villa D, Maddocks K, Churnetski M, Gerrie AS, Goyal S, ShanmugasundaramK, Calzada O, Kolla B, Bachanova V, Gerson JN, Barta SK, Hill BT, Sawalha Y, Martin P,Maldonado E, Gordon M, Danilov AV, Grover NS, Mathews S, Burkart M, Karmali R, Ghosh N, ParkSI, Epperla N, Badar T, Guo J, Hamadani M, Fenske TS, Malecek MK, Kahl BS, Flowers CR, BlumKA, Cohen JB. Early relapse identifies MCL patients with inferior survival after intensive or lessintensive frontline therapy. Blood Adv. 2021 12 14;5(23):5179-5189.

308. Shadman M, Pasquini M, Ahn KW, Chen Y, Turtle CJ, Hematti P, Cohen JB, Khimani F, Ganguly S,Merryman RW, Yared JA, Locke FL, Ahmed N, Munshi PN, Beitinjaneh A, Reagan PM, Herrera AF,Sauter CS, Kharfan-Dabaja MA, Hamadani M. Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission. Blood. 2022 03 03;139(9):1330-1339. PMCID:PMC8900276

309. Ahmed G, Hamadani M, Shah NN. CAR T-cell therapy for secondary CNS DLBCL. Blood Adv. 2021 1228;5(24):5626-5630. PMCID: PMC8714710

310. Herrera AF, Ahn KW, Litovich C, Chen Y, Assal A, Bashir Q, Bayer RL, Coleman M, DeFilipp Z,Farhadfar N, Greenwood M, Hahn T, Horwitz M, Jacobson C, Jaglowski S, Lachance S, Langston A,Mattar B, Maziarz RT, McGuirk J, Mian MAH, Nathan S, Phillips A, Rakszawski K, Sengeloev H,Shenoy S, Stuart R, Sauter CS, Kharfan-Dabaja MA, Hamadani M. Autologous and allogeneichematopoietic cell transplantation for diffuse large B-cell lymphoma-type Richter syndrome. BloodAdv. 2021 09 28;5(18):3528-3539. PMCID: PMC8945575

311. Riedell PA, Hamadani M, Ahn KW, Litovich C, Brunstein CG, Cashen AF, Cohen JB, Epperla N, HillBT, Im A, Inwards DJ, Lister J, McCarty JM, Ravi Kiran Pingali S, Shadman M, Shaughnessy P, SolhM, Stiff PJ, Vose JM, Kharfan-Dabaja MA, Herrera AF, Sauter CS, Smith SM. Effect of time torelapse on overall survival in patients with mantle cell lymphoma following autologous haematopoieticcell transplantation. Br J Haematol. 2021 12;195(5):757-763. PMCID: PMC8627449

312. Dhakal B, Thapa B, Dong H, Tarima S, Chhabra S, D'Souza A, Drobyski W, Abid M, Shah N, Fenske T,Longo W, Hari P, Hamadani M. Budesonide Prophylaxis Reduces the Risk of Engraftment SyndromeAfter Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. Clin LymphomaMyeloma Leuk. 2021 10;21(10):e775-e781.

313. Dhakal B, Abedin S, Fenske T, Chhabra S, Ledeboer N, Hari P, Hamadani M. Response to SARS-CoV-2vaccination in patients after hematopoietic cell transplantation and CAR T-cell therapy. Blood. 2021Oct 07;138(14):1278-1281. PMCID: PMC8332674

314. Karmali R, Switchenko JM, Goyal S, Shanmugasundaram K, Churnetski MC, Kolla B, Bachanova V,Gerson JN, Barta SK, Gordon MJ, Danilov AV, Grover NS, Epperla N, Mathews S, Burkart M,

47 / 59

Sawalha Y, Hill BT, Ghosh N, Park SI, Bond DA, Maddocks KJ, Badar T, Fenske TS, Hamadani M,Guo J, Malecek M, Kahl BS, Martin P, Blum KA, Flowers CR, Cohen JB. Multi-center analysis ofpractice patterns and outcomes of younger and older patients with mantle cell lymphoma in therituximab era. Am J Hematol. 2021 11 01;96(11):1374-1384. PMCID: PMC8511300

315. Abedin S, Rashid N, Schroeder M, Romee R, Nauffal M, Alhaj Moustafa M, Kharfan-Dabaja MA, PalmerJ, Hogan W, Hefazi M, Larson S, Holtan S, DeFilipp Z, Jayani R, Dholaria B, Pidala J, Khimani F,Grunwald MR, Butler C, Hamadani M. Ruxolitinib resistance or intolerance in steroid-refractoryacute graft-versus-host disease - a real-world outcomes analysis. Br J Haematol. 202111;195(3):429-432.

316. Karmali R, Switchenko JM, Goyal S, Shanmugasundaram K, Churnetski MC, Kolla B, Bachanova V,Gerson JN, Barta SK, Gordon MJ, Danilov AV, Grover NS, Epperla N, Mathews S, Burkart M,Sawalha Y, Hill BT, Ghosh N, Park SI, Bond DA, Maddocks KJ, Badar T, Fenske TS, Hamadani M,Guo J, Malecek M, Kahl BS, Martin P, Blum KA, Flowers CR, Cohen JB. Multi-center analysis ofpractice patterns and outcomes of younger and older patients with mantle cell lymphoma in therituximab era. Am J Hematol. 2021 11 01;96(11):1374-1384. PMCID: PMC8511300

317. Mei M, Hamadani M, Ahn KW, Chen Y, Kharfan-Dabaja MA, Sauter C, Herrera AF. Autologoushematopoietic cell transplantation in diffuse large B-cell limphoma after 3 or more lines of priortherapy: evidence of durable benefit. Haematologica. 2022 Feb 03.

318. Savani M, Ahn KW, Chen Y, Ahmed S, Cashen AF, Shadman M, Modi D, Khimani F, Cutler CS, Zain J,Brammer JE, Rezvani AR, Fenske TS, Sauter CS, Kharfan-Dabaja MA, Herrera AF, Hamadani M.Impact of conditioning regimen intensity on the outcomes of peripheral T-cell lymphoma, anaplasticlarge cell lymphoma and angioimmunoblastic T-cell lymphoma patients undergoing allogeneictransplant. Br J Haematol. 2022 Feb 02.

319. Caimi PF, Ardeshna KM, Reid E, Ai W, Lunning M, Zain J, Solh M, Kahl BS, Hamadani M. TheAntiCD19 Antibody Drug Immunoconjugate Loncastuximab Achieves Responses in DLBCLRelapsing After AntiCD19 CAR-T Cell Therapy. Clin Lymphoma Myeloma Leuk. 2021 Nov 12.

320. Iqbal M, Savani BN, Hamadani M. New Indications and platforms for CAR-T therapy in lymphomasbeyond DLBCL. EJHaem. 2022 Jan;3(Suppl 1):11-23. PMCID: PMC8725814

321. Hamadani M. Did brentuximab vedotin's rise to the top ECHELON of Hodgkin therapeutics invalidateAETHERA results? Haematologica. 2021 Dec 30.

322. Hamadani M, Liao L, Yang T, Chen L, Moskowitz C. Characteristics and Clinical Outcomes of PatientsWith Relapsed/Refractory Diffuse Large B-cell Lymphoma Who Received At Least 3 Lines ofTherapies. Clin Lymphoma Myeloma Leuk. 2021 Nov 22.

323. Zurko J, Hamadani M. Loncastuximab tesirine for diffuse large B-cell lymphoma. Drugs Today (Barc).2021 Dec;57(12):733-743.

324. Epperla N, Hamadani M. Double-refractory Hodgkin lymphoma: tackling relapse after brentuximabvedotin and checkpoint inhibitors. Hematology Am Soc Hematol Educ Program. 2021 1210;2021(1):247-253. PMCID: PMC8791097

325. Hamadani M, Ngoya M, Sureda A, Bashir Q, Litovich CA, Finel H, Chen Y, Boumendil A, Zain J,Castagna L, Cashen AF, Blaise D, Shadman M, Pastano R, Khimani F, Arat M, Dietrich S, Schmitz N,Glass B, Kharfan-Dabaja MA, Corradini P, Sauter CS, Montoto S, Kwon M, Herrera AF, Dreger P.Outcome of allogeneic transplantation for mature T-cell lymphomas: impact of donor source anddisease characteristics. Blood Adv. 2022 Feb 08;6(3):920-930. PMCID: PMC8945300

326. Meyers G, Hamadani M, Martens M, Ali H, Choe H, Dawson P, Harris AC, van Hooren E, Klaassen W,Leifer E, MacMillan ML, van Oosterhout Y, Perez L, Pusic I, Vo P, Levine JE. Lessons learned fromearly closure of a clinical trial for steroid-refractory acute GVHD. Bone Marrow Transplant. 2022Feb;57(2):302-303. PMCID: PMC8825705

327. Patel A, Subramanian Guru Murthy G, Hamadani M, Szabo A, Knight JM. The impact of beta-blocker useat the time of hematopoietic cell transplantation on the development of acute and chronic graft-versus-host disease. Hematol Oncol Stem Cell Ther. 2021 Nov 05.

328. Ahmed S, Zhao Q, Hanel W, Qazilbash MH, Patel K, Narra R, Kansagra A, Iqbal M, Awan FT, ChristianB, Jaglowski SM, Kharfan-Dabaja MA, Hamadani M, Epperla N. Post-relapse survival inWaldenstrom macroglobulinemia patients experiencing therapy failure following autologoustransplantation. Hematol Oncol. 2022 Feb;40(1):48-56.

329. Hamadani M, Gopal AK, Pasquini M, Kim S, Qiu X, Ahmed S, Lazaryan A, Bhatt VR, Daly A, Lulla P,Ciurea S, Gauthier J, Agrawal V, Grover NS, Lekakis L, Modi D, Dahi PB, Herr MM, Johnson PC,Hashmi H, Hematti P, Locke FL. Allogeneic transplant and CAR-T therapy after autologous transplant

48 / 59

failure in DLBCL: a noncomparative cohort analysis. Blood Adv. 2022 Jan 25;6(2):486-494. PMCID:PMC8791562

330. Dhakal B, Chhabra S, Savani BN, Hamadani M. Promise and pitfalls of allogeneic chimeric antigenreceptor therapy in plasma cell and lymphoid malignancies. Br J Haematol. 2022 Apr;197(1):28-40.

331. Jella T, Cwalina TB, Hamadani M. Epidemiology of Food Insecurity in a Nationally RepresentativeSample of Lymphoma Patients. Clin Lymphoma Myeloma Leuk. 2022 02;22(2):e128-e134.

332. Ahmed N, Hamadani M. Evaluating efficacy and safety of loncastuximab tesirine injection for thetreatment of adult patients with relapsed or refractory large B-cell lymphoma. Expert Rev AnticancerTher. 2021 12;21(12):1313-1320.

333. Karmali R, Switchenko JM, Goyal S, Shanmugasundaram K, Churnetski MC, Kolla B, Bachanova V,Gerson JN, Barta SK, Gordon MJ, Danilov AV, Grover NS, Epperla N, Mathews S, Burkart M,Sawalha Y, Hill BT, Ghosh N, Park SI, Bond DA, Maddocks KJ, Badar T, Fenske TS, Hamadani M,Guo J, Malecek M, Kahl BS, Martin P, Blum KA, Flowers CR, Cohen JB. Multi-center analysis ofpractice patterns and outcomes of younger and older patients with mantle cell lymphoma in therituximab era. Am J Hematol. 2021 11 01;96(11):1374-1384. PMCID: PMC8511300

Books, Chapters, and Reviews1. Hamadani M, Devine SM Patient evaluation before transplantation (adult). In: Wingard JR, Gastineau D,

Leather H, Snyder EL, Szczepiorkowski ZM, eds. Hematopoietic Stem cell transplantation: ahandbook for clinicians, 1st ed. Bethesda, MD AABB. 2009 Sept; 27-43

2. Hamadani M, Jaffe ES. Hodgkin lymphoma. In: Abraham J, Gulle JL, Allegra CJ, eds. The BethesdaHandbook of Clinical Oncology, 4th ed. Philadelphia, PA Lippincott Williams & Wilkins. 2014March; 374-384

3. Lazarus HM, Hamadani M, Hari PN. Autologous hematopoietic cell transplantation. In: DeVita VT,Lawrence TS, Rosenberg SA, eds. DeVita, Hellman, and Rosenberg's Cancer: Principles and Practiceof Oncology, 10th ed. Philadelphia, PA Lippincott Williams & Wilkins. 2014 Dec; 1907-1916

4. Hsu J, Hamadani M, Devine SM. Patient evaluation before transplantation (adult). In: Wingard JR, GastineauD, Leather H, Snyder EL, Szczepiorkowski ZM, eds. Hematopoietic Stem Cell Transplantation: AHandbook for Clinicians, 2nd ed. Bethesda, MD AABB. 2015 Jan; 43-58

5. Saber W, Hamadani M, Hashmi S, Hari P. Lymphoma: working committee and data reporting aftertransplantation in lymphoma. In: Savani BN, Mohty M, eds. Clinical Guide to Transplantation inLymphoma, 1st ed. Hoboken, NJ Wiley-Blackwell. 2015 Aug; 13-22

6. Kharfan-Dabaja MA, El-Jurdi N, Hamadani M, Ayala E. Preparative regimens for lymphoma: allogeneichematopoietic stem cell transplantation. In: Savani BN, Mohty M, eds. Clinical Guide toTransplantation in Lymphoma, 1st ed. Hoboken, NJ Wiley-Blackwell; 2015 Aug; 57-68

7. Veltri L, Savani BN, Kharfan-Dabaja MA, Hamadani M, Kanate AS. Diffuse large B-cell lymphoma. In:Savani BN, Mohty M, eds. Clinical Guide to Transplantation in Lymphoma, 1st ed. Hoboken, NJWiley-Blackwell. 2015 Aug; 145-160

8. Epperla N, Hashami H, Hamadani M: “Hematopoietic cell transplantation in indolent non-Hodgkinlymphomas.” In: Abutalib SA., Hari P., eds. Clinical Manual of Blood and Bone MarrowTransplantation, 1st ed. Hoboken, NJ: Wiley-Blackwell; 2017: 140-150.

9. Hamadani M, Hari PN: “Indications and outcomes of allogeneic hematopoietic cell transplantation forhematologic malignancies in adults” In: Hoffman R.., Benz EJ Jr., Silberstein LE., Heslop H., Weitz J.,Anastasi J., Abutalib SA., eds. Hematology: Basic Principles and Practice, 7th ed. Philadelphia, PA:Elsevier; 2017: 1596-1607.

10. Epperla N, Hamadani M, Horowitz MM: “Indications for allogeneic hematopoietic cell transplantation inadults.” In: Gluckman E., Niederwieser D., Aljurf M., eds. Establishing a Hematopoietic Stem CellTransplantation Unit, 1st ed. Cham, Switzerland: Springer International Publishing AG. 2018: 83-110.

11. Lazarus HM, Hamadani M, Hari PN: “Autologous hematopoietic cell transplantation.” In: DeVita VT.,Lawrence TS., Rosenberg SA., eds. DeVita, Hellman, and Rosenberg's Cancer: Principles and Practiceof Oncology, 11th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2019: 2008-2019.

12. Guru Murthy GS, Hamadani M, Hari PN. “Haploidentical hematopoietic cell transplantation inlymphomas.” In: Ciurea SO., Handgretinger R, eds. Haploidentical Transplantation: Concepts andClinical Application, 1st ed. Cham, Switzerland: Springer International Publishing AG. 2018:245-260.

13. Kanate AS, Craig M, Hamadani M. “Hematopoietic cell transplantation.” In: Abraham J., Gulle JL., AllegraCJ., eds. The Bethesda Handbook of Clinical Oncology, 5th ed. Philadelphia, PA: Lippincott Williams& Wilkins; 2019: 404-416.

49 / 59

Non-Refereed Journal Publications/Original Papers1. Hamadani SM, Chaudhary L. Limitations of Sokal score in patients with chronic myeloid leukemia. J Coll

Physicians Surg Pak. 2007 Mar;17(3):182; author reply 182. 2. Hamadani M, Kraut EH. Review: isolated skeletal involvement in hairy cell leukemia. Clin Adv Hematol

Oncol. 2008 Apr;6(4):294-6. 3. Hamadani M, Blum W Role of hematopoietic stem cell transplantation in adults with acute myeloid

leukemia. Clinical Leukemia. 2009 February; 3(1):47-574. Hamadani M, Mohty M, Kharfan-Dabaja MA. Reduced-intensity conditioning allogeneic hematopoietic cell

transplantation in adults with acute myeloid leukemia. Cancer Control. 2011 Oct;18(4):237-45. 5. Chaudhary L, Hamadani M. Management strategies for follicular lymphoma patients in remission after

modern frontline chemoimmunotherapies. J Blood Disorders Transf. 2013 January; 4(1):1000e1056. Hamadani M. Reappraising the role of autologous transplantation for indolent B-cell lymphomas in the

chemoimmunotherapy era: is it still relevant? Bone Marrow Transplant. 2013 Aug;48(8):1013-21. 7. Hamadani M, Kanate AS Dawn of a new era: targeting the B-cell receptor signaling pathway to conquer B-

cell lymphomas. Community Oncology. 2013 October;10(10):279-2818. Hamadani M, Abu Kar SM, Usmani SZ, Savani BN, Ayala E, Kharfan-Dabaja MA. Management of relapses

after hematopoietic cell transplantation in T-cell non-Hodgkin lymphomas. Semin Hematol. 2014Jan;51(1):73-86.

9. Hamadani M. Antithymocyte globulin in reduced-intensity conditioning allografting: is the benefit simply inthe eyes of the transplanter? Biol Blood Marrow Transplant. 2014 Mar;20(3):292-4.

10. Kanate AS, Pasquini MC, Hari PN, Hamadani M. Allogeneic hematopoietic cell transplant for acutemyeloid leukemia: Current state in 2013 and future directions. World J Stem Cells. 2014 Apr26;6(2):69-81. PMCID: PMC3999783

11. Epperla N, Fenske TS, Hari PN, Hamadani M. Recent advances in post autologous transplantationmaintenance therapies in B-cell non-Hodgkin lymphomas. World J Transplant. 2015 Sep 24;5(3):81-8.PMCID: PMC4580930

12. Epperla N, Hamadani M. “Hematopoietic cell transplantation for diffuse large B-cell and follicularlymphoma: Current controversies and advances.” Hematol Oncol Stem Cell Ther. 2017December;10(4):277-284.

13. Hamadani M, Horowitz MH. “Allogeneic transplantation for follicular lymphoma: Does one size fit all?” JOncol Pract. 2017 Dec; 13(12):798-806.

14. Hamadani M. “Advances in transplantation for lymphomas resulting from CIBMTR Lymphoma WorkingCommittee’s research portfolio: A five-year report (2013-2018).” Advances in Cell and GeneTherapy. 2018 Nov;1(3):e17-e21.

15. Hashmi H, Hamadani M, Awan FT. “Choosing the appropriate salvage therapy for B-cell non-Hodgkinlymphoma.” Expert Opin Pharmacother. 2018 Oct;19(15):1631-1634.

Abstracts1. Mosallaei-Benjamin M, Hamadani M, Scofield H, Holla P, Selby G. The effects of hyperglycemia on

hematopoietic stem cell transplantation. Poster Presentation: 39th Annual Meeting of the AmericanSociety of Hematology 1997, San Diego, CA.

2. Sethi S, Hamadani M, Kamble R, Kharfan-Dabaja M, Selby G, Ozer H. Pure red cell aplasia (PRCA)following ABO-incompatible allogeneic bone marrow transplantation. Poster Presentation: BMTTandem Meetings 2005, Keystone, CO.

3. Hamadani M, Kamble R, Sethi S, Kharfan-Dabaja M, Kern W, Ozer H, Selby G. Elevated mean corpuscularvolume (MCV) following autologous hematopoietic stem cell transplantation: incidence andsignificance. Poster Presentation: BMT Tandem Meetings 2005, Keystone, CO.

4. Hamadani M, Tfayli A, Kojouri K, Awab A. Comparison of ondansetron, granisetron, and dolasetron withdexamethasone in the prevention of acute nausea and vomiting associated with platinum-basedtherapy. Poster Presentation: ASCO 2005, Orlando, FL.

5. Hamadani M, Padmanabhan R, Chaudhary L, Tfayli A. Relative efficacy of various 5- hydroxytryptaminereceptor antagonists in the prevention and control of acute nausea and vomiting associated withplatinum-based chemotherapy. Poster Presentation: ASCO 2006, Atlanta, GA.

6. Hamadani M, Awan F, Elder P, Porcu P, Lin T, Blum K, Scholl D, Devine SM. Allogeneic hematopoieticstem cell transplantation for peripheral T-cell lymphoma: evidence of graft-versus-lymphoma effect.

50 / 59

Poster Presentation: ASH 2007, Atlanta, GA.7. Hamadani M, Hade EM, Elder P, Benson DM, Hofmeister CC. The effect of statin use at the time of

autologous transplant on response and survival in patients with multiple myeloma. ASH 2007, Atlanta,GA.

8. Hamadani M, Elder P, Awan F, Krugh D, Blum W, Lin T, Andritsos L, Bechtel T, Blum K, Klisovic R,Devine SM. High rates of early donor chimerism and low risk of chronic GVHD can be achieved inpoor risk patients undergoing unrelated donor stem cell transplantation using a reduced intensityconditioning regimen incorporating fludarabine, busulfan, and rabbit ATG. ASH 2007, Atlanta, GA.

9. Hamadani M, Phillips G, Elder P, Jansak B, Blum W, Penza S, Lin TS, Farag SS, Devine SM. Phase-II studyof infliximab for the prophylaxis of acute graft-versus-host disease (GVHD) Following allogeneichematopoietic stem cell transplantation (AHSCT). Poster Presentation: BMT Tandem Meetings 2008,San Diego, CA.

10. Hamadani M, Awan FT, Elder P, Lin TS, Andritsos L, Blum W, Blum KA, Devine SM. Rapid engraftmentand low rates of graft-versus-host disease (GVHD) following reduced intensity conditioning (RIC)with fludarabine/busulfan/ATG (FBA) and Stem cell transplantation (SCT) using unrelated donors(URD). Poster Presentation: BMT Tandem Meetings 2008, San Diego, CA.

11. Hamadani M, Awan FT, Elder P, Devine SM. Statins reduce acute graft-versus-host disease in patients withacute leukemia undergoing allogeneic transplantation. Poster Presentation: ASCO 2008, Chicago, IL.

12. Awan FT, Hamadani M, Lin TS, Porcu P, Blum KA, Benson DM Jr, Devine SM. Comparison of allogeneicvs. autologous transplantation for follicular lymphoma after transformation into diffuse large B-celllymphoma. Poster Presentation: ASCO 2008, Chicago, IL.

13. Hamadani M, Blum KA, Elder P, Lin TS, Porcu P, Hofmeister CC, Blum W, Marcucci G, Benson D,Devine S. Allogeneic stem cell transplantation for patients with chemo-refractory or progressiveaggressive non-Hodgkin's lymphomas. Poster Presentation: ASH 2008, San Francisco, CA.

14. Hamadani M, Blum W, Benson D, Blum KA, Porcu P, Elder P, Krugh D, Bechtel T, Andritsos L, GarzonR, Penza S, Lin TS, Devine S. Assessment of rabbit antithymocyte globulin (rATG) dose-intensity inpatients with hematological malignancies undergoing allogeneic stem cell transplantation (ASCT)following reduced intensity conditioning (RIC) with fludarabine, busulfan and rATG (FBA). ASH2008, San Francisco, CA.

15. Benson D, Andritsos L, Hamadani M, Lin T, Flynn J, Jones J, Blum W, Elder P, Lozanski G, Byrd J,Devine S. Natural killer cell immune reconstitution predicts outcomes for patients with chroniclymphocytic leukemia undergoing allogeneic stem cell transplantation. Poster Presentation: ASH 2008,San Francisco, CA.

16. Ferreri AJM, Govi S, Dognini GP, Bouzani M, Bollinguer RC, D'Incan M, Delaporte E, Hamadani M,Jardin F, Martusewicz-Boros M, Montanari M, Szomor A, Crocchiolo R, Zucca E, Cavalli F, PonzoniM. A cumulative series from 14 western countries suggests that rituximab significantly changed thedismal natural history of intravascular large B-cell lymphoma (IVL). Poster Presentation: ASH 2008,San Francisco, CA.

17. Andritsos L, Hamadani M, Heerema NA, Benson D, Hofmeister CC, Blum W, Flynn J, Jones JA, Elder P,Lin TS, Lozanski G, Byrd JC, Devine S. Attainment of minimal residual disease negative state iscrucial for successful outcome of reduced intensity conditioning allogeneic stem cell transplantation inadvanced chronic lymphocytic leukemia (CLL). Poster Presentation: ASH 2008, San Francisco, CA.

18. Pant S, Hamadani M, Crilley P, Szer J, Dodds AJ, Stevenson DE, Phillips G, Elder P, Nivison-Smith I,Avalos B, Penza P, Topolsky D, Sobecks R, Kalaycio M, Bolwell BJ, Copelan E. Incidence of latefailure following myeloablative conditioning with BuCy2 and matched sibling allogeneic stem celltransplantation for acute myeloid leukemia. Poster Presentation: ASH 2008, San Francisco, CA.

19. Hamadani M, Benson DM, Porcu P, Elder P, Andritsos L, Hofmeister CC, Krugh D, Garzon R, Lin T,Marcucci G, Blum W, Devine SM. Evaluation of rabbit antithymocyte globulin (rATG) dose-intensityin patients undergoing allogeneic stem cell transplantation (ASCT) following reduced intensityconditioning (RIC) with fludarabine, busulfan and rATG (FBA). Oral Presentation: BMT TandemMeetings 2009, Tampa, FL.

20. Hamadani M, Baiocchi R, Lin T, Blum KA, Ezzone S, Benson DM, Devine SM. Feasibility of allogeneicperipheral blood stem cell transplantation (Allo-SCT) following reduced intensity conditioning (RIC)in HIV+ patients with hematological malignancies. Poster Presentation: BMT Tandem Meetings 2009,Tampa, FL.

21. Benson DM, Hofmeister CC, Hamadani M, Panzner K, Smith MK, Penza SL, Elder P, Krugh D, O'DonnellL, Devine SM. Pre-mobilization bone marrow plasmacytosis predicts successful stem cell mobilization

51 / 59

in patients with multiple myeloma receiving lenalidomide based induction regimens. PosterPresentation: BMT Tandem Meetings 2009, Tampa, FL.

22. Grauer A, Hamadani M, Blum KA, Porcu P, Benson DM, Devine SM. Allogeneic versus autologous stemcell transplantation (SCT) for follicular lymphoma (FL). The James comprehensive cancer centerexperience. Poster Presentation: BMT Tandem Meetings 2009, Tampa, FL.

23. Hamadani M, Liu K, Anthony BA, Gaughan A, Wang JJ, Shana'ah A, Byrd JC, Devine SM, Johnson AJ,Hadley GA. CD103 deficiency separates graft-versus-host disease and graft-versus-leukemia effectsmediated by donor CD8T Cells. Poster Presentation: BMT Tandem Meetings 2010, Orlando, FL.

24. Hamadani M, Craig M, Abraham J, Tse W, Cumpston A, Stotler CJ, Remick SC, Bunner P, Leadmon S,Elder P, Hofmeister C, Penza S, Andritsos L, Blum W, Benson DM, Devine SM. Evaluation Ofbusulfan's dose-intensity in patients undergoing allogeneic stem cell transplantation (ASCT) with twodifferent fludarabine/busulfan/ATG (FBA)-based reduced intensity conditioning (RIC) regimens.Poster Presentation: BMT Tandem Meetings 2010, Orlando, FL.

25. Jaglowski SM, Heerema N, Elder P, Scholl D, Hamadani M, Byrd JC, Devine S, Andritsos LA. Complexkaryotype predicts poor response to salvage therapy and ineligibility for reduced intensity conditioningtransplantation in CLL . Poster Presentation: BMT Tandem Meetings 2010, Orlando, FL.

26. Osman S, Kanate AS, Bunner P, Leadmon S, Tse W, Cumpston A, Gibson L, Remick S, Abraham J, CraigM, Hamadani M. Response to induction chemotherapy with novel agents does not predict outcomesof multiple myeloma patients undergoing autologous hematopoietic cell transplantation. PosterPresentation: ASH 2010, Orlando, FL.

27. Kanate AS, Osman S, Cumpston A, Hobbs G, Leadmon L, Bunner P, Watkins W, Gibson L, Tse W,Abraham J, Remick S, Craig M, Hamadani M. Higher infused CD34+ cell dose improves survival inpatients undergoing in-vivo T-cell depleted, but not T-cell replete peripheral blood hematopoietic celltransplant. Poster Presentation: ASH 2010, Orlando, FL.

28. Awan F, Osman S, Kochuparambil ST, Remick S, Abraham J, Craig M, Jillella AP, Hamadani M. Impact ofresponse to thalidomide, lenalidomide or bortezomib containing induction chemotherapy on outcomesof multiple myeloma patients undergoing autologous transplantation - A multicenter analysis. PosterPresentation: ASH 2010, Orlando, FL.

29. Kanate AS, Osman S, Cumpston A, Hobbs G, Leadmon L, Bunner P, Watkins W, Gibson L, Tse W,Abraham J, Remick S, Craig M, Hamadani M. In-vivo T-cell depletion does not improve rates ofgraft-versus-host disease and transplantation outcomes in patients undergoing peripheral bloodhematopoietic cell transplant. ASH 2010, Orlando, FL.

30. Stauffer N, Hamadani M, Heaphy C, Santhanam R, Sandhu S, Costinean S, Nuovo J, Perrotti D, Croce CM,Hadley G, Marcucci G, Devine SM, Garzon R. Regulation of acute graft-versus-host disease bymicroRNA-155. Oral Presentation: ASH 2010, Orlando, FL.

31. Hamadani M, Craig M, Abraham J, Tse W, Cumpston A, Gibson LF, Remick SC, Leadmon S, Elder P,Hofmeister C, Penza S, Andritsos L, Blum W, Benson DM, Devine SM. Higher busulfan doseintensity does not improve outcomes of patients undergoing allogeneic hematopoietic celltransplantation following fludarabine/busulfan/ATG-based reduced toxicity conditioning. PosterPresentation: BMT Tandem Meetings 2011, Honolulu, HI.

32. Kanate AS, Osman S, Cumpston A, Hobbs G, Leadmon S, Bunner P, Gibson L, Tse W, Abraham J, RemickS, Craig M, Hamadani M. In vivo T-cell depletion does not improve rates of graft-versus-host diseaseand transplantation outcomes in patients undergoing peripheral blood allogeneic hematopoietic celltransplant. Poster Presentation: BMT Tandem Meetings 2011, Honolulu, HI.

33. Osman S, Kanate A, Bunner P, Leadmon S. Hart K, Goff L, Tse W, Cumpston A, Remick S, Abraham M,Craig M, Hamadani M. Cyclophosphamide/G-CSF cannot completely overcome Imid-inducedimpairment of peripheral blood stem cell mobilization in patients with multiple myeloma. PosterPresentation: BMT Tandem Meetings 2011, Honolulu, HI.

34. Kanate AS, Chaudhary L, Cumpston A, Leadmon S, Bunner P, Bulian D, Gibson L, Tse W, Abraham J,Remick S, Craig M, Hamadani M. High rates of non-relapse mortality and graft-versus-host diseasein patient undergoing allogeneic stem cell transplantation following non-myeloablative conditioningwith TLI/ATG. Poster Presentation: BMT Tandem Meetings 2011, Honolulu, HI.

35. Anthony B, Hamadani M, Wang JJ, Gaughan A, Hadley GA. CD103 blockade reduces CD8 T cellaccumulation during GVHD, but does not attenuate GVL effects. Poster Presentation: AAI 2011, SanFrancisco, CA.

36. Covey T, Gulrajani M, Hawtin R, Gayko U, Cumpston A, Craig M, Hamadani M, Rishel A, Park J,Abraham J, Remick S, Tse W. Integrating in vitro signaling and drug response data from single cell

52 / 59

network profiling (SCNP) to inform on individual's AML biology. Poster Presentation: AACR-NCI-EORTC International Conference 2011, San Francisco, CA.

37. Hamadani M, Kochuparambil TS, Osman S, Speir E, Craig M, Deremer D, Cumpston A, Morrison DD,Leadmon S, Sterling K, Bunner P, Sterrett M, Kota V, Jillella AP, Awan FT. Intermediate- VersusLow-Dose Cyclophosphamide and Granulocyte Colony Stimulating Factor for Peripheral BloodProgenitor Cell Mobilization in Patients with Multiple Myeloma Treated with Novel InductionChemotherapies - A Multicenter Analysis. Oral Presentation: ASH 2011, San Diego, CA.

38. Kharfan-Dabaja M, Hamadani M, Reljic T, Bensinger W, Djulbegovic B, Kumar A. Comparative efficacyof tandem autologous-autologous versus tandem autologous-reduced intensity allogeneichaematopoietic cell transplantation in multiple myeloma: results of a systematic review and meta-analysis. Oral Presentation: BMT Tandem Meetings 2012, San Diego, CA.

39. Forero A, Hamadani M, Goswami T, Sonet A, Verhoef G, Fanale MA, Bello CM, Huang W, Cheson BD.Phase I/II study of MEDI-551, a humanized monoclonal antibody targeting CD19, in subjects withrelapsed or refractory advanced B-cell malignancies. Poster Presentation: ASCO 2012, Chicago, IL.

40. Richardson P, Berdeja J, Niesvizky R, Lonial S, Vesole D, Hamadani M, Chari A, Hari P, Htut M, Roy V,Stewart K, Berg D, Lin L, Gupta N, Di Bacco A, Hui A-M, Kumar S. MLN9708, an investigationalproteasome inhibitor, combine with lenalidomide and dexamethasone in previously untreated multiplemyeloma patients: Evaluation of weekly and twice-weekly dosing regimens. Oral Presentation: 17thCongress of the EHA 2012, Amsterdam, NL.

41. Kumar S, Berdeja J, Niesvizky R, Lonial S, Hamadani M, Stewart A, Roy V, Hari P, Vescio R, Berg D, LinJ, Bacco A, Gupta N, Hui Ai, Richardson P. A phase 1/2 study of weekly MLN9708, an investigationaloral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients withpreviously untreated multiple myeloma. Oral Presentation: ASH 2012, Atlanta, GA.

42. Lust J, Usmani S, Hamadani M, Barranco C, Lacy M, Dispenzieri A, Gertz M, Dingli D, Russell S, BuadiF, Zeldenrust S, Hayman S, Rajkumar S, Kumar S, Thompson J, Taylor C, Dondero R. Phase 1b/2adose-escalation study to evaluate the safety and tolerability of SNS01-T administered by intravenousinfusion in patients with relapsed or refractory multiple myeloma. Poster Presentation: ASH 2012,Atlanta, GA.

43. Forero A, Hamadani M, Fanale M, Bello C, Kipps T, Offner F, Verhoef G, Federico M, Gregory S, SonetA, Assouline S, Oteyza J, Tomas J, Cuneo A, Zhang W, Goswami T, Ibrahim R, Yao Z, Herbst R,Cheson B. MEDI-551, a humanized monoclonal anti-CD19, in adults with relapsed or refractoryadvanced B-cell malignancies: results from a phase 1/2 study. Poster Presentation: ASH 2012, Atlanta,GA.

44. Hamadani M, Craig M, Remick S, Gibson L, Petros W, Abraham J, Cumpston C, Bunner P, Basu B, Tse W,Hennelly C, Vasu S, Klisovic R, Blum W, Jaglowski S, Benson, D, Andritsos L, Penza S, HofmeisterC, Geyer S, Devine S, Efebera Y. Immunomodulation of both donors and recipients with atorvastatinas a strategy for the prevention of acute graft-versus-host disease: results of two parallel prospectivetrials in recipients of matched sibling allogeneic hematopoietic cell Transplantation. PosterPresentation: ASH 2012, Atlanta, GA.

45. Hamadani M, Saber W, Carreras J, Ahn K, Laport G, Montoto S, Maloney D, Lazarus M. Impact ofconditioning regimen intensity on the outcomes of allogeneic hematopoietic cell transplantation forrefractory grade-III follicular and diffuse large B-cell lymphomas: A CIBMTR Analysis. OralPresentation: ASH 2012, Atlanta, GA.

46. Hamadani M, Saber W, Carreras J, Ahn K, Laport G, Montoto S, Maloney D, Lazarus M. Effect of graftsource and transplant conditioning regimen intensity on the outcomes of allogeneic hematopoietic celltransplantation for refractory mantle cell lymphoma: A CIBMTR Analysis. Oral Presentation: ASH2012, Atlanta, GA.

47. Awan F, Kochuparambil S, Craig M, Cumpston A, Leadmon S, DeRemer D, Watkins K, Pantin J, Kota V,Jillella A, Hamadani M. A multicenter analysis of intermediate-dose cyclophosphamide versusplerixafor and granulocyte-colony stimulating factor for PB progenitor cell mobilization in patientswith multiple myeloma treated with novel induction chemotherapies. Poster Presentation: BMTTandem Meetings 2013, Salt Lake City, UT.

48. Veltri L, Regier M, Kanate A, Cumpston A, Leadmon S, Abraham J, Craig M, Hamadani M. Incidence andpattern of graft-versus-host disease in patients undergoing allogeneic hematopoietic cell transplantationafter non-myeloablative conditioning with total lymphoid irradiation and antithymocyte globulin.Poster Presentation: BMT Tandem Meetings 2013, Salt Lake City, UT.

49. Hamadani M, Gibson L, Remick S, Petros W, Abraham J, Basu S, Tse W, Cumpston A, Bunner P, Craig M.

53 / 59

Prospective evaluation of a 'two-pronged' strategy of atorvastatin administration as acute graft-versus-host disease prophylaxis, to both donors and recipients of matched related donor allogeneichematopoietic cell transplantation. Oral Presentation: BMT Tandem Meetings 2013, Salt Lake City,UT.

50. Kharfan-Dabaja M, Nishihori T, Reljic T, Vazquez-Otero C, Baz R, Hamadani M, Ochoa-Bayona J, AlsinaM, Djulbegovic B, Kumar A. Comparing efficacy of double- versus triple-combination therapy innewly diagnosed, transplant-eligible, patients with multiple myeloma: results of a metaanalysis. PosterPresentation: EBMT 2013, London, UK.

51. Chaudhary L, Awan F, Cumpston A, Tse W, Craig M, Hamadani M. Efficacy and cost of peripheral bloodstem cell mobilization with low-dose cyclophosphamide compared with plerixafor in multiplemyeloma patients treated with novel induction therapies. Poster Presentation: ASCO 2013, Chicago,IL.

52. Cooper BW, Kindwall-Keller T, Lazarus H, Hamadani M, Tse W, Basu S, Craig M. Phase I study ofmidostaurin and azacitidine in relapsed and elderly AML. Poster Presentation: ASCO 2013, Chicago,IL.

53. Truong QV, Shah N, Knestrick M, Curley B, Craig M, Hamadani M. Limited utility of surveillance imagingfor detection of relapse in non-Hodgkin lymphoma. Poster Presentation: ASCO 2013, Chicago, IL.

54. Hamadani M, Forero A, Kipps T, Fanale M, Cuneo A, Perez de Oteyza J, Gladstone D, Goswami T,Ibrahim R, Liang M, Eck S, Elgeioushi N, Herbst R, Cheson BD. MEDI-551, an anti-CD19 antibodyactive in chronic lymphocytic leukemia (CLL) patients previously treated with rituximab. PosterPresentation: ASCO 2013, Chicago, IL.

55. Younes A, Radford J, Ansell S, Gallamini A, Kim W, Feldman T, Hamadani M, Chung J, Wang J, HuebnerD, Connors JM. Phase III study of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazineversus doxorubicin, bleomycin, vinblastine, and dacarbazine as front-line treatment for advancedclassical Hodgkin lymphoma. Poster Presentation: ASCO 2013, Chicago, IL.

56. Richardson P, Berdeja J, Niesvizky R, Lonial S, Hamadani M, Stewart A, Hari P, Vesole D, Roy V, Berg D,Lin J, Hui A, Kumar S. Weekly oral investigational proteasome inhibitor MLN9708 plus lenalidomide-dexamethasone in elderly patients with previously untreated multiple myeloma: Subset analysis of aphase I/II study. Poster Presentation: 18th Congress of the EHA 2013, Stockholm, SE.

57. Efebera Y, Ranganathan P, Yu X, Hofstetter J, Garman S, Gibson F, Petros W, Craig M, Fernandez-Cymering C, Volinia S, Hamadani M, Marcucci G, Devine S, Garzon R. Serum microRNA signaturein acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. PosterPresentation: 18th Congress of the EHA 2013, Stockholm, SE.

58. Brown J, Hamadani M, Arnason J, Karlin L, Hayslip J, Wagner-Johnston N, Cartron G, Ribrag V, GuibertS, Ganguly S, Ailawadhi S, Ruiz-Soto R, Kersten M. SAR245409 monotherapy in relapsed, refractoryfollicular lymphoma: preliminary results from the phase II ARD12130 study. Oral Presentation: ASH2013, New Orleans, LA.

59. Forero-Torres A, Hamadani M, Fanale M, Bello C, Kipps T, Offner F, Verhoef G, Sonet A, Cuneo A,Goswami T, Ibrahim R, Cheson B. Safety profile and clinical response to MEDI-551, a humanizedmonoclonal anti-CD19, in a phase 1/2 study in adults with relapsed or refractory advanced B-cellmalignancies. Poster Presentation: ASH 2013, New Orleans, LA.

60. Lust J, Barranco C, Usmani S, Rhee R, Hamadani M, Dondero R, Browne L, Siegel D, Bensinger W. Phase1b/2a open-label, dose-escalation study to evaluate the safety and tolerability of of SNS01-T inpatients with relapsed/refractory multiple myeloma, mantle cell lymphoma, or diffuse large B celllymphoma. Poster Presentation: ASH 2013, New Orleans, LA.

61. Efebera Y, Ranganathan P, Gibson L, Craig M, Fernandez-Cymering C, Hamadani M, Marcucci G, DevineSM, Fabbri M, Garzon R. Serum Mir-29a is up-regulated in acute graft versus host disease afterallogeneic hematopoietic stem cell transplantation and activates dendritic cells. Poster Presentation:ASH 2013, New Orleans, LA.

62. Kanate A, Rauenzahn S, Leadmon S, Truong Q, Cumpston A, Londia L, Evans K, Zhang J, Wen S, Craig M,Hamadani M. Predictors and impact of 30-day readmissions on patient outcomes and healthcare costsafter allogeneic transplantation. Poster Presentation: ASH 2013, New Orleans, LA.

63. Forero A, Hamadani M, Kipps T, Fanale M, Cuneo A, Gladstone D, Andre M, Bellam N, Goswami T,Ibrahim R, Eck S, Elgeioushi N, Herbst R, Cheson B. Safety and disease response to MEDI-551, ananti-CD19 antibody, in chronic lymphocytic leukemia patients previously treated with rituximab.Poster Presentation: SITC 2013, National Harbor, MD.

64. Shah N, Rauenzahn S, Wen S, Craig M, Kanate A, Hamadani M, Cumpston A. Long term outcomes of

54 / 59

autologous hematopoietic cell transplant following thiotepa-based high-dose therapy in patients withnon-Hodgkin lymphoma. Poster Presentation: BMT Tandem Meetings 2014, Grapevine, TX.

65. Kumar A, Reljic T, Hamadani M, Castrovinci P, Nishihori T, Ayala E, Savani B, Djulbegovic B, Kharfan-Dabaja M. Efficacy of high-dose therapy and autologous hematopoietic cell transplantationintensification after rituximab-based front-line treatment of aggressive lymphomas: results of asystematic review and meta-analysis. Poster Presentation: EBMT 2014, Milan, IT.

66. Dhakal B, Strouse C, Arce-Lara C, D'Souza A, Esselman J, Eastwood D, Pasquini C, Saber W, Drobyski W,Hari P, Hamadani M. Plerixafor plus G-CSF (P+G) compared with G-CSF alone (G) forhematopoietic progenitor cell (HPC) mobilization in AL amyloidosis (AL). Poster Presentation: ASCO2014, Chicago, IL.

67. Hamadani M, Hari P, Zhang Y, Carreras J, Maloney D, Smith S, Montoto S, Saber W. Early rituximabfailure (ERF) in relapsed diffuse large b-cell lymphoma (DLBCL) and prediction of futility ofautologous hematopoietic cell transplantation (AHCT). Poster Presentation: ASCO 2014, Chicago, IL.

68. Gonzalez R, Shillingburg A, Newton M, Wen S, Leadmon S, Kanate A, Craig M, Hamadani M, CumpstonC. Impact of body mass index (BMI) on plerixafor efficacy during hematopoietic progenitor cell(HPC) mobilization. Poster Presentation: ASCO 2014, Chicago, IL.

69. Kumar S, Berdeja J, Niesvizky R, Lonial S, Laubach J, Hamadani M, Stewart K, Hari P, Roy V, Vescio R,Kaufman J, Berg D, Liao E, Hui A, Rajkumar S, Richardson P. Long-term ixazomib maintenance istolerable and improves depth of response following ixazomib-lenalidomide-dexamethasone inductionin patients with previously untreated multiple myeloma: phase 2 study results. Oral Presentation: ASH2014, San Francisco, CA.

70. Veltri L, Cumpston A, Shillingburg A, Lipinski C, Wen S, Leadmon S, Watkins K, Craig M, Hamadani M,Kanate A. Cost and efficacy of upfront plerixafor versus a “just-in-time” (JIT) approach inhematopoietic progenitor cell (HPC) mobilization. Poster Presentation: ASH 2014, San Francisco, CA.

71. Satwani P, Ahn K, Carreras J, Maloney D, Sureda A, Smith S, Hamadani M. Risk factors predictingoutcomes of autologous hematopoietic cell transplantation (autoHCT) in children, Adolescents andyoung adults (CAYA) with relapsed/refractory (Rel/Ref) classical Hodgkin lymphoma (HL): ACIBMTR analysis. Oral Presentation: BMT Tandem Meetings 2015, San Diego, CA.

72. Bachanova V, Burns L, Ahn K, Carreras J, Maloney D, Sureda A, Smith S, Hamadani M. Positive pre-allogeneic hematopoietic cell transplantation (alloHCT) PET scan in patients with non-Hodgkinlymphoma (NHL) predicts higher risk of relapse but has no impact on survival. Oral Presentation:BMT Tandem Meetings 2015, San Diego, CA.

73. Klyuchnikov E, Bacher U, Kröger N, Hari P, Ahn K, Maloney D, Smith S, Sureda A, Carreras J, HamadaniM. Association of reduced intensity conditioning (RIC) allograft (alloHCT) as first transplant approachin relapsed/refractory grade 3(G-3) follicular lymphoma (FL) with improved outcomes in long-termsurvivors. Oral Presentation: ASCO 2015, Chicago, IL.

74. Veltri L, Dhakal B, Singavi A, Wen S, Luo J, Craig M, Cumpston A, Shillingburg A, Watkins K, EsselmanJ, Pasquini M, Fenske T, Hari P, Hamadani M, Kanate A. Chemomobilization with (R)-ICE(rituximab, ifosfamide, carboplatin, etoposide) compared to G-CSF and plerixafor (G+P) mobilizationin lymphoid malignancies. Poster Presentation: ASCO 2015, Chicago, IL.

75. Klyuchnikov E, Bacher U, Kröger N, Hari P, Ahn K, Maloney D, Smith S, Sureda A, Carreras J, HamadaniM. Reduced intensity conditioning (RIC) allo transplantation is associated with superior long-termdisease control in relapsed/refractory grade I/II (G-I/II) follicular lymphoma. Oral Presentation: 19thCongress of the EHA 2015, Milan, IT.

76. Sureda A, Zhang M, Dreger P, Carreras J, Fenske T, Finel H, Schouten H, Montoto S, Robinson S, Smith S,Boumendil A, Hamadani M, Pasquini M. Allogeneic stem cell transplantation for relapsed/refractory(R/R) follicular lymphoma (FL). a joint study between the European Society for Blood and MarrowTransplantation (EBMT) and the Center for International Blood and Marrow Transplant Research(CIBMTR). Oral Presentation: ASH 2015, Orlando, FL.

77. Kharfan-Dabaja M, Reljic T, El-Asmar J, Nishihori T, Ayala A, Hamadani M, Ambuj K. Myeloablative orreduced intensity conditioning allogeneic hematopoietic cell transplantation for mantle cell lymphoma?a systematic review and meta-analysis. Poster Presentation: ASH 2015, Orlando, FL.

78. Dhakal B, Ramalingam S, Shuff J, Epperla N, Rein L, Banerjee A, Siker M, Hosking P, Hari P, D'Souza A,Atallah E, Erisckson B, Fenske T, Hamadani M. Local control of ocular adnexal lympho-proliferativedisorders (OALD): Similar Outcomes in MALT and non-MALT histologies. Poster Presentation: ASH2015, Orlando, FL.

79. El-Asmar J, Reljic T, Ayala A, Nishihori T, Hamadani M, Ambuj K, Kharfan-Dabaja M. Efficacy of high-

55 / 59

dose therapy and autologous hematopoietic cell transplantation in peripheral T-cell lymphomas as front-line consolidation or in the relapsed/refractory setting: a meta-analysis. Poster Presentation: ASH 2015,Orlando, FL.

80. Scott B, Pasquini M, Logan B, Wu J, Devine S, Porter D, Maziarz R, Warlick E, Fernandez H, Alyea E, Hamadani M, Bashey A, Giralt S, Leifer E, Geller N, Le-Rademacher J, Mendizabal M, Horowitz M,Deeg J, Horwitz M. Results of a phase III randomized, multi-center study of allogeneic stem celltransplantation after high versus reduced intensity conditioning in patients with myelodysplasticsyndrome (MDS) or acute myeloid leukemia (AML): Blood and Marrow Transplant Clinical TrialsNetwork (BMT CTN) 0901. Oral Presentation: ASH, 2015, Orlando, FL.

81. Mussetti A, Kanate A, Kharfan-Dabaja M, Ahn K, DiGilio A, Ciurea S, Armand P, Salit R, Fenske T, SmithS, Sureda A, Bolanos-Meade J, Hamadani M. Survival after T-cell replete haploidentical relateddonor transplant using post-transplant cyclophosphamide compared with matched unrelated donor(MUD) transplant for lymphoid malignancies. Oral Presentation: ASH 2015, Orlando, FL.

82. Chen Y, Le-Rademacher J, Kiefer D, Hamadani M, DiPersio J, Litzow M, Craig M, Horwitz M, Artz A,McClune B, Waller E, Fernandez H, Duong H, Kobusingye H, Proue M, Drexler R, Horowitz M,Miller J, Devine S. A Phase II study evaluating the safety and efficacy of subcutaneous plerixafor forthe mobilization and transplantation of HLA-matched sibling donor hematopoietic stem cells inrecipients with hematological malignancies. Oral Presentation: ASH 2015, Orlando, FL.

83. Fenske T, Graff T, Ahn K, Digilio A, Smith S, Sureda A, Hamadani M. Reduced-intensity allogeneichematopoietic cell transplantation (allo-HCT) provides durable progression-free survival (PFS) in asubset of diffuse large B-cell lymphoma (DLBCL) patients relapsing after autologous (auto-) HCT.Oral Poster Presentation: ASH 2015, Orlando, FL.

84. Hamadani M, Pasquini MC, Visotcky A, Ahn KW, Horowitz M, Boyd J, Rizzo J, Saber W, Drobyski W,Arce-Lara C, D'Souza A, Fenske T, Cumpston A, Bunner P, Craig M, Hari P, Kanate A. Prospective,multicenter clinical trial of atorvastatin-based acute graft-versus-host-disease (aGVHD) prophylaxis inrecipients of HLA-matched related donor (MRD) and matched unrelated donor (MUD) allogeneichematopoietic cell transplantation (alloHCT). Oral Presentation: BMT Tandem Meetings 2016,Honolulu, HI.

85. Karmali R, Ghosh N, Rocha V, Ahn K, DiGilio A, Armand P, Salit R, Fenske T, Smith S, Sureda A,Johnston N, Bolanos-Meade J, Hamadani M Survival after T-cell replete haploidentical related donorhematopoietic cell transplantation (Haplo-HCT) using post-transplant cyclophosphamide (PT-CY)compared with HLA-matched related donor (MRD) transplant for lymphomas. Oral Presentation:BMT Tandem Meetings 2016, Honolulu, HI.

86. Shillingburg A, Craig M, Kanate A, Hamadani M, Cumpston A Treatment of severe mucositis pain withoral ketamine mouthwash. Biology of Blood and Marrow Transplantation. Poster Presentation: BMTTandem Meetings 2016, Honolulu, HI.

87. Hari P, Kanate A, Pasquini M, Saber W, Drobyski W, Horowitz M, Rizzo J, Craig M, Hamadani M.Atorvastatin is effective for graft versus host diseas prophylaxis – Results of a phase II prospectivetrial. Oral Presentation: EBMT 2016, Valencia, Spain.

88. Sureda A, Zhang M, Dreger P, Carreras J, Fenske T, Finel H, Schouten H, Montoto S, Robinson S, Smith S,Boumendil A, Hamadani M, Pasquini M. Allogeneic stem cell transplantation for relapsed/refractory(R/R) follicular lymphoma (FL). A joint study between the European Society for Blood and MarrowTransplantation (EBMT) and the Center for International Blood and Marrow Transplant Research(CIBMTR). Oral Presentation: EBMT 2016, Valencia, Spain.

89. Mateos M, Masszi T, Grzasko N, Hansson M, Sandhu I, Pour L, Viterbo L, Jackson S, Stoppa A, Gimsing P,Hamadani M, Borsaru G, Berg D, Lin J, Velde H, Richardson P, Moreau P. “Impact of prior therapyon efficacy and safety of oral ixazomib-lenalidomide-dexamethasone (IRd) vs placebo-Rd in patients(pts) with relapsed/refractory multiple myeloma (RRMM) in TOURMALINE-MM1. PosterPresentation: ASCO 2016, Chicago, IL.

90. Chung Ki, Hamadani M, Kahl B, Heffner L, Caimi P, Feingold J, O'Connor O. A phase 1 adaptive dose-escalation study to evaluate the tolerability, safety, pharmacokinetics, and antitumor activity ofADCT-402 in patients with relapsed or refractory B-cell lineage non Hodgkin lymphoma (B-NHL).Poster Presentation: ASCO 2016, Chicago, IL.

91. Guru Murthy G, Mehta P, Hari P, Hamadani M. Predictive factors and outcomes for ibrutinib therapy inrelapsed/refractory (R/R) mantle cell lymphoma (MCL). Poster Presentation: ASCO 2016, Chicago,IL.

92. Epperla N, Hamadani M, Ahn K, Oak E, Cashen A, Kanate A, Calzada O, Farmer Z, Tallarico M, Nabhan

56 / 59

C, Costa L, Kenkre V, Ghosh N, Cohen J, Hari P, Fenske T. Allogeneic hematopoietic celltransplantation (AHCT) for hematological malignancies (HM) in United States: A comparison ofhospitalization outcomes between young and elderly patients.Poster Presentation: ASCO 2016,Chicago, IL.

93. Kline J, Armand P, Kuruvilla J, Moskowitz C, Hamadani M, Ribrag V, Zinzani P, Chlosta S, Thompson S,Balakumaran A, Bartlett N: “KEYNOTE-013: An open-label, multicohort phase 1b trial ofpembrolizumab for advanced hematologic malignancies.” Journal for ImmunoTherapy of Cancer.2016;4:Suppl 1. [Poster Presentation]

94. Khalil M, Reljic T, El-Asmar, Hamadani M, Nishihori T, Ayala E, Kumar A, Kharfan-Dabaja M: “Reduced-intensity or myeloablative allogeneic hematopoietic cell transplantation for myelofibrosis: A side-by-side systematic review/meta-analysis”Blood (ASH Annual Meeting Abstracts), 2016;128:3551. [PosterPresentation]

95. Costa L, Landau H, Chhabra S, Hari P, Salzman D, Saad A, Innis-Shelton R, Hamadani M, Tamari R,Godby K, Petrovic V, Orlando E, Williams L, Dixon P, Giralt S: “Carfilzomib plus high dosemelphalan conditioning prior to autologous hematopoietic cell transplantation followed by carfilzomibmaintenance in patients with relapsed multiple myeloma.” Blood (ASH Annual Meeting Abstracts),2016;128:4630. [Poster Presentation]

96. Wang M, Martin P, Phillips T, Goy A, Lossos I, Rule S, Hamadani M, Ghosh N, Reeder C, Barnett E,Bravo M, Schuster S: “Effectiveness of lenalidomide in patients with mantle cell lymphoma whorelapsed/progressed after or were refractory/intolerant to ibrutinib: The MCL-004 study.” Blood (ASHAnnual Meeting Abstracts), 2016;128:1786. [Poster Presentation]

97. Bashey A, Zhang M, McCurdy S, Ciurea S, Martin A, Anasetti C, Argall T, Fasan O, Gaballa S, HamadaniM, Al-Malki M, Munshi P, Nakamura R, O’Donnell P, Perales M, Raj K, Rocha V, Romee R, RowleyS, Salit R, Solh M, Soiffer R, Wingard J, Weisdorf D, Horowitz M, Fuchs E, Eapen M: “Comparisonof peripheral bood stem cells (PBSC) to bone marrow (BM) for T-replete HLA-haploidentical donortransplantation using post-transplant cyclophosphamide.” Blood (ASH Annual Meeting Abstracts),2016;128:683. [Oral Presentation]

98. Maddocks K, Epperla E, Chavez J, Reddy N, Karmali R, Umyarova E, Costa C, Bachanova V, Glenn M,Calzada O, Xavier A, Zhou Z, Hossain N, Hernandez-Ilizaliturri F, Al-Mansour Z, Barta S, Chhabra S,Lansigan F, Mehta A, Jaglal M, Evans E, Peker D, Forero-Torres A, Flowers C, Fenske T, Cohen J, Hamadani M, Costa L: “Diffuse large B-cell Lymphoma with primary treatment failure: identificationof ultra-high risk patients and benchmarking for experimental therapies.” Blood (ASH Annual MeetingAbstracts), 2016;128:103. [Oral Presentation]

99. Costa L, Reddy N, Maddocks K, Epperla E, Chavez J, Karmali R, Umyarova E, Costa C, Bachanova V,Glenn M, Calzada O, Xavier A, Zhou Z, Hossain N, Hernandez-Ilizaliturri F, Al-Mansour Z, Barta S,Chhabra S, Lansigan F, Mehta A, Jaglal M, Evans E, Peker D, Forero-Torres A, Flowers C, Fenske T,Cohen J, Hamadani M: “Primary failure diffuse large B-cell lymphoma: early autologous or donorhematopoietic cell transplantation not effective in patients with ultra-high risk features.” Blood (ASHAnnual Meeting Abstracts), 2016;128:103. [Oral Presentation]

100. Casulo C, Friedberg JW, Ahn K, DiGilio A, Sureda A, Fenske T, Smith S, Hamadani M: “Autologoustransplantation (autoHCT) is associated with improved overall survival (OS) in follicular lymphoma(FL) patients (Pts) experiencing early therapy failure after frontline chemo-immunotherapy: ANational Lymphocare Study (NLCS) & CIBMTR Analysis.” Biology of Blood and MarrowTransplantation. March 2017;23(3):S46-47. [Oral Presentation]

101. Epperla N, Kodali D, Kleman A, Hari P, Pasquini M, D'Souza A, Saber W, Shah N, Fenske T, Craig M,Kanate A, Hamadani M: “Post-relapse survival in lymphoma patients (Pts) after experiencing therapyfailure following an allogeneic hematopoietic cell transplantation (alloHCT).” Biology of Blood andMarrow Transplantation. March 2017;23(3):S48. [Oral Presentation]

102. Epperla N, Ahn K, DiGilio A, Jagasia M, Armand P, Ahmed S, Devine S, Jaglowski S, Kharfan-Dabaja M,Kennedy V, Rezvani A, Smith S, Sureda A, Fenske T, Hamadani M: “Rituximab (R) versus non-rituximab (NR) containing reduced-intensity conditioning (RIC) regimens for allogeneic hematopoieticcell transplantation (alloHCT) in B-cell non-Hodgkin lymphomas (B-NHL): A CIBMTR Analysis.”Biology of Blood and Marrow Transplantation. March 2017;23(3):S47-S48. [Oral Presentation]

103. Kanate A, Olteanu H, Ahn K, DiGilio A, Sureda A, Fenske T, Smith S, Hamadani M: “Allogeneichematopoietic cell transplantation (alloHCT) for extranodal natural killer (NK)/T-cell lymphoma, nasaltype (ENKL): A CIBMTR analysis.” Biology of Blood and Marrow Transplantation. March2017;23(3):S49-S50. [Oral Presentation]

57 / 59

104. Godfrey J, Smith S, Ahn K, Digilio A, Fenske T, Sureda A, Hamadani M: “Autologous (auto) versusmatched sibling donor (MSD) or matched unrelated donor (MUD) allogeneic (allo) hematopoietic celltransplantation (HCT) in follicular lymphoma (FL) patients (pts) with early chemoimmunotherapyfailure (ECF): A Center for International Blood and Marrow Transplant Research (CIBMTR)analysis.” J Clin Oncol. 2017;35:(suppl; abstr 7508). [Oral Presentation]

105. Horwitz SM, Fanale M, Spira A, Havenith K, He S, Feingold J, Hamadani M: “Interim data from the firstclinical study of ADCT-301, a novel pyrrolobenzodiazapine-based antibody drug conjugate, inrelapsed/refractory Hodgkin/non-Hodgkin lymphoma.” Hematol Oncol. 2017 35: Supplement S2.14-ICML, 14th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano(Switzerland). [Poster Presentation]

106. Kahl B, Hamadani M, Caimi P, Reid E, Havenith K, He S, Feingold J, O’Connor O: “First clinical resultsof ADCT-402, a novel pyrrolobenzodiazapine-based antibody drug conjugate, in relapsed/refractory B-cell non-Hodgkin lymphoma.” 2017 35: Supplement S2. 14-ICML, 14th International Conference onMalignant Lymphoma, Palazzo dei Congressi, Lugano (Switzerland). [Oral Presentation]

107. Horwitz S, Hamadani M, Fanale M, Feingold J, Spira A, Fields P, Menne T, Karnad A, Moskowitz A,Hildyard C, He S, Boni J. Collins G: “Interim results from a phase 1 study of ADCT-301(camidanlumab tesirine) show promising activity of a novel pyrrolobenzodiazepine-based antibodydrug conjugate in relapsed/refractory Hodgkin/non-Hodgkin lymphoma.” Blood (ASH AnnualMeeting Abstracts), 2017;130:1510. [Poster Presentation]

108. Pawarode A, D'Souza A, Pasquini M, Johnson B, Braun T, Dhakal B, Hamadani M, Magenau J, Shah N,Riwes M, Parkin B, Reddy P, Hari P: “Phase 2 study of pembrolizumab during lymphodepleted stateafter autologous hematopoietic cell transplantation in multiple myeloma patients.” Blood (ASHAnnual Meeting Abstracts), 2017;130:339. [Oral Presentation]

109. Kahl B, Hamadani M, Caimi P, Carlo-Stella C, Reid E, Feingold J, Ardeshna K, Radford J, Solh M, ChungK, Heffner L, He S, Boni J, O'Connor O: “Encouraging early results from the first in-human clinicaltrial of ADCT-402 (loncastuximab tesirine), a novel pyrrolobenzodiazepine-based antibody drugconjugate, in relapsed/refractory B-cell lineage non-Hodgkin lymphoma.” Blood (ASH AnnualMeeting Abstracts), 2017;130:187. [Oral Presentation]

110. Chhabra S, Hari P, Visotcky A, Shah N, Rizzo J, Saber W, D'Souza A, Dhakal B, Anshu A, Thompson R,Fenske T, Shaw B, Drobyski W, Pasquini M Hamadani M: “Ixazomib for chronic graft-versus-host-disease (cGVHD) prophylaxis in patients undergoing allogeneic transplantation (alloHCT):Preliminary results of a phase I/II study.” Blood (ASH Annual Meeting Abstracts), 2017;130:1974.[Poster Presentation]

111. Badar T, Hamadani M, Bachanova V, Maddocks K, Umyarova E, Chavez J, Epperla N, Chhabra S, XavierA, Karmali R, Salhab M, Reddy N, Hernandez-Ilizaliturri F, Flowers C, Evens A, Zhou Z, Lansigan F,Barta S, Cohen J, Fenske T, Costa L: “Efficacy of salvage chemotherapy in diffuse large B celllymphoma with primary treatment failure according to putative cell of origin.” Blood (ASH AnnualMeeting Abstracts), 2017;130:4141. [Poster Presentation]

112. Shah N, Ahn K, Litovich C, Sureda A, Smith S, Fenske T, Hamadani M. Outcomes of patients 65 yearsand older with non-Hodgkin lymphoma receiving reduced-intensity conditioning allogeneichematopoietic stem cell transplantation compared to patients 55-64 years of age: A CIBMTR analysis.Biology of Blood and Marrow Transplantation. March 2018;24(3):S77-S78. [Oral Presentation]

113. Levis M, Hamadani M, Logan B, Rosales M, Perl A, Devine S, Bahceci E, Chen YB. A phase 3, trial ofgilteritinib, as maintenance therapy after allogeneic hematopoietic stem cell transplantation in patientswith FLT3-ITD+ AML. J Clin Oncol. 2018;36:(suppl; abstr TPS7075). [Poster Presentation]

114. Hamadani M, Ahn KW, Litovich C, Herve F, Smith S, Fenske T, Boumendil A, Dietrich S, Robinson S,Montoto S, Dreger P, Sureda A. Post-transplant cyclophosphamide (PT-Cy) based haploidenticaltransplantation (haploHCT) versus matched sibling (MSD) or matched unrelated donor (MUD)reduced intensity conditioning (RIC) HCT for diffuse large b-cell lymphoma (DLBCL): A CIBMTRand EBMT analysis. J Clin Oncol. 2018;36:(suppl; abstr 7056). [Poster Presentation]

115. Hamadani M, Collins G, Samaniego F, Spira A, Davies A, Radford J, Caimi P, Menne T, Boni J, Cruz H,Feingold J, He S, Wuerthner J, Horwitz S. Phase 1 atudy of Adct-301 (camidanlumab tesirine), a novelpyrrolobenzodiazepine-based antibody drug conjugate, in relapsed/refractory classical Hodgkinlymphoma. Blood (ASH Annual Meeting Abstracts), 2018;132:928. [Oral Presentation]

116. Epperla N, Ahn K, Litovich C, Kharfan-Dabaja K, Sonali S, Sureda A, Fenske T, Hamadani M. Impact ofallogeneic hematopoietic cell transplantation (allo-HCT) on the outcomes of angioimmunoblastic T-cell lymphoma (AITL): A Center for International Blood and Marrow Transplant Research (CIBMTR)

58 / 59

analysis. Blood (ASH Annual Meeting Abstracts), 2018;132:969. [Oral Presentation]117. Collins G, Horwitz S, Davies A, Karnad A, Samaniego F, Spira A, Fields P, Menne T, Boni J, Cruz H,

Feingold J, He S, Wuerthner J, Hamadani M. Adct-301 (camidanlumab tesirine), a novelpyrrolobenzodiazepine-based CD25-targetting antibody drug conjugate, in a phase 1 study ofrelapsed/refractory non-Hodgkin lymphoma shows activity in T-cell lymphoma. Blood (ASH AnnualMeeting Abstracts), 2018;132:1658. [Poster Presentation]

118. Dhakal B, Giri S, Levin A, Lisa R, Fenske T, Chhabra S, Shah N, Szabo A, D’Souza A, Pasquini M, HariP, Hamadani M. Incidence and predictors of 30-day readmissions following autologous hematopoieticcell transplantation (auto-HCT) in the U.S. Blood (ASH Annual Meeting Abstracts), 2018;132:3544.[Poster Presentation]

119. Dhakal B, Giri S, Levin A, Lisa R, Fenske T, Chhabra S, Shah N, Szabo A, D’Souza A, Pasquini M, HariP, Hamadani M. Association between transplant volumes and 30-day readmission followingallogeneic hematopoietic cell transplantation (allo-HCT) in the U.S. Blood (ASH Annual MeetingAbstracts), 2018;132:617. [Poster Presentation]

120. Kanakry J, Ahmed S, Ahn K, Litovich C, Kharfan-Dabaja M, Fenske T, Sureda A, Hamadani M. Post-transplant cyclophosphamide (PTCy)-based haploidentical (Haplo) donor vs. calcineurin-inhibitor(CNI)-based matched related donor (MRD) reduced-intensity conditioning (RIC) allogeneichematopoietic cell transplantation (alloHCT) for classical Hodgkin lymphoma (cHL). Biology ofBlood and Marrow Transplantation. March 2019;25(3):S406–S407. [Poster Presentation]

121. Pidala J, Hamadani M, Dawson P, Alousi A, Jagasia M, Efebera Y, Chhabra S, Pusic I, Holtan S, FerraraJ, Levine J, Anasetti C, Pritchard T, Martens M, Horowitz M, MacMillan M. Sirolimus vs. prednisoneas initial systemic therapy for Minnesota standard risk (MN-SR), Ann Arbor 1/2 acute graft-vs-hostdisease (GVHD): primary results of the multi-center randomized phase II BMT CTN 1501 trial.Biology of Blood and Marrow Transplantation. March 2019;25(3):S50–S51. [Oral Presentation]

122. Chhabra S, Hari P, Visotcky A, Zhu F, Cantrall K, Abedin S, Dhakal B, D’Souza A, Drobyski W, FenskeT, Jerkins J, Rizzo JD, Runaas, Saber W, Shah N, Shaw B, Pasquini M, Hamadani M. Phase I/2 studyof ixazomib for chronic graft-versus-host disease (cGVHD) prophylaxis after allogeneictransplantation (alloHCT). Biology of Blood and Marrow Transplantation. March2019;25(3):S224–S225. [Poster Presentation]

123. Ghosh N., Ahmed S., Litovich C., Ahn K., Khanal M., Kharfan-Dabaja M., Sureda A., Fenske T., Hamadani M.: “Comparison of reduced-intensity conditioning (RIC) regimens for allogeneichematopoietic cell transplantation (alloHCT) in non-Hodgkin lymphomas (NHL)-a Center forInternational Blood & Marrow Transplant Research (CIBMTR) analysis.” Blood (ASH AnnualMeeting Abstracts), 2019;134:319. [Oral Presentation]

124. Ahmed S., Ghosh N., Litovich C., Ahn K., Khanal M., Kharfan-Dabaja M., Sureda A., Fenske T., Hamadani M.: “Comparison of reduced-intensity conditioning (RIC) regimens for allogeneichematopoietic cell transplantation (alloHCT) in classical Hodgkin lymphoma-a Center for InternationalBlood & Marrow Transplant Research (CIBMTR) analysis.” Blood (ASH Annual Meeting Abstracts),2019;134:3318. [Poster Presentation]

125. Jagadeesh D., Majhail N., Yizeng H., Litovich C., Ahn K., Kharfan-Dabaja M., Sureda A., Fenske T., Hamadani M.: “Does addition of rituximab (R) to BEAM conditioning improve outcomes of patientswith diffuse large B-cell lymphoma (DLBCL) undergoing autologous hematopoietic celltransplantation (auto-HCT)?” Blood (ASH Annual Meeting Abstracts), 2019;134:785. [OralPresentation]

Powered by TCPDF (www.tcpdf.org)

59 / 59

http://www.tcpdf.org

mehdi h. hamadani md curriculum vitae cv

Documents